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Abstract
The purpose of this study was to examine the symptom burden and severity of 
symptom distress reported by ICU patients at high-risk for death and to compare patient­
rated symptoms and distress for concordance with symptoms reported by a family 
member.
A prospective, correlational design with two data-points was used to study a 
convenience sample of 80 patients and 53 family members. The Condensed Memorial 
Symptom Assessment Scale (CMSAS) was used to gain patient/proxy report of 
symptoms on the first and third day after admission to the ICU.
The majority of patients were symptomatic (98%), reporting an average of 10.23 
symptoms. Most common symptoms reported on Day-1, were lack of energy (fatigue) 
and difficulty concentrating, with a mean symptom distress score of 2.96 (SD = 0.70) and 
2.79 (SD = 0.84), scored on a scale of 1 = low symptom distress to 4 = high symptom 
distress, respectively. The CMSAS Total Distress Score was 2.24 (SD=0.66).The 
Physiological Symptom Distress Subscale (CMSAS-PHYS) score was 2.19 (SD=0.71). 
Approximately 97.9% of patients reported psychologic symptoms (sadness, worry, 
nervousness) with a mean symptom distress score of 2.45 (SD=0.66), measured by the 
Psychological Symptom Distress Subscale (CMSAS-PSYCH). On Day-3, 65 of the 
patients were still in the ICU. The most prevalent symptom reported was difficulty 
sleeping (90.8%), with a medium intensity distress score of 3.79 (SD=1.06). Eighty 
percent of patients reported additional symptoms: lack of energy, lack of appetite, pain, 
dry mouth, feeling drowsy, shortness of breath, and difficulty concentrating, with a 
moderate intensity mean score of 3.42. Overall distress increased among all symptoms, as
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measured by the CMSAS-Total Distress Score of 3.17 (SD=0.44), and the two distress 
subscales: CMSAS-PHYS mean score of 3.07 (SD=0.46) and CMSAS-PSYCH means 
score of 3.46 (SD=0.52). Hospital mortality was 17 (21%) during initial hospitalization 
and 16 (25%) at 3-months follow-up. Family members correctly estimated the presence 
and absence of symptoms 85.5% of the time, yet rated the patients' physiologic symptoms 
higher than psychological distress.
This study identified ICU patients near death experience a significant burden of 
multiple symptoms, yet receive limited treatment for significant symptom distress. A 
need for widespread institution of symptom management strategies with proven 
effectiveness is indicated. Further research is needed to develop and test new evidence- 
based interventions to serve as a practice standards in the delivery of consistent, high 
quality care for all dying patients.
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Chapter 1 
Introduction
Overview o f  Problem
Improvements in medical science and healthcare have gradually changed the
nature of dying (National Institutes of Health [NIH], 1999). Death is no longer most
likely to be the sudden result of infection or injury, but is now more likely to occur
slowly, in old age, and at the end of a period of life-limiting or chronic illness (Field &
Cassel, 1997). As a result, a demographic shift is beginning to occur that will include an
increase in the number of seriously ill and dying people requiring end-of-life care
(EOLC), while the number of caregivers decreases. Faced with this challenge, the best
evidence that science can offer must be applied to guarantee the quality of care provided
to dying individuals and their surviving loved ones (National Institutes of Health, 1999).
Many end-of-life care (EOLC), experts as well as patients and families, consider
effective symptom management along with the psychosocial and spiritual aspects of
dying, as the essential components of excellent EOLC. Despite these goals, current
evidence suggests the care that patients with cancer and terminal illness, receive at end-
of-life (EOL) is sub-optimal. For example, recent studies indicate that care is often
fragmented among providers and provider settings, leading to a lack of continuity of care
1
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and impeding the ability to provide high-quality, multi-professional care (Clarke, Curtis, 
Luce, Levy, & Danis, 2003; Emanuel, 2006; Tranmer et al., 2003; Treece, 2006; von 
Gunten, 2005; Walke, Byers, Gallo, Endrass, & Fried, 2007). Symptoms such as pain, 
nausea, and dyspnea are inadequately treated, while depression and delirium are often 
underdiagnosed; and conversations with patients and families about advance care 
planning occur late in the course of life-prolonging treatments, if discussed at all (Field & 
Cassel, 1997; Iwashyna, 2004; Jablonski, 2007; James, 2005). Although these problems 
were initially noted in the care of cancer patients, anecdotal evidence is beginning to 
emerge documenting similar problems in the care of patients for a number of chronic life- 
limiting illnesses, such as renal failure, heart failure, dementia, cirrhosis, and obstructive 
lung diseases (Barnes et al., 2006; Jablonski, 2007; Kris & Dodd, 2004; Solano, Gomes, 
& Higginson, 2006; Weisbord et a l, 2003).
While there is a growing body of scientific inquiry addressing end-of-life care, 
covering a range of issues, the research is still in its infancy in terms of rigorous testing 
and evaluation of models of care, in terms of patient and family outcomes, resource 
utilization and measurement with respect to distressing symptoms other than pain 
(Nelson & Danis, 2001). To date, our current understanding of the symptom burden at 
EOL is derived primarily from studies recruiting individuals with cancer, with a paucity 
of research in critically ill patients with life-threatening illness, in intensive care units 
(ICUs). The symptom burden during critical illness has not been prospectively studied in 
a systematic way in any large cohort, despite the recommendations by NIH, National 
Institute of Nursing Research (NINR), and the Institute of Medicine (IOM). (Nelson & 
Danis, 2001; NIH Panel Final Statement: February 2005; Steinhauser, 2005; Tranmer et
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al., 2003).
There is a need and desire to know the diverse and subjective symptom 
experiences of patients as it relates to their health, and the effects of treatment. The 
current study attempts to add to the body of knowledge of symptom management, as well 
as to close the scientific gap in understanding the symptom prevalence and burden among 
critically ill patients, from the real-time perspective of the patient through self-report. 
Only one such study of symptoms self-reported “in real time” by ICU patients, has been 
conducted by Nelson and colleagues (2001). Their empirical study of 100 cancer patients 
revealed a 56% mortality and multiple, unrelieved symptoms were common at significant 
levels of severity among survivors and non-survivors. Data of this type is particularly 
limited in ICUs, as it is commonly thought that critically ill patients cannot report their 
symptoms. This is surprising since the comfort needs of patients dying in other settings 
have received much attention. Yet, with respect to ICU, where mortality among patients 
with and without malignancy is typically high (20% to 40%), research relating to 
symptom prevalence and management remains scant (Allen, Haley, Small, & McMillan, 
2001; Baggs & Schmitt, 2000; Ciccarello, 2003; Desbiens & Wu, 2000). An explanation 
and major challenge in research into care at EOL in ICU, is the difficulty of obtaining 
views and experiences of representative samples of patients, due to their critical condition 
(Allen et al., 2001. Patients often lack capacity, or become too critical to continue in a 
study, hence, attrition is high either by death or inability to continue. An alternative 
approach that overcomes this problem is the reliance on surrogate raters, through either a 
prospective or retrospective (after death) approach (Lobchuk, Degner, Chateau, &
Hewitt, 2006). Generally, next-of-kin or significant others have had more exposure
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seeing the patient cope with illness in a variety of situations and during a longer period 
(Lobchuk, Degner, Chateau, & Hewitt, 2006; Nekolaichuk et al., 1999).
One of the problems noted by most researchers in gathering information indirectly 
from proxies at a later point in time, is the introduction of potential problems regarding 
the validity of reports (Sulmasy & Mcllvane, 2002; Teno, 2004). Validity in this context, 
refers to the degree to which proxy accounts accurately reflex the experiences of the 
individual they are representing (Heyland, Rocker, O'Callaghan, Dodek, & Cook, 2003.). 
At present, there are only limited studies regarding the accuracy of proxy responses, 
despite the fact that inaccuracy may compromise validity and lead to erroneous 
conclusions. According to Teno (2004), proxies are a significant source of information, 
and often the only sources for a large proportion of dying patients. Therefore, it is crucial 
to understand how and why their accounts might differ from those of the patient. 
Numerous authors have offered sound arguments for including a designated surrogate as 
proxy respondents on patients’ illness experience (Coppolino & Ackerson, 2001;
Desbiens & Mueller-Rizner, 2000; Hayes, 2003; Hickman, Tilden, & Tolle, 2001; Kane et 
al., 2005; Kutner, Bryant, Beaty, & Fairclough, 2006). Results from some studies 
indicate that on the whole, there is more agreement concerning the more overt symptoms 
and aspects of the patient’s functioning, for example immobility, activities of daily living, 
and for some, symptoms such as fatigue, difficulty sleeping, dyspnea, and vomiting 
(Hayes, 2003; Kane et al., 2005; Kutner et al., 2006; Lobchuk & Voraurer, 2003). Others 
suggest that agreement seems to be poorest for subjective aspects of the patient’s 
experience, such as pain, anxiety and depression (Addington-Hall & McPherson, 2001; 
Hickman et al., 2001), which are often some of the most distressing symptoms that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 5
patients experience.
According to (Steinhauser, 2005; Steinhauser, Christakis, Clipp, McNeilly, & 
McIntyre, 2000), and Teno (2004) there are methodological challenges that plague both 
prospective and retrospective EOL data collection among terminal and acutely ill 
patients. Teno posits, that “An argument claiming that one method is superior is wrong. 
Rather, multiple methods, either combined or in sequence, are needed to examine a 
complex, multi-dimensional phenomenon such as end-of-life care” (p. 44). Prospective 
studies are primarily limited to diseases such as cancer that have an identifiable terminal 
phase, and where patients are likely to be known to relevant services and care, thus, there 
continues to be a gap in studies in real time among critically ill patients (McPherson & 
Addington-Hall, 2003). This is in part because of the inability of ICU clinicians to be 
able to accurately identify critically ill patients who will not survive, although numerous 
prognostic systems are available.
Clinical research involving critically ill patients is necessary to reduce the 
extreme morbidity and mortality encountered in the ICU setting. The most 
comprehensive approach to understanding the multiplicity of symptoms at the end-of-life, 
as noted previously, is to take into consideration information from multiple sources, 
including patients, family members and providers. Within such a framework, the present 
study included evaluation of the concordance and quality of proxy reporting (family 
respondent), since it varies by rater relationship, by EOL domain, and over time 
(Steinhauser, 2005). Proxy data will provide a more comprehensive approach to 
understanding the multidimensional nature of symptoms at EOL and their impact on 
different aspects of quality of life.
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Current reports on the way people die indicate that the majority of older and 
seriously ill persons -one in five (-500,000) Americans- die in hospitals following 
treatment in the ICUs each year (Nelson et al., 2006; Walke et al., 2007; Wood & Ely, 
2003). Unfortunately, data suggests that despite resource-intensive treatment, outcomes 
for many patients remain poor with high rates of mortality (15-40%), high symptom 
distress, and extreme functional dependence among survivors (Squires et al., 2004). The 
frequency of death following ICU care is also high and has been reported to range from 
6.1 to 27% (Azoulay et al., 2003; Friedrich, Wilson, & Chant, 2006). Studies indicate 
that death after ICU discharge can be related to factors occurring before or after the ICU 
stay, and is usually associated with advanced age, poor chronic health status, severe 
comorbidities and often sepsis-related organ failure (Azoulay et al., 2003; Laupland, 
Kirkpatrick, Kortbeek, & Zuege, 2006) The morbidity and mortality of critical illness 
underscores the need for effective clinical research.
Although the burden of critical illness is immense today, this trend will most 
likely accelerate, because according to the projections by the U.S. Census Bureau (2000), 
the population aged 85 years > is likely to grow from about 4 million in 2000 to 19 
million by 2050. Changes in the way Americans die are mirrored in health care cost 
patterns. The overwhelming preponderance of U.S. health care costs now takes place in 
the final years of life (Berge, Maiers, & Schreiner, 2005). For example, in 2000, ICU 
expenditures represented 13.3% of hospital costs, 4.2% of national health expenditures, 
and 0.56% of the U.S. gross domestic product (GPD). According to a study generated by 
the Centers for Medicare and Medicaid Services, real inpatient expenditures for the 
Medicare fee-for-service population increased by 60 percent from $58 billion in 1985 to
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$90 billion in 1999, one quarter of which were accrued by elderly decedents (Bamato & 
Angus, 2004). Furthermore, inpatient admissions to ICUs increased from 30.5 percent to 
35.0 percent among decedents, along with a ten percent increase in the use of one or more 
intensive care procedures. Although Bamato & Angus findings indicate that the majority 
of patients who received intensive care procedures were survivors, it was noted in the 
analysis that in 1999, 50% of feeding tube placements, 60 % of intubations / 
tracheostomies, and 75% of cardiopulmonary resuscitations were in patients who died. 
These ICU procedures are somewhat emblematic of end-of-life care, and known to cause 
distress and suffering during critical illness.
Other studies have also provided anecdotal evidence that ICU patients are at risk 
for suffering considerable amount of pain and distress from their diseases, traumatic 
injuries, invasive ICU procedures, blood draws, and other routine care such as suctioning, 
turning, positioning, drain and catheter removal, and wound care (Nelson, Meier, Oei, 
Nierman, & Senzel, 2001; Novaes et al., 2001; Puntillo, 2001). Additionally, data from 
studies conducted by (Rotondi, Lakshmipathi, & Sirio, 2002; Schelling, Richter, & 
Roozendall, 2003; Thomas, 2003) have further documented the physiological and 
psychological distress of ICU patients’ unrelieved pain during their ICU stay.
According to the Medicare data presented by (Barnato, Mcclellan, Kagay, & 
Garber, 2004), one of the most frequent diseases noted in ICU patients is respiratory 
failure, (Diagnosis Related Group-DRG 475), which by definition is > 96 hours of 
prolonged mechanical ventilation in critically ill patients. Prolonged mechanical
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Table 1
Challenges o f  unrelieved pain
Physical suffering
* 40% of 80 post-ICU Acute Respiratory Distress Syndrome (ARDS) patients recalled having 
pain while in ICU
* 40% higher frequency of chronic pain than in the controls’
* 87% of 97 post-ventilation patients remembered being moderately to extremely bothered by 
pain
Psychic suffering
* Significantly higher Post-Traumatic Stress Disorder (PSTD) scores in post-ICU ARDS 
patients than in controls (28% vs 12%)
* Traumatic memories associated with pain after cardiac surgery 
(81.6% of 184 patients)
*  Dyspnea, anxiety fear, and pain perceived by mechanically ventilated patients causing a 
stressful experience 42%-56%
Modified and reprinted with permission from K. Puntillo, UCSF, School o f Nursing, March 2007.
ventilation and subsequent ARDS are contributing factors causing increased length of 
stay (LOS), increased costs and increased suffering and distress, as noted in Table 1. This 
further highlights the disparity of care in the prospective management of individuals with 
multiple co-morbidities throughout their illness trajectory; and flaws inherent in a system 
that cannot even provide comfort and pain relief in society’s most vulnerable subjects, 
according to the domains of quality end-of-life care (Wolff, Starfield, & Anderson,
2002).
Domains of Quality Care at End of Life 
Advancing the science of end-of-life care requires knowledge and a foundation of 
clear domains and variables to guide research and clinical practice (Ferrell, 2005). 
Numerous researchers, organizations, and expert clinicians—including the professions of 
nursing, medicine, social work, psychology, and clergy—have collaborated together to 
conceptualize the important domains that should be addressed by high-quality care at
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EOL and hence by measures of quality. While experts do not agree on a single best 
conception, most domains and variables overlap considerably to provide uniformity for 
quality clinical care and services and shared measures of quality care (Clarke et al., 2003; 
Ferrell, 2005). Table 2 provides an overview of the various organizations and expert 
groups which have identified key domains of quality EOL care, through a rigorous, 
scientific and consensus process.
Although, the extent of activity in developing and testing quality measures is 
encouraging, much more is needed to assess and improve the EOL care received by the 
elderly and those with advanced life-limiting illness, known to spend their last days and 
hours in ICUs. These domains of end-of-life care were used as a framework to explore 
the variables and concepts relevant to symptom burden in critically ill patients/and 
families, where death may be near. The broad domains addressed in the current study can 
be seen in Table 3.
















Comparison o f Quality Indicators for End-of-Life Care (EOLC) Domains Identified Across Select Sources
NCP Domains 1 N H PCO 2 Emanuel and Emanuel A G S 4 N C C N 5 Institute o f RWJF Critical Care End-
3 Medicine (IOM) 6 of-Life Peer Work Group
Structure and Patient and family Palliative care Improve Continuity o f  care
Processes o f Care expectations; assessment; environment and Communication within
Survival time; Early referral for structure; provider team and with patients
Provider palliative care continuity & skill; and families
continuity & skill
Physical Aspects o f Safe and Physical symptoms Physical and Management o f  key Physical well­ Symptom management
Care comfortable dying symptoms symptoms pain; being and and comfort care
dyspnea; functioning Standardize & follow best
anorexia/cachexia; clinical practices for
fatigue symptom management
Psychological and Self-determined Psychological and Psychosocial/ Management o f Psychosocial well­ Emotional and practical
Psychiatric Aspects life closure; cognitive symptoms Emotional delirium; being and support for patients and
o f Care Effective grieving symptoms After-death care / functioning families
Global QOL bereavement Emotional &
organizational support for
ICU clinic
Social Aspects o f Safe and Economic demands Support o f Resource Psychosocial well­
Care comfortable dying and care-giving needs; function and management, social being and
Social relationships autonomy; family support functioning
and support burden
Spiritual, Religious, Spiritual and Spiritual and Spiritual support for
and Existential existential beliefs Cultural well­ patients and families
Aspects being
Cultural Aspects Provide comprehensive
Care o f  the Lack o f aggressive Imminently dying comfort care to patient
Imminently Dying care near death Relieve symptoms /family
Ethical and Legal Hopes and Advance care Advance care Advance care Patient and family-
Aspects o f  Care expectations planning planning; “Special” planning; centered decision making
palliative care (PC) PC interventions
interventions
1) National Consensus Project (National Consensus, 2004); 2) National Hospice and Palliative Care Organization (National Hospice and Palliative Care, 
2002); 3) (Emanuel & Emanuel, 1998); 4) American Geriatrics Society (AGS) (American Geriatrics Society, 1997); 5) IOM (Institute o f  Medicine, 
1997); 6) Robert Wood Johnson Foundation (RWJF) Critical Care End-of-Life Peer Work Group (Clarke et al., 2003)
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Table 3
Domains o f  Quality End-of-Life Care
Broad Domains Used In Study
• Structure and Processes of Care / Continuity of Care / Communication within Team 
and with Patients/ Families
• Symptom Management / Physical Aspects of Care
• Psychological and Psychiatric Aspects of Care
• Emotional / Social Aspects of Care
• Cultural Aspects of Care
• Care of the Imminently Dying Patient
• Ethical and Legal Aspects of Care/Patient & Family Centered Decision Making 
National Consensus Guidelines, 2004; (Clarke et al., 2003)
Conceptual Framework—Symptom Management Model 
In order to explore the scope of the multidimensional nature of the symptom 
experience among critically ill patients, a broad-based theoretical framework is 
necessary. The University of California, San Francisco (UCSF) School of Nursing, 
Symptom Management Conceptual Model (see Figure 1) guided this study (Dodd et al., 
2001). In this model, a symptom is defined as “a subjective experience reflecting changes 
in the biopsychosocial functioning, sensations, or cognition of an individual” (Dodd et 
al., 2001, p.669). Three interrelated dimensions, the symptom experience, symptom 
management strategies, and symptom outcomes, characterize the model.
Two important components of the symptom experience are symptom evaluation 
and response (Dodd et al., 2001; Larson, Uchinuno, Izumi, Kawano, & Takemoto, 1999; 
Larson, Carrieri-Kohlman, & Dodd, 1994). Symptom evaluation refers to how 
individuals describe their symptoms, for example, in terms of frequency, duration, 
intensity and distress. Symptom response includes physiological, emotional, and/or 
behavioral reactions to a symptom, such as physical, cognitive, and affective alterations.
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Viewed in the context of the model, the symptom experience influences both symptom 
management and symptom outcomes.
Successful management of a troubling symptom usually requires a partnership 
between the patient and the healthcare provider (Dodd et al., 2001; Larson et al., 1999). 
Self-management strategies are those practices initiated or maintained by the patient to 
control the symptom experience and outcomes and may include recommendations from 
the healthcare provider and family. Self-management strategies may or may not be based 
on scientific evidence and are often derived from experience with trial and error and 
suggestions of family and friends. Symptom management strategies on the other hand, 
influence both the symptom experience and symptom outcomes (Larson et al., 1999).
Symptom outcomes are the third dimension of the symptom management model 
(Dodd et al., 2001). Symptom outcomes are assumed to influence both the symptom 
experience and self-management strategies.
In the current study, the three components of the symptom experience were 
assessed via a self-report method, using the Condensed Memorial Symptom Assessment 
Survey (CMSAS) (Chang, Hwang, Kasimis, & Thaler, 2004). The identification of 
symptoms is determined by the patient’s identification of the presence or absence of 
symptoms. The evaluation of prevalence, intensity, and distress are assessed to 
characterize the symptom experience. Although degree of distress is not clearly specified 
in the SMCM, in this study the degree of distress caused by symptoms is considered a 
psychological response to symptoms. Symptom distress has been defined as patient 
reported discomfort in relation to their perception of the symptom experience (McCorkle 
& Young, 1978) and has been characterized as the physical or mental suffering that
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results from the symptom experience and/or the perception of feeling states (Rhodes & 
Watson, 1987). In the critical care setting, there are numerous procedures/treatments, 
including nursing care commonly performed on critically ill patients. Yet, little is known 
about the patient’s pain perception and distress, nor their responsiveness across 
procedures in ICU, despite the high use of procedures in dying patients (Bamato et al., 
2004; Nelson et al., 2001; Puntillo, 2001; Puntillo, 1990). In order to capture patients 
distress related to their ICU care, patients in the current study were also asked to 
complete a Treatment and Procedure Survey (TPS) on day-3 of their ICU stay, in order 
gain a more comprehensive assessment of patients suffering and distress, related to ICU 
treatments and environmental risks.
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Figure 1 provides a schematic presentation of the UCSF’s Symptom Management 
Conceptual Model (SMCM). Symptom status is considered the central outcome of the 
model.
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Figure 1. University of California, San Francisco, School of Nursing Symptom 
Management Conceptual Model
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Significance of the Study 
The huge human and financial costs of critical illness creates a pressing need for 
a sound research base on the epidemiology of various diseases among critically ill 
patients, during their dying trajectory, so that care can be customized based on age, co­
morbidities, anticipated outcomes and patient/family preferences (Wolff et al., 2002; 
Wood & Marik, 2004; Wu, 1995; Wu et a l, 2002). While the symptom profile and 
experience for patients with cancer has garnered much attention in the literature, 
characterization of the symptom experience of patients with chronic, critical illnesses at 
EOL has received minimal attention. Care of the dying has become a focus of intense 
attention both inside and outside the medical and nursing profession. According to the 
IOM 1997 report, the rights of elderly and dying individuals to have autonomy, integrity, 
safety, quality of care and freedom of choice, in their medical care has never been greater 
(Field & Cassel, 1997). Prospective research studies are needed to examine the symptom 
experience and distress, as reported by the ICU patients, given the high morbidity 
associated with ICUs (Cook, Giacomini, Johnson, & Willms, 1999; Cook, Rocker, & 
Heyland, 2004).
The current study is one of the first to extend the work of Nelson and colleagues 
(2001) who first examined the symptom experience of cancer patients in ICU (2001), and 
most recently examined the symptom burden, ventilator outcomes and functional status at 
discharge, in a small, cohort of chronic critically ill (CCI) patients in a respiratory ICU 
(Nelson et al., 2004). In the later study, results indicated that seventy-two percent (36 of 
50) of patients were able to self-report symptoms during the period of respiratory care 
unit treatment. Results indicated that approximately 90% were symptomatic. Forty-four
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percent of patients reported having pain at the highest levels, while more than 60% 
reported psychological symptoms at these levels; and 90% of patients reported severe 
distress due to communication difficulties (2004).
Finally, the current research adds to the science of end-of-life research by 
enhancing the body of literature of earlier empirical studies on symptom burden 
(Klinkenberg, Willems, Wal, & Deeg, 2004; Kris & Dodd, 2004; Tilden, Tolle, Drach, & 
Hickman, 2002; Tranmer et al., 2003).
Purpose of the Study 
The purpose of this exploratory study was to explore the symptom burden at end- 
of-life in critically ill patients with life-limiting illness in ICUs; and to examine the 
relationships among variables related to patient (age, gender, physiologic acuity, previous 
health status), symptom distress and overall mortality.
Study Aims
Aim #1: Examine the perceived symptom burden (prevalence, intensity, 
frequency), and overall distress, as reported by ICU patients with complex 
disease states, at high-risk for dying.
Aim  #2: Examine the relationships between the independent variables o f  
demographic characteristics, antecedent conditions, and the dependent variable 
o f symptom burden and overall distress using the (CMSAS-PSYCH and CMSAS- 
SUM Subscales). .
Aim  #3: Explore the relationship between symptom distress and overall patient 
mortality.
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Aim  #4: To compare the critically-ill patient-rated symptoms (prevalence, 
intensity, frequency) and distress scores for concordance, with those rated by 
designated surrogate-responders. This will provide a more comprehensive 
approach to understanding the differences in various raters, regarding the 
multidimensional nature o f  symptoms at EOL and their impact on different 
aspects o f  quality o f  life. (Dependent Variable)
Nursing Implications 
The proposed research study is an essential first step towards informing nursing 
science by filling in the gaps of our knowledge surrounding the multidimensional nature 
of the symptom burden of critically ill patients with multiple diagnoses. Quite often, 
patients are admitted to the ICUs to receive treatment aimed at prolonging life, yet, 
because of the patients advanced disease state these treatments may only prolong dying, 
while patients experience pain and other distressing symptoms. The SMCM guided this 
study, and was characterized in this review to present how the symptom experience / 
burden was studied to achieve the aims of the research protocol. Previous research has 
indicated that EOL research is still in its infancy, therefore, there is a need to understand, 
interpret and measure the symptom experience in frail and vulnerable populations, who 
are at risk for extreme suffering and stress, or death. Knowledge of symptom prevalence 
and burden can enable interdisciplinary teams to help in the identification of patients’ 
needs in terms of interventions to relieve symptoms’ and service provision to 
patients/families so that strategies can be targeted to achieve the desired outcome of 
increased quality of life at end of life.
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Review of the Literature 
The purpose of this chapter was to review and critique literature focused on the 
symptom experience for critically ill patients and families at end-of-life. It gives a 
comprehensive overview of the current state-of-the-science research on EOL and 
symptom measurement among patients with cancer and non-cancer disease states, 
particularly those cared for across care settings. The explanation of the method used for 
the literature review is presented in the first section. While the second section examines 
the historical context of end-of-life research, gaps in science related to symptom research 
in non-cancer patients, particularly those cared for in intensive care units and the impetus 
for reform in end-of-life care. In the third section, the UCSF Symptom Management 
Conceptual Model (SMCM) is portrayed to illuminate factors such as disease, 
demographic information, physiologic acuity, and the risk for dying; thought to influence 
the symptom experience. The final section analyzes and synthesizes the literature on the 
variables specific to this study, including symptom burden (prevalence, intensity, 
frequency) and distress; antecedent conditions, morbidity and mortality, age, gender and 
symptom experience perceived by patient and proxy assessment.
18
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Method of Literature Review
To establish a thorough review of the extant literature the following steps were 
taken. An electronic search was conducted among the following databases of MEDLINE, 
EMBASE, CINAHL, ERIC, Ageline, Psychlnfo, and Sociological Abstracts for 
published articles that reported on symptom burden, individual symptoms, symptom 
clusters, end-of-life experience in cancer and non-cancer diseases and critical illness, that 
went beyond mortality data. The key words used for the article search strategy included 
key words, title, or abstract, such as symptoms, symptom experience, symptom 
assessment, symptom distress, death, dying, measurement, end-of-life care, intensive care 
unit, intensive care, critical care, critical illness, critical care medicine, critical care 
nursing, mortality rate, palliative care, pain, pain measures, mechanical ventilation, 
cancer, dyspnea, quality of life, prognostication models, self-report, and symptom 
instruments. In addition, author searches were done, which yielded further research 
articles.
The list was then limited to English-language articles relevant to symptom 
experience, symptom distress, pain, suffering, dying and hospitalized acutely ill and 
terminal patients, and the intensive care units, reduced the number to 524. Limiting the 
search further to articles to exclude children and adolescents eliminated 152 studies, 
yielding 372 studies for review.
After the initial electronic database searches, hand searches were also conducted 
of the citations in the reference lists of relevant articles. Electronically searchable 
meeting abstracts (e.g. Society for Critical Care Medicine, American Association of 
Critical Care Nurses, Trauma Nurses Society, American Society of Clinical Oncology,
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Oncology Nursing Society, Hospice and Palliative Care Association, Medical-Surgical 
Nurses Association, American Society for Pain Management, Chest Society), and printed 
proceedings (e.g., University of California, San Francisco, Symptom Management 
Symposia; Western Institute of Nursing Assemblies; Sigma Theta Tau International), also 
were examined. Book chapters, editorials, and presentations that did not report research 
were excluded. Eliminating dissertations and theses in which the operationalization of 
symptoms, critical care, dying, end-of-life could not be determined from the abstract 
further reduced the list. The research articles included instrument validation, descriptive 
and exploratory, intervention, and evaluation studies.
The literature synthesis highlights the many issues related to the care of chronic 
and critically ill patients with life-limiting illness-approaching end-of-life. Future 
research is necessary, in order to further develop a multiple interventional approach to 
reduce the symptom burden and improve the quality of care and the death experience, for 
a rapidly growing population of frail, high-risk patients receiving treatment in intensive 
care units.
Symptom Experience at End-of-Life 
Although death is an inevitable fact of life, the experience of a peaceful death is 
not. The final days of life are frequently marked by needless physical, emotional, and 
spiritual suffering (Field & Cassel, 1997; Hanson, 1997). Despite the availability of 
effective management strategies across care settings, unrelieved symptoms continue to be 
a major source of distress for both patients and families throughout the illness trajectory. 
The fact that symptoms often go unrecognized, under-diagnosed, and under-treated has 
become a concern of healthcare professionals, researchers, policymakers, and the public
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at large. This has resulted in a number of initiatives being launched in recent years aimed 
at improving the quality of EOL care, particularly in the area of symptom management 
(Last Acts, 2002; National Institutes of Health, 1999).
According to the literature, the quality of care and quality of life changes 
substantially for those with a serious chronic illness and nearing the end of their lives 
(Field & Cassel, 1997; Teno, Byock, & Field, 1999; Teno, Field, & Byock, 2001). As one 
dies, life takes on new shape—values change and things once ignored become more 
important. Existing quality of care measures do not attend to the changes in priorities or 
to dimensions that acquire new significance (e.g., spirituality and transcendence) for 
patients and families. An important barrier to addressing the inadequacies in the evidence 
base for palliative care, improving shortcomings of care, and holding institutions or 
health care systems accountable for the quality of care at EOL, is the lack of valid and 
reliable measurement tools, and the lack of inclusion of critically ill patients in empirical 
studies (Tonelli, 2005). Inclusion of acute and critically ill patients is of particular 
importance, since there is wide recognition that the principles of palliative care should be 
applied as early as possible in the course of any chronic, ultimately fatal illness.
Understanding the patient’s symptom burden in critical illness will allow 
clinicians to understand the dying experience and offer palliative care throughout the 
hospitalization. According to the World Health Organization (WHO), palliative care can 
be defined as:
Palliative care is an approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable
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assessment and treatment of pain and other problems, physical, psychosocial and
spiritual (WHO, 2002).
Definitions of palliative care and descriptions of a good death would suggest great 
sensitivity to the physiological, psychosocial, existential, and spiritual aspects of patient 
well-being. Yet, in spite of this, there are aspects of EOL distress that are not routinely 
assessed, let alone effectively treated or managed, particularly in ICUs (Chang, Thaler, 
Polyak, Lepore, & Portenoy, 1998; Chochinov, 2006). Few studies have addressed the 
gaps in understanding the suffering at EOL, nor other antecedent conditions, that may 
influence a patients’ perception of suffering, particularly in patients with life-limiting 
illness in ICUs. Anecdotal studies, such as a recent report by Abraham, Kutner, & Beaty 
(2006), have shown that factors other than physical symptom distress, such as diagnosis, 
age, and quality of life (QOL) appear to affect the perception of suffering. While study 
findings are extremely important and contribute to our understanding of the dying 
experience, the study population was drawn from a large population-based hospice 
program, thus, it is limited to primarily cancer patients (Abraham, Kutner, & Beaty,
2006).
According to the WHO, end-of-life care is defined as "the active, total care of 
patients whose disease is not responsive to curative treatment. The philosophy of this care 
is to attain maximal QOL through control of the myriad physical, psychological, social, 
and spiritual distress of the patient and family” (World Health Organization, 1998). 
Although the imperative of care is providing optimal symptom relief and alleviation of 
suffering, there is clear evidence in the current medical literature that we are failing to do 
this. For example, despite wide dissemination of pain management guidelines, many
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patients with lung cancer and other diseases continue to suffer not only from pain, but 
also from other troubling symptoms and interpersonal scenarios in their final days 
(Desbiens, Mueller-Rizner, Connors, Wenger, & Lynn, 1999; Doorenbos, Given, Given, 
& Verbitsky, 2006; Walsh, Donnelly, & Rybicki, 2000; Wolff, Dy, Frick, & Kasper,
2007).
Although the symptom experience is complex and multifaceted, knowledge of it 
has been limited by a paradigm that has been mostly directed toward studying a limited 
number of symptoms, such as pain or fatigue, rather than total symptom burden in this 
patient population (Beck, 2004; Becker, 2006; Dodd et al., 2001). Thus, gaps in 
knowledge exist concerning symptom burden, which includes the prevalence and severity 
of physical and psychological symptoms and their relationship to interference of life in 
patients, with chronic and life-limiting illnesses. Large well-designed, well-controlled 
prospective studies in non-cancer patients, particularly those hospitalized and in the 
ICUs, have not been performed to date (Kirkova et a l, 2006; von Gunten, 2005). In fact, 
most of the existing evidence regarding symptom burden for this review has been gleaned 
from high-quality studies among ambulatory care, hospice and palliative care populations 
(Bowman, Martin, & Singer, 2000; Bradley, Fried, Kasl, & Idler, 2000; Chang et al., 
1998; Cleeland et a l, 2000; Degner & Sloan, 1995; Doorenbos et a l, 2005; Gift, 
Stommel, Jablonski, & Given, 2003). While some progress has been made in studying 
hospitalized patients with non-cancer conditions, the lack of evidence base is disturbing, 
given that over 1 million Americans die in hospitals today. Thus, definitive studies are 
needed to study the epidemiology of the symptom experience at EOL, in order to 
implement measures to relieve symptoms in terminally ill and improve the dying
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experience for patients and families (von Gunten, 2005; Wood & Ely, 2003; Wood & 
Marik, 2004; Zimmerman, Kramer, McNair, & Malila, 2006).
Theories of symptom experiences and symptom management in nursing describe 
and explain clinical phenomena and serve as a foundation for planning, implementing, or 
evaluating effective management protocols (Hegyvary, 1993; Lenz, Pugh, Milligan, Gift, 
& Suppe, 1997). Understanding the interaction of the components of the symptom 
experience is essential, along with critical measurement of outcomes of symptom 
distress, as the suffering experienced by dying patients extends beyond just the physical 
distress, but also includes the emotional, social and spiritual dimensions (Lobchuk & 
Degner, 2002). The symptom experience is the individual’s perception of the symptom, 
evaluation of its meaning and subsequent response. Because the SMCM is broad and 
extensive, it provides a framework by linkage of the concepts, to guide the assessment of 
the symptom experience (see Figure 1). This model also facilitates understanding the 
impact of any of the antecedent conditions influencing a persons’ response or distress, 
thus, the outcomes as well (Armstrong, 2003). For the purposes of this study, the 
antecedents to the production of the symptoms experience in critically ill patients have 
been broadly classified as demographic characteristics (age, gender) disease 
characteristics (disease type, co-morbid conditions, severity of illness) and individual 
characteristics (previous health status).
Organizing the findings of previous research within the context of the symptom 
management model provided a lens to elucidate the gaps in our current knowledge 
regarding the symptom experience of critically ill patients at end-of-life.
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Symptom Prevalence 
Discussion of symptoms, and the accompanying distress experienced at end-of- 
life, are often confined to physical symptoms (Teno, Weitzen, & et al, 2001; 
Yennurajalingam, Braiteh, & et al, 2005). However, psychological symptoms and distress 
may also be present (Ahlberg, Ekman, Wallgren, & Johansson-Gaston, 2004; Andenaes, 
Kalfoss, & Wahl, 2004). Also, suffering can arise from social and spiritual problems 
(Chochinov, 2006; McMillan, 1996; Steinhauser & et al., 2000).
Symptom assessment is important because the prevalence of symptoms influence 
a patient’s distress, QOL, and survival. Yet, symptom assessment is challenging because 
of the evolving course of cancer, and other progressive, chronic diseases. Symptoms are 
disease related, treatment related, related to concurrent comorbid illnesses, or a 
combination of all three (Oi-Ling, Man-Wah, & Hung-Kam, 2005). Although there are a 
number of existing valid instruments to assess the symptom experience in cancer patients, 
few instruments have been tested in prevalent non-cancer conditions or among ICU 
patients (Bergner, Bobbitt, & Carter, 1981; Bruera, Kuehn, Miller, Selmser, &
Macmillan, 1991; Emanuel, Fairclough, Slutsman, & Emanuel, 2000; Portenoy et al., 
1994; Rhodes, McDaniel, Homan, Johnson, & Madsen, 2000). Related methodological 
issues include assessing patients with dementia or acute cognitive impairment and better 
understanding of the opportunities, yet limitations of proxy response (Steinhauser, Clipp, 
& Tulsky, 2002). Another barrier in measurement of symptoms in critically ill patients is 
that most existing valid, self-report, instruments have a range of 16 to 50 questions, and 
take between 15 to 45 minutes to complete, which may cause extreme fatigue and harm 
in critically ill patients. Hence, this is in part an explanation for the lack of research using
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self-report instruments among ICU patients to date. Most measures need to be refined, 
validated for dying elderly patients with non-cancer, and tested for responsiveness to 
changes in the items being measured (Emanuel, 2000).
Symptoms have been relatively well-characterized in cancer, with most studies 
revealing a high symptom burden (Adenaes, Kalfoss, & Wahl, 2004; Ahlberg et al., 2004; 
Allen et al., 2001; Arnold & Liao, 2006; Barnes et al., 2006; Doorenbos et al., 2006; 
Ellershaw & Ward, 2003; Walke et al., 2007; Walsh et al., 2000). However, high quality 
studies of the incidence, epidemiology of pain and other symptoms, including the 
relationship among symptoms, and the clinical significance of symptoms remain sparse, 
among other life-limiting illnesses, such as congestive heart failure (CHF), end-stage 
renal disease (ESRD), chronic obstructive pulmonary disease (COPD), liver failure, and 
dementia, particularly in the intensive care units.
Recently, (Kirkova et al., 2006), conducted a systematic review for cancer 
symptom assessment instruments, where twenty-eight prevalence/incidence (severity 
and/or symptom burden) studies were identified. Among these studies, symptom 
prevalence and severity were the main determinants of symptom burden (2006). Twenty- 
one of the studies were prospective studies, nine were longitudinal, and one was a 
randomized, controlled trial (RCT). Seven studies included cancer and noncancer 
patients, one was particular to hospice patients. Out of the 21, only eight used validated 
symptom assessment instruments, three were original, and the rest modified (Kirkova et 
al., 2006). The remaining 21 studies used nonvalidated symptom checklists containing 4 
to 38 symptoms (2006). Only one study in this review, involved consecutive patients in a 
prospective design with a modified validated instrument. According to Kirkova and
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colleagues (2006), “Symptom lists varied among the surveys, however, anorexia, dry 
mouth, fatigue, lack of energy, pain, shortness of breath, and weight loss, were included 
consistently. The mean number of symptoms reported per patient ranged from (± two) to 
(± six)” (p. 1461). Findings noted in this systematic review suggest that symptom 
prevalence and burden among cancer and non-cancer patients is very high, and that 
designs of symptom prevalence studies need to be improved, because of the 
methodological disparities in symptom assessment and designs.
In another study, Potter, Hami, Bryan & Quigley (2003), examined the 
demographics and prevalence of symptoms in patients (n=400) referred to various 
palliative care services, in London. In this study, ninety five percent (380/400) had 
cancer. Moreover, the five most prevalent symptoms overall were pain (64%), anorexia 
(34%), constipation (32%), weakness (32%) and dyspnea (31%), which is similar to other 
published reports among hospice/palliative care services including out-patient and in- 
hospital. Overall, the range of symptoms was from (±3) to (±7.21). Among this cohort 
significant differences in symptom prevalence occurred, most likely because there were 
marked differences across the sub-groups and settings, however, most interestingly, the 
majority of patients did not have advanced disease. Differences in symptom prevalence 
may also have been related to the lack of use of a valid symptom-rated instrument, since 
a standardized profoma (checklist) was used, along with qualitative notes in each setting 
Potter et al., (2003). While study findings suggest high symptom burden among cancer 
patients, more rigorous research is needed among palliative care teams, to glean more 
generalizable results, and to aid in providing appropriate interventions and planning of 
services (Potter, Hami, Bryan, & Quigley, 2003).
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Doorenbos, Given, Given, & Verbitsky (2006) examined study subjects (n=174'), 
by secondary analysis of data from three prospective, descriptive, longitudinal studies of 
individuals with cancer (Doorenbos et al., 2006). “The purpose of this study was to 
examine the symptom burden during the last year of life, and to determine if symptom 
experiences change with proximity to death, or differs by depressive, symptomatology, 
sex, site of cancer, or age” (p. 403). Fatigue, weakness, pain, shortness of breath, and 
cough were the most prevalent symptoms (2006). In addition, data revealed that the 
symptom experience in the last year of life was significantly associated with site of 
cancer, depression, dependencies in activities of daily living (ADL) and functional 
independence (Doorenbos et al., 2006). The SMCM guided this inquiry, examining the 
person domain (age, sex) (Doorenbos et al., 2006). Characteristics from the health/illness 
domain included depressive symptomatology, site of cancer and ADL and functional 
independence (2006). Insights from this exploration study provide clinicians with a 
greater understanding of the multiplicity of symptoms and related symptom burden, 
throughout the dying trajectory, and as death approaches. With a greater understanding of 
the symptom experience, intervention strategies reflected in the SMCM as the domain of 
symptom management, can be targeted to achieve the desired outcome of the increased 
QOL at end-of-life. A limitation of this study is that while data analysis is pooled from 
three longitudinal descriptive studies, the sample size (n-174) remains small, and limited 
to cancer patients. Most likely increasing the sample size would allow greater 
differentiation between the various cancer diagnoses.
While research among cancer patients is robust, only a few recent studies have 
addressed the symptom management needs of patients with other life-threatening
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diseases, even though these cause three of four deaths in developing countries. Some 
studies suggest that people with noncancer conditions experience a similar degree of 
symptom distress as cancer patients, and would benefit from a more holistic, inclusive, 
and supportive care network (Dudgeon, Kristjanson, Sloan, Lertzman, & Clement, 2001; 
Dudgeon & Lertzman, 1998; Dudgeon, Lertzman, & Askew, 2001; Mancini & Body, 
1999; Soares et al., 2006; Solano et al., 2006; Stromgren et al., 2006; Tranmer et al., 
2003).
For example, recently Solano, Gomes & Higginson (2005) conducted a systematic 
review of medical databases, to determine to what extent patients with progressive 
chronic diseases have similar symptom profiles. The review yielded 64 original studies 
reporting the prevalence of 11 common symptoms among end-stage patients with cancer, 
acquired immunodeficiency syndrome (AIDS), heart disease, chronic obstructive 
pulmonary disease, or renal disease. Data was extracted into a comparative table, where 
analysis revealed the prevalence of 11 symptoms, which were often widely but 
homogeneously spread across the five diseases (2005). Three symptoms—pain, 
breathlessness, and fatigue—were found among more than 50% of patients, for all five 
diseases, which is consistent within the current literature review. There appears to be a 
common pathway toward death for malignant and nonmalignant diseases, which creates 
the need for introduction of palliative care early in the disease trajectory (Solano et al., 
2006).
Although variable evidence is emerging, which recognizes that persons with 
chronic disease experience a large number of symptoms (Tranmer et al., 2003), most of 
these studies have examined the association of a limited number of symptoms, including
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pain, fatigue, and dyspnea, with a single health outcome (Adenaes et al., 2004; Ahlberg et 
al., 2004; Hewitt, Smeeth, Bulpitt, Tulloch, & Fletcher, 2005; Heyland, Rocker, &
Dodek, 2002). Developing a targeted approach to symptom management based on 
evidence, is the best means of addressing this challenge. If symptoms are considered as 
potentially modifiable risk factors for a range of health-related outcomes, strategies could 
be directed to decrease symptoms morbidity and thereby enhance their quality of life 
Walke et al., (2007).
The study done by Walke and colleagues (2007), attempted to determine the 
association of a range of symptoms with quality of life, self-rated health, and functional 
status among chronically-ill, community-dwelling adults (n=226), and to assess methods 
for evaluating the independent associations of symptoms that may be interrelated. Seven 
symptoms (physical discomfort, pain, fatigue, problems with appetite, feelings of 
depression, anxiety, and shortness of breath) were assessed, using the Edmonton 
Symptom Assessment Scale (Bruera et al., 1991), and were examined for their 
association with self-rated quality of life, self-rated health, and functional status (Walke 
et al., 2007).
Principal component analysis and logistic regression revealed similar results. The 
latter demonstrated that physical discomfort was associated with lower self-rated 
health and functional disability. Feelings of depression were associated with 
poorer quality of life, and shortness of breath was associated with lower self-rated 
health. The association between a range of symptoms and quality of life, self- 
rated health, and functional status differed across outcomes, but only three 
symptoms—physical discomfort, feelings of depression, and shortness of
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breath—maintained their associations when multiple symptoms were examined 
concurrently. These findings suggest that interventions targeting these symptoms 
could improve several health-related outcomes (p. 58).
Pain, which has been the focus of much investigation (Arbour, 2000; Bonham, 
2001; Ellershaw, 2001; Feldt, 2004), has also been shown to be associated with poor 
quality of life, low self-rated health and disability. The results of Walke et al., (2007) 
study in contrast, showed that when compared to pain, physical discomfort had a higher 
prevalence and stronger associations with quality of life, self-rated health, and functional 
status. In addition, feelings of depression were associated with poorer quality of life in 
chronically ill adults. Further studies are needed, particularly randomized clinical trials 
(RCTs); clinical controlled trials (CCTs), and intervention studies, to rigorously test 
symptom management strategies to improve the QOL among patients with advanced 
diseases. An overarching goal, would be to prevent frequent hospitalizations for patients 
with advanced, life-limiting diseases, through rigorous symptom management, and 
reduce suffering and mortality among a rapidly, growing number of aging adults 
(Casarett, 2005; Desbiens & Mueller-Rizner, 2000; Desbiens & Wu, 2000).
As noted, evidence continues to suggest that we are not rigorously managing 
patients’ symptoms to reduce pain and suffering in any healthcare setting. Data reflects 
that patients have a high symptom burden in most palliative care settings, and in the acute 
care hospital, where evidence-based therapies are prescribed and available (Paice, Muir 
& Shott, 2004). For example, in a quantitative study (n =134) conducted by Kris & Dodd 
(2004), data showed that hospitalized medical-surgical patients reported multiple 
symptoms (average of 9.3) and had high levels of symptom distress. The most commonly
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reported symptoms in this study included pain (n=242, 74.0%) and dryness of the mouth 
(n=218, 66.5%). The next most commonly reported symptoms appear to be somewhat 
interrelated: lack of energy («= 193, 58.3%), difficulty sleeping (>7=181, 55.4%) and 
feeling drowsy (>7=162, 49.7%) (Kris & Dodd, 2004). Another important aspect of this 
study, interestingly, was that pain was the only symptom that ranked consistently high in 
frequency, severity and distress. While standards issued by the Joint Commission on the 
Accreditation of Healthcare Organizations have required assessment and intervention to 
alleviate pain since 2001, pain management continues to be inadequate (2004). These 
findings suggest poor management of pain, despite available therapies (Kutner et al., 
2006; Tranmer et al., 2003). Most authorities believe that by using medications that are 
readily available, the American health care system has the means at hand to decrease the 
pain and suffering of patients in hospitals and nursing homes. What has been lacking is 
sensitivity to the issue and determination to solve it. The failure of our health care system 
to address pain and suffering seriously is a major ethical issue for our times (Desbiens & 
Wu, 2000). The public and the legal profession are quickly becoming aware of the failure 
of medicine to pay adequate attention to its traditional nemeses—pain and suffering 
(Rocker & Curtis, 2003).
Specific Symptoms
Dyspnea
Dyspnea is a source of distress for 21-70% of dying patients in the days and 
weeks prior to death (Burdon, Pain, Rubinfeld, & Nana, 1994; Desbiens, Riznera, 
Connorsb, & Wengerc, 1997; Desbiens & Wu, 2000; Paice, 2004), particularly in patients 
with advanced cancer. A complex physiological and psychological sensation, its causes
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are often multifactorial, including the underlying disease, cachexia, and deconditioning 
(Bruera, Schmitz B, J., Neumann, & Hanson, 2000; Hall, 2004; Mosenthal & Lee, 2002). 
Dyspnea can be caused by chemical (oxygen and carbon dioxide levels in the blood), 
mechanical (airway obstruction), or emotional (increased anxiety or panic) factors 
(Tanaka, Akechi, Okuyama, Nishiwaki, & Uchitomi, 2002; Tarzian, 2000). Dyspnea 
presents multiple challenges to the clinician, due to its poorly understood 
pathophysiology, subjective nature and lack of correlation between its severity and 
objective measurements such as oxygen saturation and pulmonary function tests. 
Furthermore, multiple psychological, spiritual, social and emotional factors may impact 
the patient’s perception and expression of dyspnea (Bruera et al., 2000; Campbell, 2004; 
Mancini & Body, 1999).
Among critically ill patients, existing literature suggests that dyspnea, anxiety, 
sleep disturbance, depression, and distress due to inability to communicate, are common 
among patients requiring mechanical ventilation, especially for prolonged periods 
(Nelson et al., 2004; Rao & Gray, 2003; Stein-Parbury & McKinley, 2000). Although 
dyspnea during ventilator weaning might be expected, there is evidence that dyspnea may 
also be prevalent when patients are receiving full ventilator support (Knebel, Janson- 
Bjerklie, Malley, & et al, 1994; Nelson et al., 2001). For example, Knebel et al., (1994), 
found that patients ventilated for at least 3 days in an ICU experienced significant levels 
of dyspnea and anxiety during the baseline period of ventilator support, before weaning 
was initiated, as well as during weaning using either intermittent mandatory or pressure 
support ventilation. Several other studies have found that among ICU survivors, 
approximately half who could recall the experience, claimed to have felt anxiety, and/or
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fear while ventilated, and 30% described feelings of agony and/or panic (Curtis &
Patrick, 2001; Desbiens & Wu, 2000; Dudgeon et al., 2001). These symptoms highlight 
the multidimensional nature of dyspnea, and warrant further research.
Despite the fact that dyspnea is the most common and distressing symptom for 
people with cancer and end-stage disease, the evidence base regarding adequate 
management of this symptom remains controversial, compared to pain management 
(Bruera et al., 2000; Desbiens & Wu, 2000). Yet, despite the lack of congruence on 
treatment of dyspnea, there is still robust research available, according to a recent 
evidence-based report on End-of-Life and Outcomes, by the (Agency for Healthcare 
Research and Quality (AHRQ), 2004). For example five systematic reviews were 
identified in the AHRQ report, addressing the topic of dyspnea in the context of end of- 
life care (see Table 4). One of the reviews focused specifically on dyspnea in cancer 
patients, one on patients with COPD, and three on mixed disease. Two additional studies 
were randomized controlled studies, two were qualitative, and one was observational.
The sample sizes ranged from 34 to 207 patients and two of the studies focused 
specifically on dyspnea in a patient population with lung cancer. Interventions included a 
nurse clinical intervention, complementary alternative methods (CAM) provide by an 
APN; home care with a focus on dyspnea treatment, palliative care services, and one with 
an unclear intervention. Four of the five intervention studies, demonstrated beneficial 
results by reducing the symptoms of dyspnea and/or the anxiety associated with dyspnea. 
While these studies generated knowledge regarding various interventions to relieve 
dyspnea among practice settings, only one study (Jennings & et al., 2003) reviewed any 
pharmacologic (opiods) or other interventions to manage acute dyspnea, which is needed
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to relieve the dyspnea patients experience at EOL. Most of the systematic reviews on 
dyspnea lacked inclusion of acute and critically ill patients.
The AHRQ review (2004) also reviewed twenty-seven randomized clinical trials 
(RCTs) / Clinical Controlled Trials (CCTs) on pain and dyspnea. Furthermore, only two 
of the RCTs were in the hospital (non-ICU) setting. According to the recommendations 
by AHRQ to improve EOL outcomes, high-quality studies are needed to characterize 
symptoms at EOL in non-cancer conditions. In addition, because of the lack of scientific 
congruence on the effectiveness of interventions to alleviate dyspnea, larger intervention 
studies are needed, among hospitalized patients, to decrease patient suffering, when death 
is near. Table 4 provides an overview of the key studies on pain, dyspnea, depression and 
anxiety, included in the AHRQ systematic review.
Table 4
Systematic reviews for symptoms: pain, dyspnea, depression /anxiety
Study Symptoms Addressed
Higginson, (Draft). Systematic Review (March 2003 Unpublished) Pain, dyspnea,
depression, anxiety
Booth, S., Anderson, H., Swannick, M., et al. (2004). The use of Dyspnea 
oxygen in the palliation of breathlessness. A report of the expert 
working group of the Scientific Committee of the Association of 
Palliative Medicine. RespirMed., 98(1), 66 -77.
Wilson, K.G., Graham, I.D., Viola, R.A., Chater, S, & Faye de, B.J., Pain
& et al. (2004). Structured interview assessment of symptoms and 
concerns in palliative care. Can J. Psychiatry, 49(6), 350-358
Carr D., Goudas, L., Lawrence, D., et. al. (2002). Management of Pain, Depression
cancer symptoms: pain, depression, and fatigue. Evidence
report/technology assessment No. 61 AHRQ Publication No. 02-
E032. Rockville, MD: Agency for Health Care Research and
Quality.
Jennings, A. L., Davies, A. N., Higgins, J. P., et al. (2002). A Dyspnea
systematic review of the use of opioids in the management of
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Study Symptoms Addressed
dyspnoea. Thorax, 57(11), 939-44.
Salman, G. F., Mosier, M. C., Beasley, B. W., et al. (2003) Dyspnea
Rehabilitation for patients with chronic obstructive pulmonary 
disease: meta-analysis of randomized controlled trials. J Gen Intern 
Med, 18(3), 213-21.
Higginson, I. J., Finlay, I. G., Goodwin, D. M., et al. (2003). Is there Pain
evidence that palliative care teams alter end-of-life experiences of 
patients and their caregivers? J Pain Symptom Management, 25(2),
150-68.
Pan C. X., Morrison, R. S., Ness, J., et al. (2000). Complementary Pain, Dyspnea 
and alternative medicine in the management of pain, dyspnea, and 
nausea and vomiting near the end of life. A systematic review. J Pain 
Symptom Manage, 20(5), 374-87.
While dyspnea is a frequent symptom in patients with advanced cancer, it is also 
highly associated across other chronic diseases, such as chronic obstructive lung disease 
(COPD), and congestive heart failure (CHF) (Barnes et al., 2006; Claessens et al., 2000), 
yet less studied. Furthermore, this is particularly evident in dying patients in the ICUs, 
because often patients/families choose to withdraw mechanical ventilation and other life- 
prolonging therapies; yet despite the fact there are national guidelines for withholding or 
withdrawal of life-sustaining therapies (Truog et al., 2001), patients often experience 
dyspnea and severe anxiety following removal of the breathing tube. Furthermore, little 
research through descriptive studies or RCTs is available, which test interventions such 
as morphine, and other sedative medications to ease the pain and suffering during the 
patients final hours (Clarke et al., 2003; Costello, 2006; Dunn, Otten, & Stephens, 2005; 
Harwood, 2004).
Barnes and colleagues (2006), explored the prevalence and burden of symptoms 
in a community-based sample of patients aged >60 with symptomatic congestive heart
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failure («=542). Compared to previous research into the symptoms of heart failure, other 
studies have mainly relied on retrospective data gathered from hospital records. This 
large, community-based study provided self-reported data as perceived by the subjects, as 
well as perspectives from primary health care professionals (2006). Older people are 
more likely to attribute symptoms such as fatigue and sleeplessness to normal aging 
rather than heart failure. Hence, treatment seeking is delayed until symptoms become 
acute and very distressing (Evangelista, Dracup, & Doering, 2000; Friedman, 1997). 
Findings from Barnes et al. (2006) study indicate high physiological distress 
(breathlessness), fatigue, chest pain, nausea, sleep disruption, and confusion. Symptom 
prevalence and burden was high in this population, with depression being a strong 
predictor of short-term decline in patients with CHF (Barnes et al., 2006).
Another study by (Levenson, McCarthy, Lynn, Davis, & Phillip, 2000), attempted 
to characterize the experiences of patients with CHF, particularly dyspnea, during their 
last 6 months of life. The study design was a retrospective analysis of data from a 
prospective cohort study, which included several data collection points. Out of 1404 
patients enrolled, 539 patients died within one year of their index hospitalization. The 
results of this study showed that EOL with CHF may be marked by increasing symptoms 
and disability for most patients (depending on stage of CHF). For example, a number of 
functional impairments, median depression scores and percent of patients reporting 
severe pain or dyspnea increased as death approached, with 41% of patient surrogates 
reporting that the patient was in severe pain and 63% reporting that the patient was 
severely short of breath during the three days before death (Levenson et al., 2000). 
Perceived quality of life did not change appreciably, with 29 to 58% of patients reporting
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good to excellent quality of life in all intervals before death (2000). The place of death 
for 40% for this cohort was the ICU, where most patients have a high prevalence of 
distressing symptoms related to their progressive disease(s) or sudden life-threatening 
illness. Prospective assessment and more aggressive symptom management in this 
population, will reduce the end-points of a death in the ICU, which is known to be 
associated with physical and psychological distress, and poor QOL (Levenson et al., 
2000; Levy & McBride, 2006).
Symptom Severity /  Pain 
One of the first prospective studies to examine end-of-life care in the United 
States, was the Study to Understand Prognoses and Preferences for Outcomes and Risks 
of Treatment (SUPPORT) (Desbiens et al., 1999). The SUPPORT study evaluated the 
prevalence of pain in cancer and noncancer patient, which included over 9,105 patients, 
in a two phase study, at five teaching hospitals across the country, from 1989-1991 
(Desbiens et al., 1999). The results of this study changed the entire landscape on EOLC 
in America. Findings revealed that 80% of Americans are dying in institutional settings, 
and are receiving end-of-life care incongruent with their wishes (Knaus & Lynn, 1997). 
Moreover, hospitalized patients were found to experience one or more symptoms, such as 
pain, at least moderate to extreme severity, gravely interfering with their quality of life 
(QOL); while 10% of the patients in the study died after spending four weeks in the 
intensive care unit. Worse yet, many patients received mechanical ventilation and life- 
sustaining measures, despite the documentation of patients’ advance directives (Desbiens 
et al., 1999; SUPPPORT & Investigators, 1995; Teno et al., 2000).
The SUPPORT data, revealed that pain is one of the most common, yet
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distressing symptoms in hospitalized patients, as not only does pain interfere with daily 
activities, it causes emotional distress, and decreases overall quality of life. Pain is one of 
the most studied symptom in general, yet patients continue to rate their pain as moderate 
to severe in intensity (Puntillo, 1990; 1997; 2002; 2004). Pain research has been 
examined through patient recollections of the symptom experience, and the effectiveness 
of clinical interventions, yet findings reveal an ongoing, unethical amount of distress and 
suffering among hospitalized patients (Ardery, Titler, Schmitt, Herr, & Sorofman, 2003) 
Carroll, 1999; Feldt, 2004; Niv & Kfeitler, 2001;Yorke, 2004 #22}). Researchers have 
also examined through comprehensive studies, descriptions of pain perceptions, including 
responses to common procedures in critical care, which uncovered a myriad of factors 
that influence the painfulness of common procedures (Arbour, 2000; Carroll et a l, 1999; 
Easley & Elliott, 2001; Gibson & Helme, 2000; Max, 2003; Puntillo, 2001; Puntillo et 
al., 1997; Puntillo, Morris, Thompson, Hutt-Stanik, & White, 2004; Puntillo et al., 2002; 
Steinhauser & et al., 2000; SUPPPORT & Investigators, 1995; van de Leur et al., 2004) 
Pain and symptom management is often the first component identified by patients, 
families, and healthcare professionals as integral to a “good death” (Steinhauser & et al., 
2000). This is illustrated, in a qualitative study by Singer, Martin, & Kelner (1999), who 
used in-depth, open-ended, face-to-face interviews to examine and describe elements of 
quality EOLC from the patient's perspective (Singer, Martin, & Kelner, 1999). A total of 
126 participants from three patient groups: dialysis patients (n = 48), people with human 
immunodeficiency virus infection (n = 40), and residents of a long-term care facility (n = 
38), were included in the study. “Participants identified 5 domains of quality end-of-life 
care: receiving adequate pain and symptom management, avoiding inappropriate
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prolongation of dying, achieving a sense of control, relieving burden, and strengthening 
relationships with loved ones” (p. 163). These findings are extremely important, as they 
characterize important domains of end-of-life care, from a patients' perspective, which 
can serve as focal points for improving the quality of end-of-life care. Yet, unfortunately 
evidence continues to accrue, which reflects we are failing to meet these needs among 
patients with terminal and life-limiting illnesses.
Symptom Assessment /  Role o f  Proxy Reports 
While assessment of symptom distress is most accurate through the perception of 
the patient, this limits our understanding of an individuals dying trajectory, as often 
patients in the final stages of death, often become cognitively impaired, or even lose 
consciousness. Therefore, family members can provide insight into this valuable phase 
across the trajectory of illness and its impact on quality of life. For example, family 
members from the SUPPORT(1995) and Hospitalized Elderly Longitudinal Project 
(HELP) (Teno et al., 2000) studies reported that during the last three days of their lives, 
almost 40% of patients had severe pain, more than 50% of patients had severe dyspnea 
(excluding patients with colon cancer), and approximately 25% of patients had severe 
confusion. These findings illuminate the need to improve the care of people nearing life’s 
end, and as patients lose the ability to provide “self-report” regarding their symptom 
experience, clinicians must seek alternative approaches to gain an integrated symptom 
assessment, by using multiple sources, such as proxy reports (professional/family 
surrogate). In another study, family members reported that 34% of dying patients were in 
moderate to severe pain during the last week of life (Tolle, 2000). More specific data 
from this study demonstrates that more hospitalized patients experienced moderate to
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severe pain during the final week of life (44%), as compared to individuals dying at home 
(34%) or dying in a nursing home (27%). At times, proxies may be the only method to 
gain an estimate of the patients symptom burden, in order to provide the scope of quality 
care that patients and families desire, according to the domains of quality care at EOL 
(Higginson, Priest, & McCarthy, 1994; Kane et al., 2005; Kutner et al., 2006; Lobchuk & 
Degner, 2002; McPherson & Addington-Hall, 2003; McPherson & Hall-Addington,
2004; Nekolaichuk et al., 1999).
Symptom Distress in Critically III Patients 
Among the extant studies available in critical care, Nelson and colleagues (2001) 
found that 55 to 75 percent cancer patients being treated in the ICU, had moderate to 
severe pain, discomfort, anxiety, sleep disturbance or unsatisfied hunger or thirst (Nelson 
et al., 2001). Other studies suggest retrospective patient recall of ICU is often very 
unpleasant and painfully distressing, as noted in the study by (Jones, Griffiths, Humphris, 
& Skirrow, 2001). Jones and colleagues examined prospectively, the relationship 
between memories of ICU and levels of anxiety after ICU discharge, the stability of these 
memories with time, and their relationship to the development of acute posttraumatic 
stress disorder (PTSD)-related symptoms (2001). Results revealed that the only 
predictors of possible acute PTSD-related symptoms at the 8-week assessment were trait 
anxiety (p = .006) and having delusional memories without recall of factual events in the 
ICU at 2 wks (p < .0001) (2001). Only delusional memories were retained over time, 
whereas, the recall of factual events in the ICU declined. The findings here suggest that 
even relatively unpleasant memories for real events during critical illness may give some 
protection from anxiety and the later development of PTSD-related symptoms when
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memories of delusions are prominent. However, more importantly this study illuminates 
that accurate patient recall is present in a number of patients, however, inclusion of proxy 
report, would most likely have provided another dimension of a patient’s symptom 
experience (Nekolaichuk et al., 1999; Nolan, 2005; Oi-Ling et al., 2005).
Although detailed prospective studies of the epidemiology of pain and other 
symptoms in ICUs are limited, it is recognized that multiple symptoms have an impact on 
the quality of life (QOL) for patients in ICUs, approaching end-of-life (Mularski & 
Osbome, 2003). For example, in a study of critically ill post-operative patients by 
(Puntillo, 2002), pain was often times so crippling; it triggered a range of problems that 
included depression, social isolation, disturbed sleep, decreased mobility, falls, difficulty 
in thinking clearly, and loss of appetite. Unfortunately, medical experts agree that at least 
90 to 95 percent of all serious pain can be safely and effectively treated, yet at least half 
of dying patients report being in pain (Puntillo, 2003).
Among ICU patients, there are also other contributing factors, such as the 
advanced technology and treatment modalities, that place these frail patients at the risk of 
undue suffering and pain from multiple sources, aside from their underlying disease state 
(see Table 5). Risks may be related to tissue injury from prolonged immobilization, 
repeated exposure to a wide variety of treatment procedures, continuous instrumentation 
of sensitive tissues and, pre-existing or new pain syndromes associated with surgery, 
trauma, bums, or other medical illnesses such as cancer. Factors such as these could 
indeed serve as an antecedent condition-initiating the mediators of pain and a further 
cascade of physical and psychological distress in critically ill patients, with a cumulative 
impact of chronic illness, and prolonged treatment (Granja, Lopes, Moreira, Dias, &
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Costa-Pereira, 2005; Green, Anderson, & al., 2003; Groeger, Lemeshow, & Price, 1998; 
Klinkenberg et al., 2004; Morrison, Ahronheim, Morrison, Darling, & Shari, 1998; 
Nelson, 2002; Novaes et al., 2001; Puntillo, 2001).
Table 5
Sources o f  Suffering and Stress in the Intensive Care Unit
Underlying diseases/Co-morbidities
• Hematological disorders; respiratory failure, massive hemorrhage, cardiovascular /vascular 
disorders, cancer, gastrointestinal (GI) [hepatic failure; GI bleeding], neurologic 
/neuromuscular, renal; multiple organ failure
Treatments
• Endotracheal/enteric intubation, mechanical ventilation, suction, intravascular/urethral 
catheterizations, arterial blood gases, phlebotomy, mechanical restraints, other procedures
Clinical interventions
• Administration of oral medications, intramuscular/subcutaneous injections, vital signs being 
taken, movement from side to side; or bed to chair, transfer to a procedure by 
stretcher/wheelchair, portable chest x-rays
• Environmental stressors
• Noise, temperature, lights, odors, sleep deprivation, alteration of biological rhythms; fatigue
• Psychological stressors
• Fear, helplessness, depersonalization, isolation, limited visiting, inability to communicate
Adapted from Nelson et al., 2002, with permission.
Recollective studies in patients who had been recently discharged from ICU 
provide insight, regarding various complaints of discomfort, pain and anxiety, which in 
several studies, seem to be the most commonly remembered experiences (Puntillo, 2001; 
Puntillo et al., 1997; Stein-Parbury & McKinley, 2000; Thomas, 2003). Lack of rest, 
placement of the endotracheal tubes, and application of face masks were some of the 
primary events most frequently associated with pain and anxiety. Patients also reported 
that they used eye signals, facial expressions, and hand and leg motions to alert ICU staff 
that they were in pain (Puntillo, 2001; Puntillo, 1990; Puntillo et al., 1997). According to 
(LaDuke, 2002) it is unethical practice not to provide pain management and comfort care, 
which is calculated, purposeful and requires collaboration with patients and families.
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These studies however, further reflect the antithesis of poor quality basic nursing 
care, while patients are being provided advanced treatment modalities. Although pain and 
anxiety are often undertreated in this population because of the difficulties in assessment 
and patient self-report, this further underscores the need for prospective research in 
critically ill patients, to assess the patients perception—including proxy reports—regarding 
the prevalence and severity of all common symptoms, known to occur in seriously ill 
patients at end-of-life (Carter, MacLeod, & McPherson, 2004; Cook et al., 2004; Todd, 
Deaton, & D'Adamo, 2000; Volker, 2003)
Fatigue
Fatigue is one of the most frequently reported symptom in patients with cancer, 
however, recent data suggests that fatigue is also prevalent among patients with chronic 
illnesses, such as COPD, CHF, and Chronic Renal Failure (CRF) at end-of-life (von 
Gunten, 2005). The term fatigue is a subjectively experienced symptom and can be 
described in terms of perceived energy, mental capacity and psychological status 
(Ahlberg et al., 2004). In Sweden, fatigue was studied among sixty women with uterine 
cancer, who were scheduled to receive external radiation therapy. Patients were asked to 
describe their experience of fatigue, psychological distress, coping resources and quality 
of life (Ahlberg et al., 2004). Findings in this study showed that patients experienced a 
low grade of fatigue and psychological distress, but their functional status and global 
QOL was high. Significant correlations were found between general fatigue and anxiety 
and also between general fatigue and depression. There was a significant negative 
correlation between general fatigue and coping resources. Depression explained 44% of 
the variance in general fatigue (2004). Another study on fatigue was done with 910
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cancer patients from five data collection sources (Ferrell, Grant, Dean, Funk & Ly, 1996). 
The results of this large quantitative study revealed fatigue was not just a physical 
symptom, but had an effect on all domains of quality of life.
Delirium
Preservation of the ability to think clearly, and in comfort, is a goal of EOL. 
Delirium is a cognitive disorder characterized by acute onset and impairment in 
perception, cognition, and behavior (Truman, 2004). Traditionally in the ICU, this 
syndrome has been called “ICU psychosis” and has been considered an expected, 
temporary, and minor consequence (Truman, 2004). This point of view has changed in 
recent years, and the Society of Critical Care Medicines (SCCM) 2002 Clinical Practice 
Guidelines, now consider the identification and treatment of delirium an important 
measure of patient comfort in addition to pain control and adequate sedation (Jacobi, 
2002).
Unfortunately, delirium is often misunderstood and underrecognized, particularly 
in patients who are near death. In fact, although up to 80% of patients in the ICU develop 
delirium, it remains unrecognized in 66-84% of patients (Ely, Shintani, Truman, Speroff, 
& Gordon, 2004; Greenberg, 2003). Furthermore, the incidence of delirium is likely to 
increase in the future, as older person with multiple co-morbidities more frequently 
receive aggressive life-prolonging care. According to Ely and colleagues (2004), delirium 
in the acute care setting has repeatedly been associated with prolonged hospital stay (21 
vs 11 days), higher costs ($22,000 vs $13,000 in ICU costs), increased mortality, greater 
dependency of care on discharge, and higher nursing home disposition rates (Ely, 
Shintoni, Bernard, & et al., 2002). Risk factors for delirium in the hospital/ICU setting
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include immobility, medications, iatrogenic events, intercurrent illness, sensory 
deprivation and social isolation (McCusker et al., 2001).
Since delirium often has an emotional component, early delirium may appear to 
be a problem in mood or anxiety (Greenberg, 2003). The patient at EOL has many 
reasons to be fearful, anxious, or sad, so the mood may be attributed to the stress of 
illness. What appears to be anxiety about the situation at first may actually be panic, 
terror, and paranoia. According to Greenberg (2003), “ The ICU patient may have 
fluctuating consciousness and is in a dreamlike state, delusions may be unspoken and 
unrecognized, so the patient may be frightened that what he or she “dreamed” is 
happening” (p. 63).
Approximately half of patients are able to recall the delirious episode (Breitbart, 
Gibson, & Tremblay, 2002). Delirium is an important symptom to assess, particularly in 
patients with a high-severity of illness index. For the patient with pain who is treated at 
EOL, pain relief often requires opiates, yet pain is difficult to assess when the patient 
appears confused, or is moaning and grimacing. All critically ill patients should be 
monitored for delirium as part of the routine assessment. The first step is to assess a 
patient’s level of consciousness/sedation using an objective sedation assessment scale 
(Jacobi, 2002). The Glasgow Coma Scale (GCS) and Richmond Agitation-Sedation Scale 
(RASS) (Ely, 2003; Sessler et al., 2002) are the most common and reliable methods to 
assess for confusion and sedation. The RASS was used to assess patients’ mentation in 
the current study, to assure that those patients receiving sedation medications were awake 
and had capacity to provide informed consent. The RASS was used in conjunction with 
the Confusion Assessment Method for Intensive Care Unit (CAM-ICU), which is the first
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delirium assessment tool designed and validated specifically to measure cognitive status 
in non-verbal ICU patients (Ely, Margolin, Francis, May, & Truman, 2001). The CAM- 
ICU was adapted for use in nonverbal ICU patients from the CAM, a well-validated 
delirium assessment scale that is widely used and is easy to administer (Inouye, van 
Dyck, Alessi, & et al., 1990).
The best way to prevent or reverse delirium at the end-of-life is to regularly 
monitor for cognitive deficits with focused attention to short-term memory loss. Care 
needs to be taken to recognize, and eliminate this very distressing symptom for 
patients/families, and reduce the risk factor for prolonged length of stay and increase 
morbidity and mortality often associated with delirium (Ely et al., 2001; Nowels, Bublitz, 
Kassner, & Kutner, 2002; Truman & Ely, 2003).
Measurement o f Symptoms 
Although substantial progress has been made in the past decade on the 
psychometric measurement of variables central to end-of-life care, demand is intense for 
better indicators of quality of care and quality at end-of-life. The need for valid and 
reliable measures is heightened by the demand to demonstrate objectively, as evidenced 
by the pressure of numerous quality-indicators projects nationally (Tilden, Drach, Tolle, 
Rosenfeld, & Hickman, 2002). A key development in recent years has been the 
recognition that symptoms are multidimensional and that accurate interpretation of 
symptom outcomes hinges on assessment of these dimensions. The measurable 
dimensions of symptoms may include prevalence, severity, frequency, and distress 
(Chang & Ingham, 2003). The impact of each symptom on a variety of family, social, 
financial, spiritual, and existential issues and on global constructs such as quality of life
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(QOL) can be evaluated as another “dimension” of symptoms (Kroenke, Stump, Clark, 
Callahan, & McDonald, 1999).
The problem of symptom assessment is particularly challenging among critically 
ill patients, because impairments of cognition and communication often may preclude 
direct, real time reports from the patients themselves, which is the gold standard of 
symptom information (Nelson & Danis, 2001). No satisfactory “patient-passive” method 
of assessing pain or discomfort has yet been found according to Nelson & Danis (2001) 
and (Tilden et al., 2002). Physical indicators of distress are known to lack sensitivity and 
specificity; distress may be experienced in the absence of such signs, and their presence 
may be the manifestation of another condition. Furthermore, measurement is especially 
intense with elderly persons, where frailty, dementias, and diminished vision and hearing, 
among other factors, affect validity, reliability, and utility of measures (de Rooij & 
Hanna, 2005).
Complex challenges complicate psychometric measurement particularly at EOL 
whether for research or quality improvement. According to (Tilden et al., 2002), some of 
these challenges include “difficulties in defining end-of-life time periods to delineate the 
denominator for statistical analyses; controlling for extraneous influences or other 
interactions on the variability of construct; minimizing subject burden while maximizing 
robustness of a scale; and using proxies as respondents for a patient population that is 
largely incapacitated at the final stage” (p. 71). Research on agreement between patients 
and families have produced conflicting reports (Desbiens & Mueller-Rizner, 2000; 
Engelberg, Patrick, & Curtis, 2005; Nekolaichuk et al., 1999; Oi-Ling et al., 2005). 
Research surrounding agreements between patients and families have primarily been in
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the area of treatment preferences (Fried, Bradley, Towle, & Allore, 2002; Hanson,
Tulsky, & Danis, 1997; Shalowitz, Garrett-Mayer, & Wendler, 2006). In their review of 
the literature, (McPherson & Addington-Hall, 2003) suggest that, while proxies are valid 
reporters for some aspects of the patient’s experience at the end of life, their reports are 
prone to bias, especially in domains concerning a patient’s subjective experiences.
(Steinhauser et al., 2000) have examined attributes of a “good death” using a 
cross-sectional sample of four types of respondents: patients, bereaved family members, 
physicians, and other clinicians. Although they found a number of attributes that were 
defined as important for a good death by all respondents, they examined similarities 
across groups, rather than concordance between paired respondents (2000). For example 
in a study by (Lobchuk & Degner, 2002), patients and caregiver achieved better levels of 
agreement on physical versus psychological symptoms. While the evidence-based is 
growing in the area of surrogate reports, further research is needed to assess the reliability 
of these reports related to their concordance regarding the symptom experience and why 
their accounts might differ from those of the patients (Kutner, Kassner, & Nowels, 2001).
This literature review found no prospective, studies examining the symptom 
experience concurrently with patients and designated proxies, among critically ill patients 
in the ICU. A more comprehensive approach to understanding the multifactorial nature of 
symptoms at the end of life is to take into consideration information from multiple 
sources, including patients, family members and providers (Lobchuk, 2003). The current 
study examined the surrogate assessment of the patients’ symptom experience 
concurrently, probing for congruence of the various rater(s). The symptom assessment 
instrument used for both patient/designated respondent was the Condensed Memorial
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Symptom Assessment Scale (CMSAS) (Chang et al., 2004), which is a valid and reliable 
instrument utilized in cancer patients, and most recently among non-cancer patients with 
critical illness (Nelson et al., 2004).
Measurement bridges the conceptual and operational levels of scientific research, 
clinical care, and quality improvement (Tilden et al., 2002). There is a large array of 
psychometric instruments used in the past ten years to assess single symptoms; and 
multiple symptoms in one or more dimensions, at end-of-life for a variety of populations 
(Portenoy et al., 1994). However, the final choice for an instrument, should be guided by 
the conceptualization of the research variables, and based on the congruence between the 
purpose for which the researcher will use an instrument and the purpose for which the 
instrument was originally developed. Overall, if the setting and the sample of the 
investigation do not match those for which the instrument was developed, the reliability 
and validity of the data collected will be compromised (Frank-Stromborg & Olsen, 2004). 
Hence, this has been one of the noted barriers in the conduct of research among critically 
ill patients, as most symptom instruments were developed specifically to measure the 
multiple aspects of cancer, and the related effect on individuals. It is only until recently, 
that these multi-dimensional instruments have been appropriately adapted and shortened 
to extend their utility in non-cancer patients, particularly for ease of use in chronic and 
critically ill patients (Chang et al., 2004; George, 2002; Tranmer et al., 2003).
A full description and discussion of the extensive array of symptom instruments is 
beyond the scope of this review. However, seven validated instruments which assess a 
broad spectrum of physical and psychological symptoms described widely in the 
literature were reviewed extensively for use in data collection for this study. Table 6
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provides a list of these instruments designed to measure symptom burden and distress in 
cancer and chronically ill patients (eg CHF; COPD; CRF; and AIDS). A full discussion 
of the instruments utilized in this study, including the CMSAS, the primary instrument 
used, to assess the patients’ symptom burden, will be discussed in detail in Chapter 3.















Symptom Assessment Instruments Reviewed for Study
Measure Name
Adapted Symptom Distress Scale-2 
(ASDS-2) (Rhodes et al., 2000; 
Rhodes & Watson, 1987)
Edmonton Assessment Scale 
(ESAS)
The Edmonton symptom assessment 
system, (ESAS): A simple method 
for the assessment o f  palliative care 
patients. (Bruera et al., 1991)
Memorial Symptom Assessment 
(MSAS)
The Memorial Symptom Assessment 
Scale: An instrument for the 
evaluation o f symptom prevalence, 
characteristics and distress.
(Portenoy et al., 1994). Measuring 
the symptom experience o f  seriously 
ill cancer and noncancer hospitalized 
patients near the end o f  life with the 
M SA S.. (Tranmer et al., 2003)
Memorial Symptom Assessment- 
Short Form (CMSAS-SF).
The memorial symptom assessment 
scale short form (MSAS-SF).
(Chang, Hwang, Feuerman, Kasimis, 
& Thaler, 2000)
Instrument B rief Description
Patient Self-Report. Measures 
symptom experience. Modified 
ASDS-1; added symptoms & 
identified subscales. Adapted from 
the McCorkle & Yung Distress 
Scale, 3 1-item, 5-point
Patient Self-Report /Assisted 
Assessment. ESAS consists o f  nine 
100 mm visual analog scales for 
pain, activity, nausea, depression, 
anxiety, drowsiness, appetite, 
shortness o f  breath and sensation o f  
well-being.
Patient Self-Report
MSAS is a multi-dimensional, 32- 
scale which measures prevalence, 
severity and distress for 32 
symptoms or conditions in the last 
week. Validation using the MSAS in 
non-cancer patients comparing to the 
Piper Fatigue Scale. Measures 
symptom experience o f  seriously ill 
cancer & noncancer hospitalized 
patients near the EOL
Patient Self-Report
Patients rated symptom distress 
associated with 26 physical 
symptoms and the frequency o f  4 







Internal consistency (Cronbach’s 3)
N-257(175) oncology, 
82 medical surgical; 
97 healthy volunteers
Construct (convergent/divergent)
Internal consistency was high for the psychological 
subscale (Cronbach’s alpha coefficients o f  0.85 for the 
cancer group and 0.77 for noncancer group and for the 
physical subscale groups, with coefficients ranging 
between 0.78 to 0.87. Sx scores were highly correlated 
with perceptions o f  fatigue.
Content
Construct (factor analysis)
Tested in cancer patients, inpatient and outpatient.
Cronbach’s alpha coefficients for (MSAS-Short Form) 
Subscales range from 0.76 to 0.87, with test-retest 







N=246 cancer in 
patients and 
outpatients
All the MSAS subscales were reliable in the MSAS-SF. 
Cronbach’s alpha coefficient was 0.80 for the GDI, 0.82 
for the physical symptom distress (PHYS), 0.76 for the 
psychologic symptom distress (PSYCH), and 0.87 for the 
CMSAS.
N=299 medical 
oncology; 45 medical 
oncology for test- 
retest
Criterion Validity















Measure Name Instrument B rief Description Validity Testing 
Reliability Data
Sample
subscales o f  the Functional Assessment Cancer Therapy 
(FACT-G) with pairwise. Pearson correlation coefficients.
Correlation coefficients were -0.74 (P < 0.001) for the 
PHYS and FACT-G PWB, -0.68 (P < 0.001) for the 
PSYCH and FACT-G EWB, and -0.70 (P < 0.001) for 
Global Distress Index (GDI) and FACT-G SUMQOL 
score.
Condensed-Memorial Symptom  
Assessment Scale (CMSAS)
Shorter symptom assessment 
instruments: The condensed 
memorial symptom assessment scale 
(CMSAS). (Chang et al., 2004).
Patient Self-Report
Shortened version o f  the MSAS, 
rates nine physical symptoms and 
three emotional symptoms, which 
combine survival and QOL. Three 
sub-scales are physical symptom 
distress (CMSAS PHYS) 10 
questions; psychological distress 
subscale (CMSAS PSYCH) 
worrying, feeling sad, and feeling 




Construct (convergent/ Kamofsky performance scale 
(KPS)




M. D. Anderson Symptom  
Inventory (MDASI) Assessing 
symptom distress in cancer patients.
(Cleeland et al., 2000)
Patient Self-Report
19 Items, Physical and 
Psychological. Measures function, 
symptom presence, severity and 
interference with life
Content
Construct -Physical (factor analysis)
Construct -  Psychological - Convergent/divergent with 
Eastern Cooperative Oncology Group (ECOG) (Grosvenor, 
Bulcavage, & Chlebowski, 1989)
Construct -  Presence/Severity (discriminative)
N=660 cancer out- 
and-inpatients
Rotterdam Symptom Checklist
Measuring psychological and 
physical distress in cancer patients: 
Structure and application o f  the 
Rotterdam symptom checklist, (de 
Haes, van Knippenberg, & Neijt, 
1990; (de Haes, van Knippenberg, & 
Neijt, 1990)
Patient Self-Report
34 -item  instrument designed to 
assess symptom experience o f cancer 
patients.
Content and construct validity have been established.
Cronbach’s alpha for the physical (.71-.88) and 
psychological (,88-.94) subscales support the internal 
consistency o f  subscales




cancer (n = 56); third 
cancer patients under 
treatment, disease-free 
'patients', and 'normal' 
controls (n = 611).
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Research Variables and Related Conceptual Framework 
Managing adverse health symptoms is a core focus of nursing research and 
clinical practice. Symptom management is essential for those with acute and chronic 
health problems for which there may be no cure, for patients who elect a conservative 
therapeutic approach, for patients on wait-lists for organ transplants, and for others whose 
disease has advanced and the risk of complications of more definitive treatments are 
deemed to outweigh possible benefits (Larson et al., 1994; Dodd et al., 2001; Nelson et 
al., 2004). More than one million Americans have chronic health problems and many will 
require treatment and care in ICUs (Wolff et al., 2002). Symptom management addresses 
these experiences to be consistent with the patient-centeredness of critical care nursing: to 
impede or prevent disability, palliate physical and emotional suffering, improve the 
quality of living and dying, involve patients in their care, and uphold the dignity of each 
individual (Carter et al., 2004; Ferrell, Virani, Grant, & Uman, 2000).
Correlates o f the Symptom Experience 
The concept of symptom experience consists of how the patient perceives the 
symptoms, evaluates and responds to symptoms (Larson et al., 1994). In the SMCM, the 
metaparadigm domains of nursing science (person, environment, and health/illness) are 
three, contextual variables that provide a lens which affect how the patient perceives the 
symptoms (Larson et al, 1994; Dodd et al., 2001). Personal variables can be further 
subdivided into demographic, psychological, sociological, and physiological. According 
to Walker and Avant (1995), all of these factors may serve as antecedents conditions 
which may affect the experience of symptoms perceived by patients, and therefore, their 
quality of life (Walker & Avant, 1995). Personal variables can be further divided into
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demographic (age/gender), psychological, sociological, and physiological (disease 
characteristics /comorbidities) all which can be antecedents to the production of the 
symptom experience among critically ill patients with life-threatening illness.
Gender
A number of studies have reported gender differences for specific symptoms and 
total number of symptoms for a wide variety of medical conditions. Yet, a quick review 
of virtually any research topic documents the pervasiveness of sex and gender bias 
throughout all of science. A large portion of both animal and human research has been, 
and continues to be, done primarily with male subjects (NIH Panel Final Statement: 
February 2005). This gender bias influences research results and often leads to 
inappropriate and questionable generalizations of research findings, usually from studies 
done with male participants to females. This bias exists in symptom management 
research on pain, fatigue, and depression in patients with cancer, although, they are 
minimal in number (Miakowski, 2004). Anecdotal studies reviewed, are restricted to 
research on the differences in prevalence rates and severity scores, and for the most part 
have yielded inconsistent results. According to Miakowski (2004) and others (Desbiens et 
al., 1999; O'Neill & Morrow, 2003; Skaug, Eide, & Gulsvik, 2007; Wachterman & 
Sommers, 2006; Walsh et al., 2000), additional investigations are warranted to determine 
whether the gender differences in prevalence rates and severity of these symptoms 
represent clinically meaningful differences among variable conditions, other than cancer.
Nonetheless, a few studies do provide further insight into the gender differences 
among non-cancer conditions. For example, (Bulpitt, Palmer, Battersby, & Fletcher,
1998) found that in diabetic patients, the total number of symptoms were related to body
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mass index, fasting plasma glucose level, and female gender. Furthermore, women and 
less educated patients with diabetes were found to be at greater risk for developing 
depression and anxiety (Goldney, Phillips, Fisher, & Wilson, 2004). More recently, Chen, 
Woods, Wilkie, & Puntillo (2005), conducted a study to compare the symptom 
experiences between men and women with acute coronary syndromes (ACS), among a 
sample of 112 subjects, with a final diagnosis of ACS in four hospitals. (Chen, Woods, 
Wilkie, & Puntillo, 2005) found that after adjusting for cardiac diagnosis, diabetes, and 
age, women were more likely than men to experience chest discomfort rather than chest 
pain; pain/discomfort only in areas of the body other than the chest; pain/discomfort that 
started first either in the arm(s) or in areas of the body other than the chest; and 
unexplained anxiety. In addition, women were less likely than men to experience chest 
pain/discomfort, pain/discomfort in the left side of the chest, and chest pain/discomfort as 
the most worrisome symptom. Significant gender differences were observed in the 
reports of several symptoms associated with ACS. This study is the first to identify 
different pain/discomfort referral patterns between men and women that require further 
validation (Chen et al., 2005). Further research in this area is needed, as heart disease in 
women has become a major health issues, unrecognized by providers and patients 
themselves.
Further studies regarding gender differences are particularly important, among 
critically ill patients, since scant studies exist, which address gender differences. Findings 
will guide the design of studies to elucidate the underlying mechanisms for these 
differences, as well as the development and testing of gender specific interventions to the 
array of symptoms known to occur in patients with variable diagnoses such as heart
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disease, COPD, chronic renal failure (CRF), liver disease and diabetes.
Age
Research on the relationship between age and symptoms has not yielded steady 
findings. Older age has been associated with specific symptoms and higher symptom 
scores in some studies (Hamel, Davis, Teno, Knaus, & Lynn, 1999; Wood & Ely, 2003). 
These variables are particularly crucial in critically ill patients, especially age for 
example, since the mean age of ICU patients is around > 80 years old (Chelluri, 2001; 
Chelluri & Grenvik, 1995). Since the elderly do not have the physiologic reserves of all 
organ function as younger individuals, with stress whether it be secondary injury or acute 
illness, the older patient cannot respond well to the increased needs because of decreased 
reserve.
A specific search of the literature was conducted to examine the symptom 
experience and risk of mortality with increased age (see Table 7), since current studies 
glean inconsistent results. In fact, some studies suggest that functional status prior to the 
illness, dementia, severity of acute illness, may have a greater influence on mortality 
during the ICU stay, and after discharge than age (Ellershaw, 2001; Hamel et al., 1999). 
Nonetheless, the relationship to age to long-term mortality is not well studied (Chelluri, 
2001; Nelson, 2002).
In the current research study, gender and age were independent variables and 
may be considered antecedent factors that influence the patients’ perception of their 
symptom experience and distress. These variables were recorded on the principal 
investigator’s (Pis) demographic log, and included with the descriptive analysis.
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Table 7








97 ICU patients Prospective 65-74 years (n = Age itself was not an adequate predictor
chart 43) and >75 o f  long-term survival and quality o f life,











Prospective > 70 years 
cohort study
ICU mortality was 31% and 6-month 
mortality was 52%; outcome predictors 
were shock on admission and previous 
health status
(Cohen & 14,848 ICU Retrospectiv >18 years In-hospital mortality, in patients
Lambrinos, patients on MV e cohort receiving mechanical ventilation aged
1995) study >85 years, was 70% versus 32% in
patients aged <29 years
(Dewar, Kurek, 37,573 patients Retrospectiv > 1 8  years Inverse relation between age and
Lambrinos, on prolonged e database survival; older survivors were often
Cohen, & MV analysis discharged to residential health care
Zhong, 1999) facilities
(Ely, Evans, & 300 ICU Prospective <75 years versus No difference in duration o f mechanical
Haponik, 1999) patients cohort study >75 years ventilation
(Montuclard et 75 ICU patients Prospective > 70 years ICU mortality was 60% in elderly
al., 2000) cohort study patients receiving ICU treatment
(Ely etal.,  902 Patients Prospective <70 years (n =  Patients aged 70 years and older were
2002) with acute lung cohort study 729) and >70 twice as likely to die than were younger
injury or ARDS years (n = 173) patients, and had greater difficulty
















18-100 years The adjusted odds o f  death increased 
with each 5-year age increment
(Djaiani & 474 ICU Prospective >70 years
Ridley, 1997) patients cohort study
The 1-year survival o f  patients aged 
<85 years was 56%, which was 
significantly better than that o f patients 
aged >85 years (27%)
(Bo et al., 2003) 659 Medical Prospective > 65 years
ICU patients cohort study
Independent predictors o f  mortality 
were functional dependence & 
cognitive impairment before admission, 
high APACHE II score & low body













> 65 years (n = 
206) and <65 
years (n =  159)
Severity o f acute illness and chronic co­
morbidities, but not age, were 
predictors o f medical ICU and hospital 
mortality in elderly ventilated patients








Mean age 65 
years
Long-term mortality rate was associated 
with old age and poor pre­
hospitalization functional status





>70 years (n = 
1612)
Patients older than 70 years had higher 
in-hospital mortality (55%) but similar 
duration o f  mechanical ventilation & 









>80 years Long-term survival after ICU stay was 
mainly related to the underlying 












>75 years (n = 
M l )
Mortality in elderly patients was higher 
than in younger patients; importantly 
risk factors were severity o f  illness, 
impaired level o f  consciousness and 
infection.
*MV = mechanical ventilation
Among the other domains of nursing science that relate to the SMCM, is the 
division o f  the environment, which refers to the aggregate of conditions or the context 
within which a symptom occurs, such as: physical, social, ethnic, and cultural variables 
(Dodd et al, 2001). The physical environment may encompass work, home and hospital. 
Within the physical environment of the ICU (see Table 5), studies support that patients 
have increased pain and discomfort related to the environment and other extraneous 
sources (Kwekkeboom & Herr, 2001; Lasch, 2000; Morrison et al., 1998; Nelson et al., 
2004), which in turn increases their perception of symptom distress. The social context 
includes one’s social support network and interpersonal relationships. While there is only 
scant data available regarding the relationship of symptom distress and social support, a 
recent study by (Kris & Dodd, 2004) found that patients who were partnered had
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significantly lower levels of symptom distress (M=l .71, STM).81), than those who were 
not partnered with (M=1.87, SD=0.84). Further assessment of the role of social support is 
needed, particularly because the ICU is an extremely stressful and frightening experience, 
and patients often report feeling lonely and isolated (Desbiens et al., 1999; Nelson et al., 
2001; Tranmer et al., 2003).
Chronic Health (Comorbidities)
The final category among the symptom management model is the health and 
illness domain, which is comprised of variables unique to the health or illness state of an 
individual, and includes risk factors, health status, and signs of illness, disease or injury 
(Larson et al, 1994). Functional status, including physical, cognitive and social 
functioning, has also been shown to be an important predictor of the hospital outcomes, 
particularly in older patients (Klinkenberg et al., 2004; Knight, 2000; Patrick, Kinne, 
Engelberg, & Pearlman, 2000; Walke et al., 2007; Wu, 1995).
In the current study, the patients ’ health status was deduced through the Acute 
Physiology and Chronic Health Evaluation (APACHE) III Scores and through patient and 
surrogate reports, using the Condensed Memorial Symptom Assessment Scale. Health 
data was obtained from patient/surrogates perception, based on the symptom assessment 
on the CMSAS collected on day one of admission, which requires patients to rate the 
prevalence and distress of various symptoms experienced in the previous seven days, 
prior to hospital admission. Additionally, the patients’ medical record was reviewed for 
any additional health problems or risk factors, which may not have been entered into the 
APACHE III prognostic system. This data was recorded on the principal investigator’s 
(Pis) demographic log, and entered into the data management system for the study.
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Symptom Evaluation /Assessment
The evaluation of symptoms reflects factors which patients evaluate and 
characterize the symptom experience and include its intensity, location, temporal nature, 
frequency, the associated pattern of disability, and an evaluation of the threat posed by a 
symptom (Armstrong, 2003). Responses to symptoms include physiological, 
psychological, and behavioral components (Larson et al., 1994; Dodd et al., 2001).
In the current study, the three components o f  the symptom experience was 
assessed using the CMSAS, which is a modified, shortened version of the Memorial 
Symptom Assessment Scale, which is a validated, multidimensional symptom instrument 
that captures patient rated severity, frequency, and distress associated with 32 highly 
prevalent symptoms (Portenoy et al., 1994). The shortened version is the CMSAS, 
developed by (Chang et al., 2004; Chang et al., 2000; Chang et al., 2004), which rates 
eleven physical symptoms in terms of frequency from 0 (not present) to 4 (almost 
constant). The prevalence of symptoms is determined by the patient’s identification of the 
presence or absence of symptoms. The evaluation of prevalence, intensity, and distress 
are assessed to characterize the symptom distress and overall experience.
Symptom Distress
Symptoms are multidimensional in nature and include the dimensions of duration, 
severity or intensity, frequency, and associated distress. Although symptom distress is not 
directly referred to in the SMCM, it can be inferred indirectly as the awareness by the 
individual of the extent of the physical or mental suffering, discomfort or bother reported 
by individuals, in relation to their perception to a symptom occurrence. The degree of 
symptom distress perceived by an individual is an influential factor that determines the
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initiation, continuation, or discontinuation of the actions intended to bring relief or 
prevent the symptoms (Fu, Lemone, & McDaniel, 2004; Rhodes & Watson, 1987).
According to (Carlet et al., 2004; Chang et al., 1998) symptom distress has effect 
on the quality of life and survival. Factors noted to influence an individual’s perception 
of symptom distress are age, gender, culture, family role, education, health knowledge, 
type of treatment, values, beliefs and past experiences (Abraham et al., 2006; Hickman et 
al., 2001; Kutner et al., 2006; Oi-Ling et al., 2005; Rhodes et al., 2000).
Researchers in the field of oncology nursing have continued to produce the major 
body of work in the area of symptom distress, although, there is no congruence regarding 
conceptual definitions of distress among the extant literature. Table 8 illuminates the 
wide interpretation and operationalization of distress in the literature.
Table 8
Operationalization o f  Symptom Distress in the Literature
Operationalization of Symptom Distress Source
Bother is equal to distress and distinct from pain (Johnson, 1973)
intensity
Distress is synonymous with discomfort. Distress from McCorkle, 1987; (McCorkle &
treatment and disease are similar. Distress is equal to the Young, 1978)
intensity and frequency of symptoms
Distress is physical or mental upset, anguish, or (Rhodes et al., 2000; Rhodes &
suffering. Distress and frequency of occurrence are two Watson, 1987)
fundamental symptom attributes.
Distress, intensity, and frequency are three fundamental (Portenoy et al., 1994)
symptom attributes.
Distress is equal to bother and one of four symptom (Lenz et al., 1997; Lenz, Suppe,
attributes (the others are quality, timing, and intensity. Gift, Pugh, & Milligan, 1995)
Distress equals symptom interference with life activities (Cleeland et al., 2000)
or emotional upset.
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Operationalization of Symptom Distress Source
Distress is psychological, emotional, social, or spiritual (National Comprehensive Cancer
concern caused by physical symptoms or other sources. Network., 2004)
McCorkle and Young (1978) were the first to attempt development of an 
instrument to measure symptom distress in oncology patients receiving chemotherapy 
and/or radiation therapy looking at the effects on the gastrointestinal system such as 
nausea, vomiting and retching and later in myocardial patients (Dodd et al., 2001; Dodd, 
Miaskowski, & Lee, 2004). Quality of life also is a measure of symptom management. 
Research findings show that an increase in the number and distress of symptoms is 
associated with decreased quality of life (Adenaes et al., 2004; Ahlberg et al., 2004; 
Chang, Hwang, Feuerman, & Kasimis, 2000; Chang et al., 1998; Granja et al., 2005; 
Kassa, 2000; Mitchella & Kempa, 2000; Wennman-Larsen, Tishelman, Wengstrom, & 
Gustavsson, 2007).
Using the CMSAS instrument, the degree of distress was measured by the mean 
total of the Physiologic (CMSAS-PHYS) and Psychologic (CMSAS-PSYCH) sub-scales. 
A CMSAS-SUM sub scale is the calculated average of all symptoms (physiologic / 
psychologic). The CMSAS-SUM sub-scale is considered to be a measure o f  overall 
symptom distress and is correlated to quality o f life (Chang et al., 2000).
Symptom Management 
Symptom management is an important component of nursing practice across care 
settings, client populations, and types of practice, and begins with the assessment of the 
symptom experience from the patient’s perspective (Larson et al., 1994). This is followed 
by the identification of focused interventions, along with actual implementation of 
interventions, and concludes with the evaluation of outcomes and the symptom
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management process itself. The goal of symptom management is to avoid or delay a 
negative outcome through biomedical, provider and self-care strategies. In the SMCM 
model, symptom management strategies can be initiated by patients, family members, 
providers, and the larger health care system.
The overarching goal of this current research was to determine the symptom 
burden reported by patients in ICU, understand the value of the meaning of that 
experience, and gain insight into the possible correlates among patient variables 
(antecedents and consequences), that may mediate the level of symptom distress by the 
patient. In this study, socio-demographic variables (>age/gender), chronic health status, 
APACHE III Score, functional outcomes (death) or (discharge) are all considered 
potential correlates of the symptom experience. Ultimately, findings from this study will 
lead to a greater understanding of the multi-faceted nature of the symptom experience 
and lay the framework to guide more comprehensive assessments among critical care 
patients who are actively dying in the ICU. Data will also be used to develop and test 
interventions through clinical trials, in order to affect the overall symptom occurrence, 
distress and quality of life in critically ill patients.
Outcomes o f Symptom Management 
Symptom status is considered the primary outcome of interest when examining 
the effects of symptom management strategies. The concept of symptom outcomes 
includes eight components of the patient’s biopsychosocial status: morbidity & co­
morbidity, and mortality outcomes functional status, emotional status, self-care ability; 
financial status; and QOL (Larsen et al., 1994).
In the present study, the primary outcomes o f  interest were the symptom
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experience and symptom status and its relationship to patient outcome (eg LOS, 
mortality). A patient’s health status, or severity of illness, is considered as the most 
influential patient characteristic related to length of hospital stay while age, gender, race, 
and type of insurance have also shown to be correlates of lengthy of stay (Bamato et al., 
2004; Garland, Shaman, Baron, & Connors, 2006; Yolker, 2005; Wood & Marik, 2004). 
Determining the severity of (co-morbidities) and (mortality) outcomes were addressed in 
the present study by extraction of clinical variables from the APACHE III Prognostic 
System (note background on the APACHE III Systems is discussed separately). Upon 
admission to the ICU, all patient data is entered into the APACHE III national data set, 
which calculates the severity of illness score (Acute Physiologic is based on four groups 
(age, co-morbidities, physiologic abnormalities, and acute diagnosis). The APACHE III 
Prognostic Model provided risk stratification for severely ill hospitalized patients; along 
with risk estimates for hospital mortality (Knaus et al, 1991), which is calculated using a 
logistic regression equation that estimates the risk of death. Mortality was evaluated at 
three time intervals, during hospitalization, at 30-days post-discharge; and at 3-months.
Mortality Outcome Prediction Models 
Acute Physiology and Chronic Health Evaluation (APACHE III) Prognostic System
The high-complexity features of ICU services and the clinical situation of patients 
themselves render correct prognosis fundamentally important not just for, their families 
and physicians, but also for hospital administrators, fund-providers and controllers. 
Although it is difficult to predict how long a patient will live, estimating prognosis is an 
important component of effective EOL discussions, both with patients and their families, 
and is essential for planning of care. Prognostic scoring systems such as the Acute
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Physiology and Chronic Health Evaluation (APACHE III) System, the Mortality 
Prediction Model II (MPMII) and the Simplified Acute Physiology Score (SAPS II), 
were developed to estimate the probability of hospital mortality rates for adult ICU 
admissions (Knaus, Wagner, Draper, Zimmerman, & Bergner, 1991; Le Gall, Lemeshow, 
& Saulnier, 1993; Lemeshow & Le Gall, 1994). In general, these systems are based on 
logistic regression models that use a set of clinical and physiological variables-evaluated 
and registered on admission or on the first day of intensive care-to predict hospital 
mortality (Rocker, 2004). These models differ considerably in the number and types of 
variables used, as well as the time frame for data collection. For example, the APACHE 
III system consists of two options: 1) an APACHE III Acute Physiologic Score (APS), 
which can provide initial risk stratification for severely ill hospitalized patients within 
independently defined patient groups. This is based on 17 physiological variables, age, 
and chronic health status and; 2) the predictive APACHE III equation which uses the 
APS, using a series of predicted equations, linked to ICU admission diagnosis, patient 
selection criteria, and the APACHE III database (Pronovost et al., 2004).
Developers of the models have used either a theoretical approach or an empirical 
approach in deciding which physiologic variables and constructs to include in their 
models. The theoretical approach involves the selection and weighing of variables based 
on past studies and expert opinion; the developers of the APACHE I-IV use this approach 
(Knaus et al., 1991; Knaus, Wagner, Zimmerman, & Draper, 1993; Zimmerman et al., 
2006). The empirical approach of the MPM II and SAPS II involves collecting 
information on groups of patients and then contrasting the physiologic patterns of 
survivors and non-survivors (Arabi, Shirawi, Memish, Venkatesh, & Al-Shimemeri,
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2003; Le Gall et al., 1993). Multiple regression techniques are used to reduce a large 
number of potential outcome predictors to a smaller set. The APACHE system, 
constructed in 1981 is the most familiar (Arabi et al., 2003; Knaus et al., 1991; Le Gall et 
al., 1993), and has undergone four revisions, most recently by (Zimmerman et al., 2006).
The usefulness of predictive models that estimates prognosis has been an 
important dimension of critical care, as patients and their families seek a prediction of 
duration and outcome of illness ((Markgraf, Deutschinoff, Pienka, Scholten, & Lorenz,
2001); Nelson & Danis, 2001). Historically, prognostication has been based on data 
obtained from studies of risk factors (smoking, age, diet, activity, and current disease), 
complications of diseases, and experience of a physician (Langendoen-Faber & Lanken, 
2000). The result is a subjective prediction that may not be sensitive to an individual’s 
severity of illness. Health care reform initiatives are being put in place to control costs, as 
it is estimated that end-of- life care consumes 10% to 12% of all healthcare costs and 
27% of Medicare cost (Moran, 2003) The number of those enrolled in Medicare will 
grow considerably in the next 20 years, raising concerns of the costs to provide care to 
the increasing elderly population (Arabi, Venkatesh, Haddad, Shimemeri, & Malik,
2002). Similarly, predicting resource use is important to hospital administrators and ICU 
directors who manage critical care services with limited resources and budgets (Tilden et 
al, 2002). Mortality prediction models can supply knowledge that provides an empirical 
basis for quality assurance and utilization services, and serve as one of many indices in 
making decisions at end of life, to assure the quality of the patients’ death in the ICU.
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Symptom Assessment and the APACHE III Model
The APACHE III Predictive Model is the most widely used system, particularly 
among academic affiliated medical centers, which value the ability to objectively 
estimate patient risk for mortality or other important outcomes, such as clinical research. 
The APACHE IV Model is currently being released and hospitals are gradually migrating 
to updated model, to have greater discrimination and calibration, which will be useful for 
benchmarking performance in the U.S. ICUs (Zimmerman et al., 2004).
The clinical site used for data collection for this study, utilized the APACHE III 
prognostic system, which currently provides 95% confidence intervals for the day of ICU 
admission, with updated predictions for subsequent ICU days (Zimmerman, Wagner, 
Draper, Wright, & Alzola, 1998). The purpose of this study did not include predicting 
mortality, whereas, the APACHE III Score and risk of death prediction (r), served as a 
clinical reference point to identify patients for study enrollment, who were at high-risk 
for death, as well as it will generated data daily, to measure the independent variables 
delineated.
Utilization of the UCSF (SMCM) is a goodness-of-fit model to help illuminate the 
symptom experience (occurrence, intensity, timing, distress level, and quality of 
symptoms) as a framework for this study (Dodd et al., 2001). The demographic data, 
physiologic factors, psychological factors, and situational factors all are potential 
correlates to the patient’s symptom burden and end-of-life experience in the ICU (2001). 
These factors overlap and affect the patient and family. Physiological derangements are 
reflected in, and may be diagnosed by the presence of unpleasant symptoms. The aspects
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of physiologic factors may be related to body function, pathology, trauma or surgery 
(Lenz et al., 1997). Physiological factors are measured and weighed by prognostication 
models and are used to predict mortality. Critical care nurses and other members of the 
ICU team need to monitor and treat derangements to promote the wellbeing of the patient 
with aggressive care in the ICU and if needed, facilitate an early transition from 
aggressive curative care to palliative care.
The psychological component o f  the SMCM  includes the individual’s mental state, 
reaction to illness, and degree of uncertainty and knowledge about the symptoms and 
their meanings (Larson et al, 1994; Dodd et al, 2001). Nurses must be aware of the 
psychological component in the ICU. Nelson and Danis (2001) show that the patient and 
family desire accurate prognostication of outcomes. They also acknowledge that the 
patient and family will have mood changes, feelings of anger and loss of control. To help 
the patient and family feel empowered the nurse, along with the entire health care team, 
must include the patient and/or family in decisions made about treatment with clear 
options, including the patient’s preference (Steinhauser et al., 2000). Situational factors 
include aspects of the social and physical environment that may affect the individual’s 
experience. Potentially relevant social situational considerations include employment 
status, marital and family status, social support and access to health care resources, and 
lifestyle behaviors. In a study of dying patients in the ICU, patients and families voiced 
the need for preparation of wills, obituaries, and funeral services. Death affects a wide 
social network, thus it’s important for the ICU patient to receive religious offerings of 
their choice, reflect and conduct a life review, and be around family and friends in the 
time of death (Steinhauser et al., 2000).
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The average daily cost in the ICU is about $3,000/day (Garland et al., 2006). Data 
from the SUPPORT study (1995), report that 20% of families had to quit work or make 
major life changes. One third of reported a loss of most or all of the family savings, 
especially in younger, poor, or functionally dependent ICU patients (Curtis, Cook, Wall, 
Angus, & Bion, 2006). Critical care nurses must be aware of how physiologic, 
psychological, and situational factors overlap to provide optimal care for the patient and 
family in the ICU. Clinical research is needed to stratify improved utilization of the 
prognostic severity-of-illness systems, to include outcomes other than survival, e.g., 
functional outcomes and quality of life.
Limitations o f  Logistic Regression Models
Mortality prediction models based on linear regression have limitations 
(Clermont, 2002). According to Clermont and colleagues, a logistic function does not 
accommodate nonlinear relationships between predictor and outcome variables. Second, 
important interactions between predictor variables may be present. These interactions 
may complicate interpreting the odds ratio and require an explanation of their presence. 
Third, these models cannot directly accommodate missing data, and finally Clermont 
states these models require large samples to model outcomes with a large number of 
predictor variables (Clermont et al., 2002).
Gaps in the Literature/Future o f  Prognostication
A shortcoming in this literature review regarding prognostic models is that no 
articles were used from nursing specific journals. The journals providing the greatest 
amount of information were: Chest, Journal of American Medical Association (JAMA), 
and Critical Care Medicine. This demonstrates the need for nursing to take a leadership
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role in research and the development of comprehensive EOL care planning in ICUs. 
Advanced Practice Nurses have the background and knowledge to participate in such 
planning when utilized in the intensive care unit. Rosenberg (2002) posits that a potential 
use of prognostication models is using them to detect the overall response to a treatment 
and the expected benefits gained by using a certain strategy.
Nursing Implications
Mortality prediction models can serve as a useful tool for the nurses in the ICU 
setting. Modeling draws on the experience of several thousand patients, and may be 
helpful in sorting patients out by providing objective estimates of the risk of death for the 
patient. Prediction models also provide objective estimates of survival, and can prove 
useful in understanding the likely outcome of a patient and be useful in staffing 
appropriate number of nurses, and triaging patient care. Prediction tools also help reduce 
errors stemming from bias and overestimating or underestimating the importance of a 
variable. However, continued research is needed, to explicate the value of predictive 
models and patient indicators, in order to guide clinicians to provide the highest quality 
end-of-life care, for those patients at risk for hospital death.
Chapter Summary
A comprehensive analysis of the empirical literature relevant to the symptom 
burden and degree of distress among patients with terminal and critical illness was 
presented. The research literature was critiqued on the variables pertinent to this study, 
which include patient characteristics (age, gender, ethnicity), antecedent conditions, co­
morbidities, and severity of illness, which may be correlates associated with the 
perceived symptom experience of patients with life-threatening illness, in ICUs. Results
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of this review revealed a robust amount of research among terminally ill cancer patients, 
who are continuously burdened by distressing symptoms at end-of-life. However, with 
respect to other life-limiting illnesses, such as CHF, COPD, ESRD and elderly patients 
admitted with sepsis research is scant. Moreover, with respect to ICUs, where mortality 
among patients with and without underlying malignancy is typically high, research 
related to symptom prevalence and management remains surprisingly limited. Existing 
anecdotal evidence suggests that the ICU can be a difficult and painful place to die. The 
present study contributes to the knowledge base of symptom management by 
documenting the relationship that exists between specific physiologic (disease severity 
and pre-morbid conditions), and situational/demographic (age, gender), factors, including 
increased ICU length of stay, and overall symptom burden in patients who have high 
rates of mortality.
This research is also one of the first to examine the multidimensional nature of 
symptoms reported in real-time by critically ill patients, which also included a concurrent 
symptom assessment of a designated family respondent (proxy), regarding the patients 
symptom burden. Study findings reveal a high level of symptom burden and distress 
among critically ill patients, which is known to be associated with decreased quality of 
life (Bowman et al., 2000; Chang & Ingham, 2003; Clarke et al., 2003). Factors 
associated with diminished QOL among critically ill patients/families were also identified 
in the current study. Findings will be helpful to guide future interventions to improve 
symptom relief (physiological and psychological) and other strategies to improve the 
lives of patients with advanced diseases.
Finally, this study ultimately, responds to an appeal from the National Institutes of
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Health (NIH); National Institute of Nursing Research (NINR), and findings from the 
1997 publication of the Institute of Medicine report “Approach Death: Improving Care at 
the End of Life, to increase activities and research to improve the quality of care and the 
quality of life at the EOL for seriously ill and dying people (National Institutes of Health, 
1999; NIH Panel Final Statement: February 2005; Steinhauser et al., 2000; Teno et al.,
1999).
Accepting this challenge, this investigation seeks to characterize the symptom 
experience of critically ill patients/families, in order to improve the scientific gaps noted 
in this literature review, which will also help further to identify future directions in 
research related to the domains central to end-of-life care, among critically ill patient and 
their families.
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Chapter 3 
Methodology
The purpose of this study was to explore the symptom burden at end-of-life in 
patients with terminal and life-threatening illness in ICUs; and to examine the 
relationships among variables related to the patient (age, gender, physiologic acuity, 
previous health status), symptom distress, and overall mortality. This chapter outlines the 
research design, methods, and procedures applied in this study. The sample, settings, 
power computation, data, statistical analysis, limitations and ethical considerations are 
also described.
Design
A descriptive, correlational repeated measure design was used in this study to 
explore the following research questions:
1. What is the perceived symptom burden (prevalence, intensity, frequency) 
and overall distress, as reported by critically ill ICU patients at high-risk 
for dying?
A. Is there a relationship between age and gender in the reported 
symptom burden (prevalence, intensity, frequency), and overall
distress experienced by subjects?
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2. What is the incidence of other sources (treatments / procedures) of pain 
and the degree of discomfort, reported by patients during their ICU stay?
3. What is the relationship between demographic characteristics, antecedent 
conditions, symptom distress and overall predicted hospital mortality 
experienced by critically ill subjects?
4. What is the relationship between overall symptom burden and distress 
(CMSAS PHYS/PSYCH and CMSAS SUM Subscale Scores) and patient 
mortality?
5. Is there concordance between critically-ill patient-rated symptom 
prevalence, intensity and distress scores, with those rated by designated 
surrogate responders, using the Condensed Memorial Symptom 
Assessment Survey (CMSAS)?
This design provided several scientific benefits, such as helping to understand the 
relationship between the variables of interest in an attempt to identify key variables for 
the future development and evaluation of targeted interventions. This design also 
permitted the recruitment of a wide variety of patients with varying ages and disease 
severity, resulting in a description of the symptom burden of a diverse and 
underrepresented population of patients during their dying trajectory. It was the intent of 
this study to provide a real-time snapshot of the symptom experience among terminal and 
critically ill patients.
Sample and Sampling
A nonprobability convenience sampling method was used to screen/enroll 
participants. A convenience sample was drawn from all adult patients admitted,
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consecutively to the ICUs, at a university-affiliated, tertiary-care, urban medical center, 
from January, 2006 -  December 2006.
Eligibility Criteria
Inclusion criteria included (1)18 years or older, (2) ability to speak, read and 
understand English or Spanish, (3) ability to complete self-report instrument by written or 
alternative method (e.g. if questionnaire read to patient by Primary Investigator [PI), (4) 
considered to have normal mental status, assessed by the Richmond Agitation-Sedation 
Scale (RASS ) and the Confusion Assessment Method for the ICU (CAMU-ICU) and, (5) 
probability factor of 60-80 % risk for hospital death, using the first 24-hour APACHE 
III predicted mortality score.
Exclusion Criteria
Patients were excluded from study enrollment if: (1) diagnosis of cancer and 
receiving related treatments; (2) patients with a principal diagnosis of dementia with 
altered cognitive status; or (3) patients with altered level of consciousness.
Recruitment
The study hospital has 3 ICUs which vary in size from 15 beds to 35 beds each, 
with an average daily occupancy ranging from 85 to 98%, and an average nurse ratio of 
1:1 approximately 85% of the nursing time. On a monthly basis, approximately 197 to 
240 patients are admitted with a mix of trauma, surgical and medical diagnoses. To help 
recruit patients for the current study, the nurses, attending physicians, residents were all 
provided with a study brochure and pocket guide. These were also posted in the ICU and 
in the family waiting room, to inform patients/families regarding the study opportunity. 
Interested patients/and families could contact the principal investigator (PI) by signing
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the recruitment flyer and giving their phone number on how to contact them to discuss 
potential eligibility for the study, or they could call the PI directly on the phone 
number(s) listed on the brochure. Each ICU had a symptom study “box” in a visible 
location for placement of referrals.
The physicians/and nurses assisted as much as possible in the screening for 
potential study subjects during daily ICU rounds, by discussing briefly the purpose of the 
study with potential subjects. If the patients expressed an interest in learning more about 
the study, the PI was then introduced to the patient/and family to discuss the purpose of 
the research and study information. Because eligible subjects needed to be screened and 
interviewed within 24 hours of admission/and upon availability of the patient’s first 24- 
hour APACHE III risk mortality score, it was necessary to obtain a Health Insurance 
Portability and Accountability Act (HIPPA) Waiver (Appendix K) thru the Institutional 
Review Board (IRB). This allowed the PI to review the daily census sheets and APACHE 
III scores within the prognostic system, for each newly admitted patient, to boost study 
enrollment and to assure adherence to the study protocol.
Following a patient’s stated interest in being a volunteer for the study, the 
investigator then reviewed each patient’s record for inclusion eligibility. Patients were 
then provided informed consent, and those who wished to participate signed two consent 
forms.
Sample Size
To determine the minimum sample size required for this study, it was necessary to 
select the desired power and effect size. Cohen (1987) recommended a power of .80 for 
behavioral sciences and behavioral science research generally utilizes a moderate effect
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size (.50). Munroe (2005) suggests that effect size should be based upon previous studies, 
if possible. There were six variables in this study: 1) gender, 2) age, 3) chronic health 
state (co-morbid conditions), 4) admission source, 5) outcomes [LOS; ICU mortality (%); 
hospital LOS / hospital mortality (%), and 6) severity of illness (odds ratio-death) 
[APACHE III predicted mortality risk (.60-.80) for hospital death and the APS Score 
[physiology; age and chronic health] for risk stratification. Thus, for the purposes of this 
research, computations were based on a 0.05 level of significance with a moderate effect 
size (.50) and an estimate power of .80 (80%) to yield a sample size of 127 SOLO Power 
Analysis Software, (Hintze, 1991).
Procedures and Measurement 
Definition o f Terms
The following section provides the conceptual and operational definitions for key 
terms used in this research.
Antecedent Condition
Conceptual definition: (Walker & Avant, 1995) define antecedents as the events 
or incidents that occur prior to the occurrence of a concept. Antecedents affecting the 
experience of symptoms include gender, age, ethnicity, disease characteristics such as 
type and stage; type of treatment; co-morbid medical and clinical conditions; individual 
characteristics (health knowledge, values, past experiences, and sense of coherence) 
(Dodd et al., 2001; Dodd, Miaskowski, & Paul, 2001; Ferris, von Gunten, & Emanuel, 
2002; Rhodes & Watson, 1987; Walker & Avant, 1995).
Operational definition: Antecedent conditions identified above, will be measured 
by looking at the occurrence of the departure, beyond normal function, as calculated by
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the APACHE III score, generated by the Acute Physiology and Chronic Health 
Evaluation Prognostic System. The APACHE III score is based on 17 potential 
physiologic variables, age, and chronic health status, and through logistic regression, the 
APACHE III Score is generated from the national data base.
Acute Physiology and Chronic Health Evaluation (APACHE) III Model
Conceptual definition: (APACHE) III is an outcome prediction model, which 
provides predictions of risk of hospital or ICU mortality. The APACHE III consists of 
two options: (1) an APACHE III score, which can provide initial risk stratification for 
severely ill hospitalized patients within independently defined patient groups; and (2) an 
APACHE III predictive equation, which uses APACHE III score and reference data on 
major disease categories and treatment location immediately prior to ICU admission to 
provide risk estimates for hospital mortality for individual ICU patients (Knaus et al., 
1991).
Operational definition: To produce an equation for predicting hospital mortality 
after the first day of ICU treatment, the model will combine the disease and patient 
location coefficients with the relative weights assigned to the first day values of the three 
groups of variables of the APACHE III score (physiology, age, chronic health). The 
APACHE III score is a cardinal number with scores that range from (0 to 299) described 
above (Knaus et al., 1991). The final acute physiology score (APS score is determined by 
adding the weights for the individual variables to determine the APS. The APS is then 
placed into an equation that includes variables and coefficients for age, chronic health 
conditions, pre-ICU length, location admitted from, reason for ICU admission, and 
whether the patient had emergency surgery or not to determine the predicted risk of
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mortality. Risk estimates for death are calculated on the patient’s initial data, and 
thereafter, reflected by the patients’ response to treatment.
Risk Estimates Equations for Hospital Mortality: An equation combining the 
explanatory power of the APACHE III score with major disease category and prior 
patient location permits the calculation of hospital death risk estimates for ICU patients 
(Knaus et al., 1991). The explanatory power of estimates calculated from the data 
obtained during the first day of ICU admission is demonstrated by the (total r =0.41 and 
Receiver Operator Characteristics [ROC] of 0.90). The explanatory power of the 
APACHE III compares well to the previous versions of APACHE I, II. Overall 
classification on the first day at a 0.50 predicted risk was 88.2 percent in the validation 
study for improving the risk stratification for APACHE III (Knaus et al., 1991). The 
current study used a 0.60 predicted risk of hospital death, as the indices to consider 
subjects for enrollment into this study.
Arousal and Agitation
Conceptual definition: Distress is common among critically ill patients, 
particularly if  they are intubated or unable to communicate easily with their caregivers. 
Patient distress may result in untoward physiologic changes, including increases in 
sympathetic tone, protein catabolism, and plasma levels of circulating catecholamines. 
Critical physiologic changes can also lead to neurohormonal changes and imbalances, 
causing aagitation and delirium. Agitation refers to an unpleasant state of extreme 
arousal, increased tension, and irritability. Extreme agitation can lead to confusion, 
hyperactivity, hostility and injury to self. Agitation can come on suddenly or gradually. It 
can last for just a few minutes or for weeks and even months. Pain, stress, and fever can
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all increase agitation. Agitation by itself may not have much clinical significance; but, if 
viewed with other symptoms, it can be a good indicator of a acute disease state (Ely et al, 
2001).
Arousal can be further defined as hyperactivity, or a state of excessive muscular 
activity. Sedative medications are widely used in intensive care units, to treat agitated 
behavior and relax patients so they may benefit more efficaciously from advanced 
treatments, such as endotracheal tubes and prolonged mechanical ventilation, along with 
other invasive therapies. Structured assessment of sedation and agitation is necessary to 
titrate sedative medications and evaluate agitated behaviors.
Operational definition: Arousal is measured using the Richmond Agitation- 
Sedation Scale (RASS), which is a 10-point scale, with four levels of anxiety or agitation 
(+1 to +4) [combative], one level to describe a calm and alert state (0), and five levels of 
sedation (-1 to -5) culminating in unarousable (-5). The RASS is a reliable and valid 
sedation tool to assess the routine arousal and agitation level of intensive care patients 
receiving sedative medication (Sessler et al., 2002). RASS is also used in the assessment 
of delirium in critically ill patients. The RASS will be used as a baseline, prior to 
completing the CAM-ICU for delirium and cognitive assessment.
Cognitive Impairment
Conceptual definition: Cognition comprises perception, memory and thinking, the 
recognition, registration, storage, and use of information processing. The loss of the 
ability to take care of one’s daily living needs due to a deficiency in the ability to think, 
perceive, reason or remember is referred to as cognitive impairment. Altered thought 
processes with cognitive impairment can be manifested as confusion/delirium or
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simultaneous disturbances in consciousness, attention, perception, memory, thinking, 
orientation, and psychomotor behavior that develop abruptly and fluctuate diumally 
(Truman & Ely, 2003).
Concordance
Conceptual definition: Concordance is defined as the patient and family 
surrogate/caregiver giving the exact same answer to a question on the symptom 
assessment instrument (CMSAS).
Death
Conceptual definition: “A widely accepted statement defines death for legal 
purposes as the irreversible cessation of circulatory and respiratory function or the 
irreversible cessation of all functions of the entire brain, including the brain stem” (Field 
& Cassel, 1997, p.27).
Operational definition: Actual death during ICU stay or at (30-day Outcome) 
end-point, will be compared with APACHE III predicted death score (Graham & Cook, 
2004) for potential correlation to symptom burden.
Delirium
Conceptual definition: Delirium is defined as an acute, reversible organic mental 
syndrome, characterized by the rapid onset with disorder of attention and cognitive 
function, increased or decreased psychomotor activity, and a disordered sleep-wake 
cycle. The essential features of delirium include disturbances of consciousness, attention, 
cognition, and perception. The disturbance develops over a short period of time (usually 
hours to days) and tends to fluctuate during the course of the day (Roberts, 2001). 
According to the fourth edition of the Diagnostic and Statistical Manual of Mental
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 83
Disorders (DSM-IV), the essential feature of a delirium is a disturbance in consciousness 
that is accompanied by a change in cognition that cannot be better accounted for by a 
preexisting or evolving dementia (American Psychologic Association, 1994).
Operational definition: In order for patients to consent for participation in the 
study, the patient’s neurologic status will be assessed for acute delirium and alterations in 
cognitive function. Delirium is measured using the Confusion Assessment Method for the 
ICU (CAM-ICU), which is a behavioral assessment scale. The CAM-ICU has four 
questions (features), and delirium is considered present if there is the presence of acute 
onset of changes or fluctuation in the course of the mental status (feature 1) and 
inattention (feature 2) and either disorganized thinking (feature 3) or an altered level of 
consciousness (feature 4) (Ely et al., 2001; Truman & Ely, 2003).
Dying
Conceptual definition: Dying is not a precise medical or diagnostic term. It is 
difficult to predict exactly when a person is within six months of death (Copp, 1998). For 
the purpose of this study, dying refers to those within days or months of death 
(unexpected & anticipated). Risk for dying will be assessed using the APACHE III 
predicted mortality score of > (0.60) risk for hospital death.
Dying Trajectories
Conceptual definition: A trajectory is essentially the time course of care needs 
and patient experiences from the onset of serious illness to the end of life (Teno et al., 
2001). Currently, clinicians are embracing the concept of “dying trajectories”, as being 
more useful in designing reliable and effective care arrangements surrounding end of life, 
than strategies that rely upon diagnoses, procedures, or settings of care. Lunney and
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colleagues (2003), builds the case for a relatively small set of trajectories that could 
warrant separate planning for care needs. They propose one trajectory for a short course 
of rapidly progressive disability in the last two months of life (often seen with solid 
cancers), one for a longer course of slow decline with intermittent life-threatening 
exacerbations and usually a sudden death (often seen with chronic lung or heart failure), 
and one for a very long course of slow decline with self-care disability arising from 
dementia or frailty (Lunney, Lynn, & Foley, 2003).
Family
A family is defined as a basic human social system that involves commitment and 
interaction between its members. Current definitions of families have been expanded to 
include those that are biologically related, and those who are not, but are living as a 
unified family unit. The family commitment includes a responsibility for the physical and 
emotional well-being and successful development of the children in that family. A 
healthy family is not necessarily a family where all members are at optimal health. A 
healthy family is one that can successfully adapt to crises, challenges, and changes during 
the life cycle. The role of the nurse is to help families adapt to these changes across the 
life-span (Leifer & Harston, 2004).
Palliative Care
Conceptual definition: The World Health Organization defines palliative care as 
the active total care of patients whose disease is not responsive to curative treatment, 
including control of pain, other symptoms, and psychological, social, and spiritual 
problems (WHO, 1998).
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Quality o f  Life (QOL)
Conceptual definition: Quality of life is defined as ‘the gap between the 
expectations and the present situation of the individual (Lynn, 1997).
Conceptual definition: According to Rhodes & Watson (1987), signs are 
described as alterations ascertained by the sense of the observer and symptoms as 
changes in the functions of the parts affected.
Symptoms
Conceptual definition: “A symptom is defined as a subjective experience 
reflecting changes in the biopsychosocial functioning, sensations, or cognition of an 
individual. Change in normal functioning as experienced and verified “ Dodd et al., 2001, 
p.669).
Symptom Burden
Conceptual definition: According to (Haubrich, 1997), a symptom is the 
subjective evidence of disease or physical disturbance observed by a patient. Self- 
perceived symptom burden (one-six symptoms) is described as “a multidimensional 
constmct arising from the patients’ subjective interpretation of the prevalence of physical 
and psychological distress. Symptoms can be the subjective expression of the disease 
itself, or the products of disease treatment (e.g. life-prolonging therapies, such as 
mechanical ventilation), or a patients response may be side effects and toxicities. 
Symptom burden can be thought o f as the subjective counterpart o f  summary expressions 
o f disease such as tumor burden.
Patients typically experience multiple concurrent symptoms, due either to the 
disease or its treatment, thus, it is proposed that a measure of symptom burden be a
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summative indicator of: 1) The severity of the symptoms that are most associated with a 
disease or treatment 2) A summary of the patient’s perception of the impact of these 
symptoms on daily living, including activity, mood, ability to work, and ability to relate 
to others (Cleeland & Reyes-Gibby, 2002).
Operational definition: Symptom burden is correlated with quality of life (QOL), 
and many QOL measures (Functional Assessment of Cancer Therapy [FACT]) (Celia, et 
al., &, 1993); Symptom Distress Scale (McCorkle & Young, 1978); Rotterdam Symptom 
Checklist (de Haes et al., 1990); Memorial Symptom Assessment Scale (Portenoy et al., 
1994); and CMSAS (Chang et al., 2004), have components that measure symptoms and 
their related severity. Symptom severity is a strong predictor of scores on QOL measures, 
suggesting the potential of symptom- burden measures as an immediate indicator of 
deteriorating quality of life. The current study utilized the CMSAS instrument, which is 
correlated to quality of life in the validation studies, and is evidenced by the increased 
score > 1 on the CMSAS-PSYCH and CMSAS-SUM Subscales.
Symptom Experience
Conceptual definition: The symptom experience is dynamic, and involves the 
interactions between three components: the patient’s perception (frequency, intensity, 
distress) and evaluation of the meaning and response to symptoms (Dodd et al., 2001). 
The perception of symptoms refers to an individual conscious recognition of perceived 
changes in the way one usually feels or behaves and can be conceived as an individual’s 
identification of symptoms.
Operational definition: The occurrence of a departure from normal function as 
measured on a symptom scale which lists 11 physiologic symptoms and 3 psychologic
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symptoms, rated present (Yes) or not present (No), rated on the Condensed Memorial 
Symptom Assessment Scale (CMSAS) (Chan et al. 2004). The mean is calculated for the 
number of symptoms, the most commonly reported symptoms, degree of distress and 
frequency.
Symptom Frequency
Conceptual definition: Frequency refers to how often a symptom occurs as 
perceived by the patient (Dodd & et al., 2001).
Operational definition: The frequency of a departure from normal function as 
measured on a scale from zero for N, 1 (a little bit) to 4 (very much) = “almost 
constantly.” Symptom frequency will be measured using the CMSAS psychological 
symptoms (worrying, feeling sad, feeling nervous) (Chan et al., 2004). Means for each 
symptom and frequencies will be calculated.
Symptom Distress
Conceptual definition: The extent of physical or mental suffering attributed to the 
attributed to the occurrence of a symptom (Dodd et al., 2001).
Operational definition: The distress rating is derived from nine physiologic 
symptoms, and is comprised of the following: (lack of energy, lack of appetite, pain, dry 
mouth, weight loss, feeling drowsy, shortness of breath, difficulty sleeping and difficulty 
concentrating). The symptoms are given a rating of 0 if symptom not present, 0.8 if it 
was present, but caused no distress, 1.6 for a little bit, 2.4 if symptom present and caused 
Somewhat of distress, 3.2 if symptom present and caused quite a bit of distress, and 4.0 if 
symptom present and caused very much distress. A mean symptom distress among the 
sample of patients will be calculated using the nine-items from the physiological
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symptoms (Chang, Hwang, & Feuerman, 2000; Chang et al., 2004).
Symptom Severity
Conceptual definition: The dimensions of a symptom that refers to the strength, 
and is often associated with timing (duration and frequency)
Operational definition: Symptom severity on the CMSAS is measured in one- 
dimension (CMSAS-PHYS), unlike the three-dimensions captured on the original MS AS 
32-Item instrument (Portenoy et al., 1994). The CMSAS symptom severity is measured 
on of overall symptom distress of nine-weighted symptoms (Chang et al., 2000; Chang et 
al., 2004).
Physiological Symptom Distress (PHYS)
Conceptual definition: The CMSAS has a total of eleven physical symptoms 
which are ranked by the patient to specify the frequency and degree of bother or distress 
(intensity) of each physical symptom. The physical (PHYS) symptoms are rated by the 
patient, summed and averaged, to produce a (PHYS) subscale score. The CMSAS-PHYS 
score indicates the degree of suffering or distress associated with the patients perception 
the intensity and occurrence (Kris & Dodd, 2004).
Operational definition: The (CMSAS-PHYS) subscale average is derived from
the distress rating of nine (*) physiologic symptoms, comprised of the following: (lack of
!
energy, lack of appetite, pain, dry mouth, weight loss, feeling drowsy, shortness of 
breath, difficulty sleeping and difficulty concentrating (Chang et al., 2004; Chang et al.,
2000).The physical symptoms are given a rating of 0 if symptom not present, 0.8 if it 
was present, but caused no distress, 1.6 for a little bit, 2.4 if symptom present and caused 
Somewhat of distress, 3.2 if symptom present and caused quite a bit of distress, and 4.0 if
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symptom present and caused very much distress.
Psychological Symptom Distress (PSYCH)
Conceptual definition: The CMSAS has three psychologic symptoms, which may 
be marker for predicting quality of life and decreased survival in patients with terminal 
diseases (Chang et al., 1998; Desbiens & Wu, 2000; Feldt, Ryden, & Miles, 1998; 
Hwang, Chang, & Fairclough, 2003; Rushton, 2004; Truog, Cist, & Brackett, 2001). The 
patient rates the frequency of each psychological symptom, and a CMSAS-PSYCH 
subscale score is derived by determining the average frequency rating associated with 3 
psychological symptoms (Chang et al., 2000; Chang et al., 2004).
Operational definition: The CMSAS-PSYCH subscale average is derived from 
the average frequency rating associated with 3 psychological symptoms (worrying, 
feeling sad, feeling nervous). The psychological symptoms are given a rating on a scale 
from zero for N, 1 (a little bit) to 4 (very much) = “almost constantly.”
Measurement
Instruments were selected based on their brevity and simplicity of use, as well as 
their conceptualizations and psychometric properties. The relationship between the 
conceptual framework, instruments, and their timing of administration is presented in 
Table 9. The schedule of instrument administration was chosen after consideration of the 
following factors: (a) respondent burden (b) frequency required to gain a temporal trend 
of perceived symptom burden during ICU care (c) projected survival of the patients.
Instrument Translation 
Collecting accurate health data on the growing number of ethnic minorities in the 
United States has increased in policy relevance in recent years. Hence, a number of valid
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and reliable instruments used in the general population, require translation into Spanish 
and often other languages as well. The technique of translation-backtranslation, was used 
to translate the survey used in this study into Spanish, (versions for patient and family), 
attempting to achieve an equivalent version of the instrument that is culturally 
appropriate. The translation procedure attempted to achieve: translation equivalence 
(translation process should be appropriate) linguistic equivalence (each item retains same 
meaning) conceptual equivalence (instrument measures the same concept in different 
cultures) and lastly measurement equivalence (similar scores on instrument mean the 
same thing) (Hambleton & Patsula, 1998).
Efforts were made to select appropriate, yet varied translators, in order to assure 
that the final survey instrument(s) were culturally appropriate for Latinos in the United 
States. The forward translation of the instrument(s) for this study was done by two 
Mexican Americans, with Spanish as their first language. The reverse-translation was 
then conducted by two other Mexican Americans with English as their first language. All 
translators held certification credentials. The back-translation process produced Spanish- 
language versions of the survey instruments that were adequate for least educated 
respondents, to assure that all study participants were able to understand and respond to 
survey items accurately. In the future, researchers may also be required to modify the 
English versions of instruments as well as subjecting Spanish-language instruments to 
more rigorous testing that includes cognitive testing, pretesting, and an evaluation of the 
reading level by a literacy expert (Hambleton & Patsula, 1998)
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Instrumentation
Investigator Demographic Data Log
Demographic information was collected through chart review, and included the 
following: age, sex, and ethnicity of each patient; insurance, diagnosis, admission 
location, specific treatments (mechanical ventilation; medications, particularly analgesics 
and sedatives that may alter the patients’ level of consciousness or sedation level). The 
APACHE III Acute Physiologic Score (APS) and Predicted Mortality (r) for hospital 
death, was extracted from the APACHE III data system daily, as this was a key indices 
for enrollment into the study. Demographics and APACHE III data were recorded on the 
investigator’s data log, along with any other pertinent anecdotal notes (Appendix A). 
Acute Physiology and Chronic Health Evaluation Prognostic Model (APACHE III)
On a daily basis, the APACHE nurse generated a unit report with APACHE Data 
for each patient. This form was used to screen all ICU patients by examining the severity 
of illness, using the APS Score and APACHE III predicted mortality risk (r) (Knaus et 
al., 1991). If patients had a > .60% mortality risk in the first 24 hours, they were 
considered for study enrollment. APACHE III Scores were recorded and monitored on 
Day-1-Day-3.
Richmond Agitation-Sedation Scale (RASS)
To assess for evidence of mental confusion, agitation and any signs of cognitive 
impairment, the RASS and the Confusion Assessment Method for ICU (CAM-ICU) 
instruments were used, as noted on the diagnostic algorithm (Appendix B). The RASS is a 
10-point scale, with four levels of anxiety or agitation (+1 to +4) [combative], one level 
to describe a calm and alert state (0), and 5 levels of sedation (-1 to -5) culminating in 
unarousable (-5). It was chosen for its completeness, ease of use, and psychometric
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properties. The RASS is a reliable and valid sedation tool to assess the routine arousal 
and agitation level of intensive care patients, who may be receiving sedative medication 
(Sessler et al., 2002).
The RASS was tested for validity an d interrater reliability in two phases. Phase 1 
demonstrated excellent (r = 0.956, lower 90% confidence limit-0.948; a-0.73, 95% 
confidence interval = 0.71, 0.75) inter-rater reliability among five investigators. Robust 
inter-rater reliability (r = 0.922-0.983) (a = 0.64-0.83). In validity testing, the RASS 
highly correlated (r-0.93) with a visual analog scale anchored by “combative” and 
“unresponsive”. Correlations between the RASS and the Ramsay Sedation Scale 
(r = 0.78) and the Sedation Agitation Scale (r = 0.78) supported validity (Ely, 2003; 
Sessler et al., 2002). The RASS and CAM-ICU was used prior to each data collection 
point.
Confusion Assessment Method-Intensive Care Unit (CAM-ICU)
The CAM-ICU is a well validated, behavior observation scale used for the 
assessment of delirium or acute mental status changes in special populations such as ICU 
patients, or difficult populations (e.g., non-verbal patients, patients with dementia 
>65years old, and patients with very high severity of illness (Truman & Ely, 2003). 
CAM-ICU was tested using a total of 471 daily paired evaluations. Study nurses, an 
intensivist who used the CAM-ICU were compared to reference standard, a delirium 
expert who used DSM-IV delirium criteria. Strong interrater reliability for CAM-ICU 
ratings with kappa statistics of 0.84 to 0.79 and 0.95 respectively (p <.001). Two nurses 
and the intensivist reference standard was 95%, 96%, and 100% respectively (Ely et al.,
2001). The CAM-ICU was designed to be a serial assessment tool for use by bedside
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clinicians (nurses and physicians). Thus, it is easy to use; it takes only 2 minutes to 
complete and requires minimal training.
The CAM-ICU assessment was considered positive if patients demonstrated an 
acute change or fluctuation in the course of their mental status, plus inattention and either 
disorganized thinking or an altered level of consciousness (LOC) (Ely et al., 2001; Ely et 
al., 2004; Truman & Ely, 2003). The RASS and CAM-ICU were available in English and 
Spanish, depending upon patient language preference.
Symptom Assessment Instruments
Condensed Memorial Symptom Assessment Scale (CMSAS
The CMSAS is a shortened version of the Memorial Symptom Assessment Sale 
(MSAS), which is a valid cancer instrument which assesses multiple dimensions 
(severity, frequency, and distress) of 32 physical and emotional symptoms (Portenoy, 
Thaler, Komblith, Lepore, & Friedlander-Klar, 1994). The CMSAS rates eleven physical 
symptoms in terms of distress from 0 (none) to 4 (very much), and three emotional 
symptoms in terms of frequency from 0 (not present) to 4 (almost constant) (Chang et al., 
(2004). In the first description of the reliability and validity of the original MSAS, 
Portenoy (1994) observed that assessment of a shortened list of symptoms provided a 
valid measure of overall symptom distress. The CMSAS was developed by (Chang et al., 
2004) by combining items and dimensions that, in the longer instrument’s (MSAS) 
validation study, showed the strongest association to quality of life and survival. The 
CMSAS was modified so that at the bottom of the form, patients had the option to 
describe the prevalence and rate the severity of any symptoms they perceived to bother 
them, which weren’t listed on the survey
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Validation o f  the CMSAS. In order to test for the total amount of symptoms 
needed to measure quality of life to validate the CMSAS, Chang and colleagues (2000) 
performed canonical correlation analyses, which identified a five-dimensional QOL 
factor structure. Symptoms important for QOL also correlated significantly with survival 
and provided the basis for the CMSAS with 14 symptoms and 3-subscales The Global 
Distress Index (GDI), the physical symptom distress score (PHYS), and the 
psychological distress score (PSYCH). In multivariate analyses, the CMSAS PSYCH 
predicted survival independently of stage of disease (Chang et al., 2004). Reliability, 
Cronbach’s alpha coefficient was 0.82 for CMSAS PHYS, 0.72 for CMSAS PSYCH, and 
0.85 for CMSAS SUM (global distress). The mean CMSAS PHYS was 1.13 (range, 0- 
3.36) standard deviation (SD) 0.86. Mean CMSAS PSYCH was 0.83 (range, 0-4, SD 
0.97); and mean CMSAS SUM was 1.04 (range, 0-23, SD 0.77).
The importance of the symptoms identified in Chang’s study is strengthened by 
the fact that they have also appeared in other widely used clinical symptom assessment 
instruments, such as the Edmonton Symptom Assessment Scale (Bruera et al., 1991), 
Rotterdam Symptom Checklist (de Haes et al., 1990) and the Symptom Distress Scale 
(McCorkle &Young, 1978). The utility of the CMSAS use has been extended to patients, 
with non-cancer conditions, whereas, studies have shown a high symptom burden at EOL 
among these populations (Abraham et al., 2006; Chang et al., 2000; Kris & Dodd, 2004; 
Kutner et al., 2006; Kutner et al., 2001; Nelson, 2002)
The advantages of the CMSAS is that it captures distress and frequency 
dimensions of the symptom experience, and includes symptoms and dimensions that have 
been correlated to quality of life. In this study, separate reliabilities were computed for
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the CMSAS physical subscale, CMSAS psychological subscale, and CMSAS global scale 
for the patient and family member on both days 1 and 3. The reliabilities for the patient 
CMSAS physical subscale on day 1 and day 3 were .76 and .43 respectively. The 
reliabilities for the patient CMSAS psychological subscale on day 1 and day 3 were .73 
and .70 respectively. The reliabilities for the patient CMSAS global scale on day 1 and 
day 3 were .82 and .60 respectively. The reliabilities for the family member CMSAS 
physical subscale on day 1 and day 3 were .75 and .54 respectively. The reliabilities for 
the family member CMSAS psychological subscale on day 1 and day 3 were .77 and .75 
respectively. The reliabilities for the family member CMSAS global scale on day 1 and 
day 3 were .82 and .70 respectively.
Treatment & Procedure Survey (TPS)
In the ICU, there are many necessary treatments and procedures performed on 
patients, to help monitor and improve their condition. The aim of this study was to 
identify the symptom burden in critically ill patients, which included asking patients to 
quantify how painful or bothersome the various treatments or procedures they have 
received during their care. This instrument was adapted from a recent study, which 
examined symptom burden in Chronic Critically 111 Patients in a step-down respiratory 
unit, using the CMSAS and a procedure survey to associate frequently performed 
procedures and patient pain (Nelson et al., 2001). This data will help us plan comfort 
measures prior to procedures and evaluate efficacy vs burden of treatment intervention 
(see Appendix D).
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Family Respondent Instruments
Family Demographic Form: Family respondents were asked to complete this 
demographic form, which included broad information such as: relationship to patient; 
age; ethnicity; religion and whether they were primary care providers for the patient. 
CMSAS- Family Respondent Survey
Family respondents completed the CMSAS symptom survey, which was modified 
to state “Which of these symptoms bothered your loved ones in the last seven days” and 
“Which of these symptoms bothered your loved ones in the past two days”. Data points 
are day 1 and day 3 of the patients ICU stay. Families also had the option to write down 
and rate the severity of any symptoms they perceived to bother the patient. The utility of 
the CMSAS has been recently used to advance the understanding of the relationships 
among proxy and patient reports of symptom distress and quality of life (Kutner et al., 
2006; Lobchuk & Degner, 2002; Lobchuk, 2003; Lobchuk & Degner, 2002) The 
CMSAS-Family Respondent form was available in English/Spanish, depending on 
surrogate preference.
Data Collection Procedure 
The data collection procedures are presented in Table 9. Once the subject agreed 
to participate, a preliminary mental status examination was conducted to detect gross 
cognitive abnormalities and capacity, and the ability to verbalize or complete the written 
questionnaire. Written informed consent was obtained (Appendix I) from the patient in 
the presence of a witness. If patients’ family or significant other was present, the study 
was explained to them, and they were invited to participate in the study at that time.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 97
Surrogate informed consent and completion of a demographic questionnaire and study 
instrument, were done in another location away from the patient to minimize potential 
bias during patient assessment. Study instruments were available in English or Spanish, 
depending on subject preference.
Patients were given specific directions on how to use the CMSAS form to rate 
their symptom experience. If patients were awake and alert, but unable to verbalize 
secondary to (intubation/tubes); or were unable to record answers on the data form 
because of intravenous and monitoring lines or soft restraints on wrists, the investigator 
read the study questions and rating scale options to patients. Many patients were alert but 
non-verbal, yet were able to respond by head nods, eye blinking, holding up fingers, or 
squeezing the researcher hand in response to the question(s).
There were several methods of data collection used for this prospective study. An 
investigator developed demographic (Appendix A), RASS and CAM-ICU, (Appendix B). 
Patient instruments included the symptom assessment survey, the Condensed Form of the 
MSAS (CMSAS) (Appendix E) (day 1, 3), and the Treatment and Procedure Survey 
(TPS) (day 3) (Appendix D). Family respondents (FR) completed a FR demographic 
form (day 1) (Appendix C); and the CMSAS-FR version (day 1, 3) (Appendix G).
Data Collection Points
Time 1 Data Point
Within the first 24-hours of admission, patients were asked to complete the 
symptom assessment instrument, to quantify their perception of their symptoms in the 
previous 7-days. The first 24-hour APACHE III Physiologic Score and Predicted 
Mortality (r) for hospital death, was retrieved from the APACHE data system. Predicted
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mortality risk(s) are calculated initially within 24-hours and every 12-hours, thereafter, as 
long as the patient remains in the ICU.
Table 9
Data Collection Procedure /  Study Variables /  Data Source







Sociodemographic Factors (IVs) Rpsparplipr
Variables* (2) (*age, gender) Race, 




* * RASS /IV
Pre-screen patient for sedation
level (Sedation/Pain Medications)
Cognitive Status-Assess for
* * IV / CAM-ICU;
capacity GCS Scale
Delirium Evaluation
Glasgow Coma Scale (GCS)
Clinical Variables (IV)
* D B -A PA C H E  III




ER, OR, hospital ward, ICUs, other
hospitals* (1)
Severity of Illness (IV) (APACHE
* * D B -A PA C H E  III
III Predicted Mortality >.60% Risk; MR
and Acute Physiologic Score *(1)
Outcomes (IV) (1)
* * M R / D B - MR/for
Hospital (LOS) / % Mortality; APACHE III IPDC
ICU LOS / % Mortality
Mortality (Outcome) Predicted /
* * MR * check hospital MR / 30-Day
Observed (DV) for IPDC / IPEXP Outcome /
ICU / Hospital Death (IPEXP) and 3-months
Symptom Burden (DV) CMSAS
Assess, o f Symptoms (14) -Items
* * Questionnaire
• Symptom prevalence * * CMSAS
• Symptom intensity * * CMSAS
• Frequency/Distress * *
Symptom Burden (DV)
* TP S/I V
ICU Sources o f  Pain & Suffering
IV = Independent variable; DV =  Dependent variable; IPEXP= Inpatient Expiration; IPDC= Inpatient discharge (alive 
at discharge).
Data sources are: medical record abstraction (MR); interview o f  patients, surrogates and staff (I/V); and existing 
databases (DB). APACHE III-APS = Acute Physiologic Score o f APACHE III severity o f illness scoring system 
(Knaus et al., 1991); CAM-ICU = Confusion Assessment Method for the Intensive Care Unit (Ely et al., 2001; Truman
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 99
& Ely, 2003); CMSAS= Condensed Memorial Symptom Assessment Scale (Chang et al., 2004); RASS =Richmond 
Agitation and Sedation Scale (Sessler et al., 2002); TPS = Treatment and Procedure Survey (Nelson et al., 2001).
Time 2 Data Point
Subjects were approached two days later (day 3) of ICU care, and assessed for 
changes in their condition and capacity. If no cognitive deficits were noted on CAM-ICU, 
patients completed the same instrument (CMSAS), which measured their perception of 
symptom burden during the first 3-days of ICU treatment and care. At this time, patients 
were also asked to complete the TPS instrument, which measured their perception of pain 
and distress related to common ICU treatments and procedures.
Data Analysis
Data analysis using descriptive and multivariable statistics were conducted on 
data collected from January 2006 to December 2006. The statistical package for Social 
Sciences (SPSS Version 14.0) was used to perform the analysis of data. All subjects who 
met the delimitations of the study sample were included in the analysis of data. 
Descriptive statistics were used to summarize the demographic variables of age, gender, 
ethnicity, religion, martial status and health insurance. Correlations were analyzed using 
Pearson’s Product Moment Correlations and Spearman’s Non-Parametric correlations.
All correlations were compared to the statistical significance level of p <.05.
Aim #1: Examine the perceived symptom burden (prevalence, intensity, 
frequency), and overall distress, as reported by ICU patients with complex 
disease states, at high-risk for hospital death.
The null hypothesis is that overall symptom burden would not be independently 
associated with disease type/number o f  co-morbidities, severity o f  illness (APACHE III 
Mortality Risk) and significant distress, as reported by critically ill patients in ICUs.
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In this study, the CMSAS was used, which has high correlations with clinical 
status and quality of life measures (Chang et al., 2004; Chang et al., 1998; Portenoy et al., 
1994). The CMSAS instrument focuses on distress related to the most prevalent 
symptoms among patients at end-of-life. CMSAS assesses a single dimension for each of 
the 11 physiologic symptoms: the dimension of distress (how much does it bother you)? 
(Five response options ranging from not at all to very much). The dimension of frequency 
(how often do you experience this?), had five response options ranging from (never to 
almost constantly) for three psychologic symptoms. The CMSAS yields several validated 
subscale scores, including (CMSAS-PHYS) score, which measures the average intensity 
of the 9/11 physical symptoms; the CMSAS-PSYCH score, which measures the degree of 
psychological distress of three symptoms (worrying, feeling sad, and feeling nervous); 
and (CMSAS SUM), the total symptom distress score. In the validation studies, the 
CMSAS PSYCH subscale was an independent predictive of survival in multivariate 
analysis (Chang et al., 2004). According to Chang and colleagues (2000), CMSAS 
subscale scores greater than 1.0, suggest the presence of significant symptom distress.
Descriptive statistics were conducted to delineate the prevalence, distress and 
frequency of patient symptom ratings on day 1 and day 3 (Table 12). A repeated 
measures analysis of variance for each symptom was done, to determine whether or not 
there were any significant differences, between the symptom dimensions on day 1 and 
day 3. The statistical significance level was set at <. 05. Cronbach’s alpha.
T-tests were conducted to determine whether the amount of symptom distress for 
each day (i.e., 1 and 3) varied between males and females. The t test is a useful statistical 
method for comparing differences between two groups. The test requires a continuous
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dependent variable on which the groups are being compared. The test assumes that the 
variable is normally distributed in the populations from which the samples are drawn and 
that the samples have equivalent variances (Munro, 2005). If the two groups being 
compared are matched or paired on some basis, the scores are likely to be similar. The 
change difference between the two groups will not be as large as when they are drawn 
independently. Correlations were conducted to determine whether age was associated 
with the prevalence and degree of distress of each symptom.
A second instrument, the Treatment & Procedure Survey (TPS), was used to 
measure the interventions that may cause pain, discomfort and suffering among ICU 
patients, which often are caused by the life-prolonging treatments themselves, the 
environment and nursing procedures. Descriptive statistics were computed to analyze the 
treatment and procedure survey (TPS), which will provide us with an expanded 
understanding of other sources of suffering, that patients’ experience, in addition to their 
physiologic and psychologic symptom experience at end-of-life.
Aim #2: Examine the relationships between the independent variables o f  
demographic characteristics, antecedent conditions, and the dependent variable 
o f  symptom burden (prevalence, intensity, frequency) and overall distress using 
the (CMSAS-PSYCH and CMSAS-SUM Subscales).
Pearson correlations were conducted to assess the relationships between gender 
and the CMSAS symptom burden (prevalence, intensity, frequency) and CMSAS 
subscales; the relationships between age and the chronic health conditions, CMSAS 
symptom prevalence. Spearman’s non-parametric correlations were conducted to 
evaluate the relationships between gender and chronic health conditions; gender and
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CMSAS prevalence; and chronic health conditions and overall distress CMSAS total 
subscale.
Aim #3: Explore the relationship between symptom distress and overall patient 
mortality.
Pearson correlations were conducted to examine the relationship of CMSAS 
symptom distress and subscales with overall patient mortality. In an attempt to keep the 
sample size as large as possible, pairwise deletion was used instead of listwise deletion, 
because it allowed the most amount of people per correlation to be included. Pairwise 
deletion was considered acceptable because the nature of the study questions did not 
require that everyone answer each question; rather, it was only necessary for a patient to 
respond to a question if it pertained to them. So, the symptoms and treatment procedures 
that did not have responses were not so much missing, as they were not relevant to 
certain respondents.
Aim #4: To compare critically-ill patient-rated symptoms (prevalence, intensity, 
frequency), and distress scores for concordance, with those rated by designated 
surrogate-responders.
Crosstabs with a chi-square statistic were used to evaluate the agreement between 
patients and their surrogate responders on CMSAS symptom prevalence and distress. 
Descriptive statistics were used to obtain the frequencies of symptom ratings and means 
for both patient/surrogates for day 1 and day 3. This data provides clinicians with a 
greater understanding in the differences in various raters; and the multidimensional 
nature of symptoms at EOL and their impact on different aspects of quality of life.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 103
Protection o f Human Subjects 
The research study was explained to each patient/and family member available. 
This included (a) study purpose, (b) review of the inclusion/exclusion criteria, (c) 
overview of the data collection procedure and the data instruments and recording process 
involved in the study, (d) confidentiality of identity of information (e) risks and benefits, 
(f) voluntary participation, (g) freedom to refuse to answer any questions, and (h) 
freedom to withdraw from the study at any time. The researcher asked potential subjects 
to state their understanding (or use some other form of communication, such as nodding 
head, squeezing researchers hand), of the purpose and procedures involved in 
participating in the study, to determine their understanding for consent purposes. The 
researcher screened patients for capacity and potential cognitive deficits, using the RASS 
and CAM-ICU, prior to obtaining written consent (in the presence of a witness). 
Subjects/legal surrogate signed two forms, whereas, one was given to the patient and the 
other retained by the investigator. Following patient consent, family respondents were 
invited to be a volunteer in the study, and provided informed consent, which included the 
study information, as noted above, and included signing two consent forms.
Procedures to Protect Confidentiality 
Confidentiality of both the written questionnaires and participant identification 
was of utmost concern. The collected data were for the sole purpose of the research 
project. Participants received verbal and written information about the purpose of the 
study, potential risk, and benefits of the study. Study surveys were separated from 
consent forms, coded, and access was limited to only those directly active in the research
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process, including the investigator, a research assistant, and the faculty dissertation chair. 
Data were analyzed using SPSS Version 14 (2006) and codes without names were used in 
the database.
Consent forms were written in accordance with HIPPA regulations, the University 
of San Diego’s Internal Review Board (Appendix Q), and other participating ethics 
committee regulations (Appendix H). No participant names appeared on any of the data 
collection tools. All data will be kept in a locked file for a minimum of 5 years before 
being destroyed.
Potential Benefits o f Proposed Research and the Safety Ratio 
The findings from this research will contribute to the scientific base of nursing 
through a greater understanding of the multifactorial nature of symptom burden in 
terminal and critically ill patients, who may be nearing end-of-life. Data will enable 
clinicians to generate potential interventions to be tested through clinical trials, in an 
effort to generate new evidence-based therapies, which will reduce a patient’s emotional 
and physical symptoms during their dying trajectory. The risk of harm was assessed to be 
minimal, since this was a casual interactive experience, while subjects complete a 
questionnaire. Subjects are free not to participate and free to refuse any questions stated 
on the questionnaire(s) and instrument. However, given the potential critical condition of 
study participants and age, there was always the risk for fatigue overall, which would be 
found in this population generally. If the subject became fatigued/or was unable to 
complete the questionnaire due to changing condition, arrangements were made for the PI 
to reassess the patient at a later time, to allow for completion of the self-report survey.
The CMSAS instrument was purposefully selected because it only takes 2-3 minutes to
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complete (compared to other symptom instruments which take 30-45 minutes), which 
minimized the potential risk of extreme fatigue in this fragile population.
There was a minimal risk for psychological harm through responding to the 
CMSAS, primarily because the questionnaire is short, and only takes a couple of minutes 
to complete. However, if  patients did exhibit anxiety or fear, a psych mental health nurse 
practitioner was available for patient referral. During data collection, no patient exhibited 
associated anxiety, fear or pain related to study procedures. This instrument has been 
used in previous research with similar populations without report of psychological harm 
(Nelson et al., 2001). If subjects experienced distress, they also had a right to discontinue 
participation in the study.
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Results
The purpose of this exploratory study was to (1) examine the symptom burden at 
end-of-life in critically ill patients with life-limiting illness in ICUs, and (2) examine the 
relationships among variables related to patients (age, gender, physiologic acuity, chronic 
health status), symptom distress and overall mortality. In this chapter, a discussion of the 
findings is presented in three sections. In the first section, a description of the sample will 
be presented, the second section presents the analysis of the study variables and finally 
study results specific to the research questions are presented in section three.
Characteristics of the Sample
The demographic questionnaire (Appendix A) was used to collect demographic 
and personal data from participants. This questionnaire was designed to obtain 
information from which a sample profile could be developed. These data included age, 
gender, chronic health status (co-morbidities), admission source, LOS (ICU/Hospital), 
severity of illness (APACHE III predicted mortality), and observed mortality.
The sample included 244 patients admitted to two intensive care units of a large 
teaching hospital during January 2006 -  December 2006, with an APACHE III mortality
106
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 107
risk of > 60% -100%, of those 170 were eligible for the current study. Eighty patients 
were enrolled and able to respond to symptom assessments on day-1 while only 66 (80%) 
were able to complete the study instruments on day-3. Reasons for study attrition were as 
follows; the patient expired (10%), the patient was discharged (5%), or the patient lacked 
capacity (5%), following a deterioration of critical illness (see Figure 2). Overall, there
was no significant difference in age, gender, ethnicity, and ICU admission source among 
those who did or did not complete day-3 symptom assessments.
Consecutive ICU (.60-.80) MR ----- -► Eligible ------- ► E nrolled — ► Self-Reported Symptoms Day 1
Patients Screened (n =244) for Study (n=170) (n=80) (n=80)
Ineligible (n =74) Not enrolled (n = 90) Self-Report Day 3 (n= 66)
Refusal /No Consent To critical/death
Sudden change in condition Discharge from ICU
Fam ilv R espondents ^
E nrolled





MR = Mortality Risk
Figure 2. Patient / Family Respondent Recruitment Trends
Once a patient was enrolled in the study, family proxies were invited to 
participate in the study in order to provide a broader perspective of the patients symptom 
burden, thus a total of 53 designated family respondents were enrolled. A descriptive 
profile of the patient sample is presented in Table 10 and family respondent 
characteristics are presented in Table 11. Each group characteristics will be discussed 
separately.
Patient Characteristics 
Patient participants ranged in age from 35 to 97 years, mean age was 70.5 ± and 
was predominately male (62.5%). Racial/ethnic composition of the group was diverse
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with 48.8% White, 22.5% Black, 15% Hispanic, 11.3% Asian and 2.5% other. The 
martial status was mixed with 35% married, 30% single, 23.8% widowed and 11.3% 
divorced. Religious affiliation included Protestant (66.3%), Roman Catholic (27.5%), 
Jewish (1.3%), not religious (3.8%) and other (1.3%). Participants were predominately 
English speaking (81.3%), 12.5% of the participants completed the symptom survey in 
Spanish.
Three quarters of the patients originated from the emergency department, 1.3% 
from the operating room, 21.3% transfers from medical floors and 2.5% from other 
hospitals. Upon ICU admission the four most common diagnostic categories among the 
cohort included respiratory (35%), gastrointestinal (13.8%), sepsis/other (12.5%), 
cardiovascular (10%) (see Table 10). Chronic health conditions (comorbidities) among 
the patients were distributed as follows: one-comorbidity (37.5%), two comorbidities 
(36.3%) three (16.3%), four (6.3%) and five (1.3%) comorbidities.
Patients included in the study were among the “most critical” patients treated in 
the ICU for > 3 days. By definition, the most critical patients were those with the first- 
ICU-day APACHE Ill-predicted hospital mortality rate > 60% -100%. Among the 
cohort, the first-ICU-day mean (%) predicted hospital mortality rate was 69%, as noted in 
Table 10. The mean first-ICU-day APACHE III score was 97± 23. The mean ICU length 
of stay (LOS) was 10, with a range of 1-49 days and mean hospital LOS was 15, (range = 
1.5-73) days. Following discharge from the ICU approximately 16% of the patients had 
to be readmitted to the ICU from the discharge unit for further treatment. The observed 
ICU and hospital mortality rates were 19% and 2% respectively. Thirty percent of the 
patients who died in the ICU, were as a result of the decision to withhold or withdraw
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 109
life-sustaining treatments while in the ICU. Of the 63 patients who survived to hospital 
discharge, 16 (25%) died within three months following discharge.
Table 10
Patient Profile and Study Characteristics


































No Insurance 2 2.5
Private/Other 5 6
A dm ission  Source
Emergency department 60 75
Floor 17 21.3
Operating room 1 1.3
Other hospital 2 2.5
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C haracteristic M  (sd) N  (% )








UTI Sepsis 4 5.0
R e-A dm ission  to IC U  from  D isch arge U nits 13 16.3
A P A C H E  III C h ron ic  H ea lth  -  T op  F ive
Heart Problems 78 97.5
Respiratory Disease 59 73.8
Gastrointestinal Disease 58 72.5
Sepsis/Other 47 58.8
Renal Disease 45 56






A P A C H E  III P red icted  M orta lity M ean ±  SD
First Day Hospital 69 ± .09
Third Day Hospital 66 ± .18
First ICU Day 49 ± .14
Third ICU Day 45 ± .21
A P A C H E  H I S core
First ICU Day 97 ± 2 3
Third ICU Day 81.9 ± 33
O utcom es M ean ±  SD
ICU LOS 10 ±8.83
Hospital LOS 15.85 ± 11.97
ICU Mortality 15 19%
Hospital mortality 2 3%
3-Month Follow-Up 16 25%
*Data are presented as mean ± SD or No. (%).
APACHE III = Acute Physiology and Chronic Health Evaluation III - Prognostic System 
ICU = Intensive Care Unit; LOS = Length o f Stay
For patients discharged alive from the hospital, follow-up information about their 
survival status was obtained from computerized medical records and a national obituary 
data-base. While the overall combined mortality among the cohort (n=80) was 46%, the 
post-discharge mortality figure may actually be higher since the data systems available 
may not have located some patients who may have died outside the immediate area or
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whose obituaries were never posted in newspapers.
Family Respondent Profile
Table 11 presents a profile of the family respondents. In this study, family 
respondents (FRs) were any close family member or significant other, designated by the 
patient. There was no attempt to create a matching dyad of patient with a specific family 
member. A voluntary convenience sample of family respondents was recruited and 
obtained once families were informed of study opportunity. Of the 80 patients who 
agreed to participate in the study, 16 did not have family or a designated family 
respondent. Although 64 FRs were identified, 11 were unavailable/or declined to 
participate. The mean age of the FRs was 59 years (25-92) and over two thirds (69.8%) 
were female. Racial/ethnic composition was diverse: White (43.4%), Black (17%), 
Hispanic (20.8%), Asian (15.1%) and other (3.8%). The relationship of the FRs to the 
patient included spouse (43.4%), patient’s child (41.5%), patient’s sibling (5.7%), 
patient’s parent (3.8%) and significant partner (5.7%). The majority of FRs were married 
(84.9%), with 5.7% single, 3.8% widowed and 5.7% divorced. Religious affiliation 
included Protestant (51.9%), Catholic (51.9%), Jewish (3.8%), other Christians (7.5%), 
and other (1.9%). Three quarters were English speaking, 9.4% Spanish speaking and 
13.2% other languages. Approximately 70% identified themselves as the primary 
caregivers. While the majority of patients lived at home 64.2%, 16% of FRs reported that 
their loved ones were receiving care in long-term facilities because caregiving needs were 
beyond what they could provide, particularly for those patients with dementia, advanced 
chronic illnesses and the frail elderly. Patients who were residing at home with limited 
functionality and complex care needs received home health services (11.3%). Finally,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 112
86.8% of family respondents reported they were the legal surrogate should the patient 
become incapacitated and unable to make their own decisions regarding life-prolonging 
treatments and advance care planning.
Table 11
Family Respondent Profile
C h aracteristics M  (sd) %
A ge






















R elationsh ip  to  P atien t
Spouse 23 43.4
Patient’s Child 22 41.5
Patient’s Sibling 3 5.7
Patient’s Parent 2 3.8
Partner 3 5.7
L egal Surrogate for  P atien t
Yes 46 86.8
No 7 13.2
P rim ary C are G iver  fo r  P atien t
Yes 37 69.8
No 16 30.2
P atien t’s R esid en ce
Home 34 64.2
Long Term Care 13 16
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Characteristics M (sd) %
Other Family Member/Friends Home 7 13.2
Patient Receiving Home Health Care at Home 6 11.3
Descriptive Findings 
Aim #1: Examine the perceived symptom burden (prevalence, intensity, 
frequency), and overall distress as reported by ICUpatients with complex disease 
states, at high-risk for dying.
Symptoms /  Symptom Distress 
The CMSAS instrument was originally designed to measure a patients perception 
of their symptoms (physiologic/psychologic) occurring in the previous seven days only. 
In this study the CMSAS was administered on day-1 ICU admission, in which patients 
reported symptoms that were most bothersome in the previous 7-days (previous health 
status) and on day-3, to report their symptoms and distress following 3-days of ICU care. 
Table 12 presents the patient report of symptom distress (prevalence, intensity, 
frequency) experienced at Day-1 and Day-3.
Among patients responding to symptom assessment, approximately 98% were 
symptomatic. Overall, patients reported an average of 10.23 out of 11 physical symptoms 
assessed. The two most common physiologic symptoms reported on day-1 by 98.8% of 
patients, were lack of energy (fatigue) and difficulty concentrating, with a mean symptom 
distress rating of 2.96 (SD = 0.70) and 2.79 (SD = 0.84) respectively on a scale of 1 = no 
distress to 4 = great distress. The next most common symptoms were feeling drowsy 
(97.5%), feeling pain (95%), shortness of breath (95%), dry mouth (95%), and difficulty 
sleeping reported by 93.8% with a mean distress level scores (with standard deviations in
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parentheses) of 2.66 (0.84), 2.52 (1.21), 3.05 (0.88), 1.18 (1.22) and 1.84 (1.42) 
respectively. The least bothersome symptoms reported on day-1 constipation (87.5%), 
and nausea (87.5%) with a mean distress level scores (with standard deviations in 
parentheses) of 2.30 (1.14), 1.07 (1.10), and 1.62 (1.28) respectively.
Nearly all of the critically ill patients (97.9%) reported psychologic symptoms 
(sadness, worry, and nervousness) with a mean distress score of 2.45 (SD=0.67) with a 
2.45 at the highest levels of frequency. Overall patients reported an elevated level of 
symptom distress on day 1, with increasing severity and number of symptoms on day-3 
ICU care, as presented in the analytic comparisons of subscale means in Table 14. 
CMSAS-PHYS, CMSAS PSYH and CMSAS-Total Distress Subscales showed increased 
mean levels of distress (standard deviations in parentheses) of 3.07 (0.46), 3.46 (0.52) 
and 3.17 (0.44).
Patients were also given the opportunity to report any other symptoms that may 
be bothering them that were not listed on the CMSAS instrument. Of the 24 additional 
symptoms reported by patients, 20% were physiological, three were psychological (4%) 
and 15% was related to noise, an added environmental stressor, which inhibits the healing 
environment for patients (Table 13).
















Means and Standard Deviations for Patient Reported Mean Symptom Distress Day 1 and Day 3
D ay 1
B oth er  or  D istress in  P ast 7 days
D a y  3
B oth er  or D istress since 2 D ays A go
P hysica l Sym ptom s n (%) Mean Sx Distress Score n (%) Mean Sx Distress Score
(Std Dev) (Std Dev)
Lack o f energy (fatigue)* 79 (98.8) 2.96 (0.70) 65 (81.3) 3.80(0.44)
Lack o f appetite* 76 (95.0) 2.30(1.14) 64 (80.0) 3.18(0.81)
Pain* 76 (95.0) 2.52(1.21) 66 (82.5) 3.62 (0.66)
Dry mouth* 76 (95.0) 1.18(1.22) 64 (80.0) 2.58 (0.88)
Weight Loss* 74 (92.5) 1.18(1.31) 64 (67.5) 1.21(1.38)
Feeling drowsy* 78 (97.5) 2.66 (0.84) 64 (80.0) 3.60(0.45)
Shortness o f breath* 76 (95.0) 3.05 (0.88) 65 (81.3) 3.75 (0.66)
Constipation 70 (87.5) 1.07(1.10) 58 (72.5) 0.99(1.25)
Difficulty sleeping* 75 (93.8) 1.84(1.42) 59 (90.8) 2.79 (1.06)
Difficulty concentrating* 79 (98.8) 2.79 (0.80) 64 (80.0) 3.40 (0.69)
Nausea 70 (87.5) 1.62(1.28) 57(71.3) 2.10(1.26)
CMSAS-PHYS Subscale 2.19(0.71) 3.07 (0.46)
CMSAS-PHYS Subscale is the average o f  the nine (*) Items
Frequency o f  Sym ptom  O ccurrence in  P ast 7 days F requency o f  O ccurrence S ince 2 D ays A go
P sychological Sym ptom s n (%) Mean Sx Distress n(%) Mean Sx Distress Score
Std Dev (Std. Dev.)
Worrying 79(98.8) 2.58(0.70) 66(82.5) 3.50(0.58)
Feeling sad 77(96.3) 2.20(1.02) 66(82.5) 3.48 (.68)
Feeling nervous 80(98.7) 2.33(0.88) 66(82.5) 3.42 (.72)
CMSAS-PSYCH Subscale 2.45(0.67) 3.46 (0.52)
CMSAS Total Distress Score 2.24(0.66) 3.17(0.44)
CMSAS-PSYCH Subscale is the average o f  the 3 Psychological Symptoms; CMSAS Total Distress Score is average o f  all symptoms.
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Table 13
Other Distressing Symptoms Identified by Patients
O ther C M SA S S ym ptom s F requency %
Leg spasms 1 1
Hand tremor 1 1
Sweaty 1 1
Numbness 1 1
Sore Lips (ETT bothersome)* 1 1





Legs hurt bad 1 1
Numbness stump 1 1
Tongue hurts 1 1
Dry eyes 1 1
Feels helpless 1 1
Afraid/Scared 2 2








*ETT = Endotracheal Tube
Table 14








(N = 66) 










0 .2 0 -3 .5 6  
1 - 4





1 .6 7 -4 .0
1 .28-3 .93CMSAS TOTAL 
SCORE
Note: CMSAS= Condensed Memorial Symptom Assessment Scale; PHYS=Physical; 
PSYCH=Psychological; Std. Dev = Standard deviation
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Aim #2: Examine the relationships between the independent variables o f  age, 
gender, chronic health conditions, and the dependent variable o f  symptom burden 
(prevalence, intensity, frequency), and overall distress (CMSAS SUM subscale).
A. Is there a relationship between age and gender in the reported symptom 
burden (prevalence, intensity, frequency) and overall symptom distress?
A correlation matrix was computed to identify relationships between gender, age, 
chronic health conditions and symptom burden (prevalence, intensity, frequency) and 
overall severity of symptom distress, using the CMSAS-PHYS/PSYCH and CMSAS- 
SUM subscales as indices.
Table 15
Significant Correlations o f  Gender and Age with Physiological and Psychological 
Symptom Prevalence on Day-1 and Day-3
Gender Age
r p-value n r p-value n
Day 1 Physiological Symptom
Lack o f Appetite .26 .02 80 - - -
Pain - - - -.27 .02 80
Dry Mouth .26 .02 80 - - -
Feeling Drowsy .22 .05 80 - - -
Constipation -.39 .00 80 - - -
Difficulty Sleeping - - - -.26 .02 80
Day 3 Physiological Symptom
Constipation -.35 .00 66 - - -
Nausea - - - -.34 .01 65
Notes: Spearman’s Correlations (significant p < .05); Gender coded: Male=l, Female=2
Table 15 presents the significant correlations of gender and age with physiologic 
prevalence; there were no significant correlations with the psychological symptoms. Data 
indicates some important gender and age-related differences among patient symptom 
reports. For example, on Day 1, females reported higher levels of distress for lack of
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appetite (r = .26, p=.02), dry mouth (r = .26, p~.02), and feeling drowsy (r = .22, p=.05). 
In contrast, males reported higher levels of distress related to constipation (r= 36,p=.05) 
on day 1 and day 3 (r= -.32, p=01). Age was negatively correlated with pain ( r = -.27, 
/?=.02) and difficulty sleeping (r = -.26, p=.02) on Day-1 and with nausea (r = .34, 
p=. 01) on Day 3.
Table 16
Significant Correlations o f  Gender and Age with Day 1 and Day 3 Physiological and
Psychological Symptom Distress
Gender Age
r p-value n r p-value n
Day 1 Physiological Symptom
Lack o f Appetite .29 .01 76 - - -
Pain - - - -.33 .00 76
Dry Mouth .33 .00 76 - - -
Constipation -.36 .00 70 - - -
Difficulty Sleeping - - - -.32 .00 75
Nausea - - - -.30 .01 70
CMSAS-PHYS Subscale - - - - - -
Day 1 Psychological Symptom
Worrying - - - -.43 .00 79
Feeling Nervous - - - -.39 .00 80
CMSAS-PSYCH Subscale - - - -.41 .00 80
CMSAS—SUM  Subscale - - - -.22 .05 80
Day 3 Physiological Symptom
Lack o f Appetite .27 .03 64 - - -
Pain -.26 .04 66 - - -
Constipation -.32 .01 58 - - -
CMSAS-PHYS Subscale - - - - - -
Day 3 Psychological Symptom
Worrying - - - -.32 .01 66
Feeling Nervous - - - -.25 .05 66
CMSAS-PSYCH Subscale - - - -.25 .04 66
Notes: Pearson’s correlations. (Significant p < .05); Gender coded: Male=l, Female=2
Table 16 presents correlations of gender and age with the physiological and 
psychological symptom distress on day 1 and day 3. There was continued distress
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reported by females on both day 1 and 3 regarding lack of appetite (r = .29, p=.01) and 
( r  = .27, pr=. 03) respectively. Males reported significant amounts of distress related to 
constipation on both day 1 (r = -.32, p=.05) and day 3 (r = -.26,/?=.01), while they 
reported pain (r = -.26, p=.04) on day-3. When correlations were computed for age, there 
was a significant negative correlation to the overall CMSAS Total Score Distress (r = - 
.22, p=.05), the physiologic symptoms of pain, difficulty sleeping and nausea, the 
CMSAS PSYCH Subscale (r =-.41, p<=.05), and the psychological symptoms of 
worrying (r = -.43, p=.01) and feeling nervous (r = -.39, p=.05), at Day 1. At day 3 
significant negative correlations were again found for the psychological symptoms of 
worrying and feeling nervous as well as for the overall CMSAS-PSYCH subscale.
Pearson correlations were next computed to examine the relationship of CMSAS 
symptom distress and chronic health conditions. In an attempt to keep the sample size as 
large as possible pairwise deletion was used instead of listwise deletion, because it 
allowed the most amount of people per correlation to be included. Table 17 and Table 18 
present the correlations of the physiological symptom distress and chronic health 
conditions Day 1 and Day 3 respectively. Findings from the analysis reveal that there are 
a number of chronic health conditions are significantly correlated with the symptom 
burden among the study cohort,
Symptom distress was significantly correlated with several of the top five 
admitting diagnoses to the ICU. Respiratory disease was the most frequent admitting 
diagnosis to the ICU. Patients with respiratory failure experienced multiple distressing 
symptoms on Day 1: lack of energy (r = 0.24, p  = .03), feeling drowsy (r = .30, p  = .01), 
shortness of breath (r = .30, p  = .01), difficulty concentrating (r = .38, p=.05) and a
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CMSAS PHYS distress score of (r = .25, p  = .03). Trauma had a significant negative 
correlation with lack of energy (r = - 0.68 ,p  = 0.05, feeling drowsy (r = -0.36, p  <.05) 
and CMSAS-PHSY subscale (r = - 0.39, p  <..05). Hematological disease is significantly 
positively correlated with feeling drowsy (r = 0.26,p  = 0.03) and nausea (r = 0.37,/? 
<.05); muscular skeletal disease has a significant negative correlation with shortness of 
breath (r = - 0.23,p  -  .05) and difficulty concentrating (r = -0.24,p  = .05). GI disease is 
significantly positively correlated with dry mouth (r = 0.23, p -  .04) and CMSAS-PHYS 
Subscale (r = 0.24, p= .03). Cerebral vascular accident has a significant negative 
correlation with difficulty sleeping (r = 0.28,/? = .01) and is significantly positively 
correlated with difficulty concentrating (r = 0.22, p  = .05). Neurological conditions is 
significantly positively correlated with weight loss (r -  0.30, p  = .01). Disease severity, 
mortality risk and a patients’ chronic health status, would appear to be an independent 
factors associated with higher symptom burden and decreased quality of life.





































































L ack  o f  E nergy 0.04 -0.04 -0.10 0.16 0.09 0.08 0.08 0.02 0.03 0.21 0.24* 0.14 -0.68* -0.01
L ack  o f  A ppetite -0.01 -0.03 -0.11 0.14 0.06 0.02 0.18 -0.06 0.13 -0.03 0.03 0.16 -0.10 -0.17
Pain -0.15 0.04 0.08 -0.04 -0.01 -0.03 0.04 0.00 -0.06 0.19 0.08 0.10 -0.18 0.07
D ry  M outh 0.05 -0.02 -0.04 0.23* 0.01 -0.04 0.17 0.03 -0.02 0.16 0.05 0.08 -0.16 -0.10
W eigh t Loss -0.10 -0.22 -0.15 0.22 0.30* 0.19 -0.12 -0.18 -0.03 0.07 0.07 0.15 0.04 -0.11
F eeling D row sy -0.03 0.07 -0.05 0.05 0.11 0.16 -0.01 -0.06 -0.09 0.26* 0.30* -0.09 -0.36* 0.11
Shortness o f  B reath -0.12 0.16 -0.16 0.02 -0.09 0.02 0.11 -0.11 -0.23* 0.05 0.30* 0.01 0.02 -0.09
C onstipation -0.15 -0.01 0.13 -0.02 0.14 -0.09 -0.18 0.03 -0.13 -0.07 0.03 0.08 0.00 0.10
D ifficu lty  S leeping -0.11 0.05 -0.09 -0.03 0.08 -0.28* 0.09 -0.02 -0.15 0.08 0.14 -0.07 0.04 0.23
D ifficulty 0.00 0.06 -0.06 0.12 0.21 0.22* 0.05 -0.07 -0.10 0.16 0.38* 0.07 -0.16 0.01
C oncentrating
N ausea -0.10 -0.15 -0.05 0.19 0.03 -0.19 0.09 0.20 -0.24* 0.37* -0.15 0.00 -0.06 0.18
C M SA S PH Y S T otal -0.03 0.00 -0.09 0.24* 0.11 0.05 0.10 -0.05 0.01 0.19 0.25* 0.12 -0.39* 0.04
*Significant p < .05; n range 56-80. Note: DM = Diabetes Mellitus; Endocr. = Endocrine; Neurol. = Neurological; CVA = Cerebral Vascular Accident; 





































































L ack  o f  
E nergy 0.08
-0.02 0.12 -0.06 0.10 0.13 -0.02 -0.22 0.11 -0.16 0.13 -0.01 -0.30* -0.03
L ack  o f  
A ppetite 0.09
0.14 -0.02 -0.01 0.08 -0.06 -0.19 -0.17 0.06 -0.18 -0.14 0.15 -0.22 -0.26
Pain
0.10
0.20 -0.02 -0.07 -0.09 -0.10 -0.07 -0.02 -0.34* -0.02 -0.10 0.16 0.04 -0.00
D ry  M outh
0.04
-0.09 -0.11 0.06 -0.05 0.06 0.21 -0.12 -0.08 0.13 0.05 0.19 -0.05 -0.28*
W eigh t Loss
0.06
-0.22 -0.12 0.18 0.22 0.25 -0.08 -0.18 0.07 0.27 0.05 0.22 -0.21 -0.25
F eeling
D row sy 0.16
0.06 -0.24 -0.03 0.03 0.09 -0.20 -0.08 -0.17 -0.07 0.06 -0.09 -0.07 -0.04
Shortness o f  
B reath 0.07
0.25* -0.16 -0.16 -0.13 0.11 -0.15 -0.12 -0.30* -0.21 0.28* -0.07 -0.01 -0.11
C onstipation
0.09
0.16 0.04 -0.09 0.02 -0.09 -0.16 0.02 -0.06 -0.13 0.12 -0.09 -0.15 0.10
D ifficu lty
Sleeping 0.00
0.25* -0.05 0.13 0.00 -0.10 -0.00 0.02 -0.14 -0.12 -0.10 0.01 0.09 0.33*
D ifficu lty
C oncentrating 0.16
0.15 0.00 -0.01 0.09 0.10 0.01 -0.11 -0.20 0.04 0.08 0.16 -0.06 -0.07
N ausea
0.12
-0.04 0.15 -0.13 -0.24 -0.32* 0.00 0.23 -0.02 -0.02 -0.38* -0.20 0.11 -0.04
C M SA S  
P H Y S T otal 0.13
0.13 -0.08 0.04 0.07 0.08 -0.08 -0.22 -0.16 -0.03 0.01 0.16 -0.12 -0.12
*Significant p < .05; n range 40-66. Note: DM = Diabetes Mellitus; Endocr. = Endocrine; Neurol. = Neurological; CVA = Cerebral Vascular Accident; 
Muscul. = Musculoskeletal; Hemat. = Hematological; Resp. = Respiratory; Vascul. = Vascular Diseases
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Relationship Analysis of the Data Related to the Research Questions 
Research Question 1: Is there a relationship between age and gender in the reported 
symptom burden (prevalence, intensity, frequency), and overall distress experienced by 
subjects?
Independent samples t-tests were performed to examine differences in symptom distress 
across males and females are presented in Table 19. Overall there was a significant difference 
with females reporting higher levels of symptom distress across various symptoms. Females 
reported a lack of energy ( t = 2.079, d f75.04, p  = .04), lack of appetite (t = 2.937, <7/73.97, 
p<.05), and dry mouth (/ = -3.009, d f  74, p<.05) while males reported increased symptoms of 
constipation (t = 3.228, df 68, p<.05). On day 3, males again reported higher symptom ratings 
than women for constipation. In contrast women reported lack of energy and lack of appetite. 
Overall these findings have some limitations, as males represent (63%) of study cohort versus 
(38%) women. Men and women differ with respect to the prevalence of diseases such as 
cardiovascular and autoimmune diseases, the sensory perception of pain, symptom report, illness 
behavior health care use, and treatment response (van Middendorp et al., 2005). The effect of age 
is unidirectional, whereas, there are some gender differences in the symptom experience as noted 
above. The most important results clinically from this research, is that persons with advanced, 
multiple-chronic diseases are polysymptomatic, and that symptom prevalence is multifactorial 
(Husain et al., 2007; van Middendorp, 2005). Multiple and interrelated determinants of gender 
and age differences in objective and subjective health characteristics need further study.
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Table 19
Significant T-Tests Comparing Symptom Distress (Days 1 & 3) for Males and Females.
N M SD t d f p-value
Day 1 Symptoms
Lack o f Energy Males 49 2.85 0.82 -2.079 75.04 p = .04
Females 30 3.14 0.42
Lack o f appetite Males 47 2.04 1.26 2.937 73.97 p < .05
Females 29 2.73 -.79
Constipation Males 44 1.38 1.04 3.228 68.00 p < .05
Females 26 .554 1.03
Dry Mouth Males 48 .883 1.11 -3.009 74.00 p < .05
Females 28 1.714 1.25
Day 3 Symptoms
Lack o f Energy Males 42 3.73 .74 -1.920 59.82 p = .06
Females 23 3.93 .51
Lack o f appetite Males 42 3.03 .88 -2.229 62.00 p = .03
Females 22 3.49 .58
Constipation Males 37 1.30 1.30 2.756 50.80 p < .05
Females 21 .46 1.00
Research Question 2: What is the incidence o f other sources (treatments /  procedures) o f  
pain and the degree o f  discomfort, reported by patients during their ICU stay?
Although patients experience a multiplicity of symptoms related to their disease state 
while in the ICU, there are also a number of interventions that cause patients additional pain and 
suffering related to the ICU environment/routine. Patients were given the Treatment and 
Procedure Survey (TPS) to complete on day 3 of their care. Data was analyzed using descriptive 
statistics to delineate how the respondents rated their pain and discomfort (Tables 20-21).
In examining the findings from procedure-related symptoms, seventy to eighty percent of 
patients reported six of the major procedures as severely painful and severely uncomfortable 
(arterial blood gas puncture; ETT, ETT suctioning, central line placement and moving from bed
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to gumey for transport, and turning in bed) which are nursing and interdisciplinary elements of 
care. Other procedures rated as moderately and severely painful or severely uncomfortable 
respectively, included arterial catheter insertion (18.8%) / (31.3%); and (20%) / (28.8%),, 
bladder catheters (27.5%) / (53.8%); and (46.3%) /(35%), nasogastric tube (NGT) in place (20%) 
/ (30%); and (32.5%) / (47.5), and mechanical ventilation (23.8%) / (50%); and (31.3%)/ 
(42.5%). Only eight percent of the patients undergoing these invasive procedures and other 
interventions were pre-medicated with sedatives and/or opiods, to reduce anxiety and pain prior 
to the procedure The three least uncomfortable procedures included medications given by 
intramuscular (IM) and subcutaneous (SQ) routes, peripheral intravenous catheter (PIC) insertion 
and vital signs (VS) being taken. A possible explanation for these low ratings is that IMs and SQ 
medications are rarely given in ICU rather most medications are delivered intravenously or thru 
enteral methods (e.g. NGTs, gastrostomy tubes). PIC insertion is also less frequent, since most 
peripheral lines are initiated in the emergency or operating rooms. Moreover, 80% of all ICU 
patients require central venous lines for delivery of large volumes of fluid/blood products and 
many medications which require central lines, to avoid injury to peripheral vessels because of the 
chemical composition and actions of the medication itself. Finally, vital signs do not seem to be 
too painful or uncomfortable, most likely because of the non-invasive blood pressure cuffs used 
and the electrocardiographic monitoring, both of which provide continuous information on the 
monitors without disturbance to the patient. The procedures identified as severely painful and 
uncomfortable are very common interventions used to treat and monitor critically ill patients, 
yet, these therapies designated to improve overall condition were causing additional pain and 
suffering to over seventy percent of critically ill patients. Studies indicate that variation in pain
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intensity and distress can depend on how patients are prepared for ICU procedure and on the 
different stimuli that may occur with various procedures, thus, anticipatory preparation that 
includes information about expected sensations may prepare patients better for the experience 
(Puntillo et al., 2001). Because of the frequency with which procedures are done on critically ill 
patients, more directed individualized attention to preparation for and control of procedure pain 
is necessary. Further research is warranted to test interventions that would maximize comfort 
prior to the initiation of these therapies, and basic nursing procedures.
















Prevalence o f Symptoms o f Most Distressing Intensive Care Unit Interventions -  (TPS Survey N=66)
Patients Experiencing Procedure as Moderately or Severely Painful or Uncomfortable (%)
Procedure
Arterial blood gas puncture
Arterial catheter insertion
Endotracheal breathing tube in place
Endotracheal suctioning (Airway)
Catheter in the bladder
Mechanical ventilation (Breathing) machine
Medications being given, Intramuscular, 
Subcutaneous
Moving from bed to gumey to transport to special 
procedures
Nasogastric tube in place (nose or mouth) 
Peripheral IV catheter insertion 
Central line insertion
Turning in bed (bath, positioning, upright for x- 
ray)
Blood being drawn for lab specimens
Vital Signs being taken 
Adapted from Nelson et al., 2001.
Painful Uncomfortable
No. Rating Moderate Severe No. Rating Moderate Severe
Procedure Procedure
66 9(11.3% ) 57(71.3%) 66 18 (22.5%) 48 (60%)
40 15 (18.8%) 25 (31.3) 39 16(20%) 23 (28.8%)
64 1 (1.3%) 58 (72.5%) 59 6 (7.5%) 53 (66.3%)
60 3 (3.8%) 57(71.3%) 60 12 (15%) 48 (60%)
65 22 (27.5%) 43 (53.8%) 65 37 (46.3%) 28 (35%)
59 19 (23.8%) 40 (50%) 59 25 (31.3%) 34 (42.5%)
60 45 (56.3%) 15 (18.8%) 60 45 (56.3%) 15 (18.8%)
66 2 (2.5%) 64 (80%) 66 14 (17.5%) 52 (65%)
64 16 (20%) 48 (60%) 64 26 (32.5%) 38 (47.5%)
66 42 (52.5%) 24 (30%) 66 45 (56.3%) 21 (26.3%)
60 3 (3.8%) 57(71.3%) 66 10 (12.5%) 50 (62.5%)
66 7 (8.8%) 59(73.8%) 66 17(21.3%) 49 (61.3%)
65 24 (30%) 41 (51.3%) 65 31 (38.8%) 34 (42.5%)

























M in. M ax.
1.86 .346 1 2 1.73 .449 1 2
Arterial blood gas puncture
.98 .886 0 2 .94 .875 0 2
Arterial catheter insertion
1.77 .627 0 2 1.70 .656 0 4
Endotracheal breathing tube in
n l o p pU l d C C
1.77 .602 0 2 1.64 .648 0 2
Endotracheal suctioning
(Airway)
1.64 .515 0 2 1.41 .526 0 4
Catheter in the bladder
1.50 .685 0 2 1.41 .679 0 2
Mechanical ventilation
(Breathing) machine
Medications being given, 1.14 .552 0 2 1.14 .552 0 2
Intramuscular, Subcutaneous
1.97 .173 1 2 1.79 .412 1 2
Moving from bed to gumey to
transport to special procedures
1.70 .525 0 2 1.55 .560 0 2
Nasogastric tube in place (nose
or mouth)
1.36 .485 1 2 1.32 .469 1 2
Peripheral IV catheter insertion
1.77 .602 0 2 1.67 .641 0 2
Central line insertion
1.89 .310 1 2 1.74 .441 1 2
Turning in bed (bath,
positioning, upright for x-ray)
1.61 .523 0 2 1.50 .533 0 2
Blood being drawn for lab
specimens
1.29 .489 0 2 1.32 .501 0 2
Vital Signs being taken
Std. Dev. = Standard Deviation; Min. = Minimum; Max. =  Maximum; Scoring Moderate =  1; Severe =  2
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Aim #3: Explore the relationship between symptom distress and overall patient 
mortality.
Research Question 3: What is the relationship between overall symptom burden 
and degree o f  bother/distress (CMSAS PHYS/PSYCH and CMSAS SUM Subscale 
Scores) and patient mortality?
Age is thought to be strongly associated with intensive care outcomes (e.g. 
mortality), however, this relationship is confounded by many clinical variables (Vosylius 
et al., 2005). Pearson correlations (2-tailed) and nonparametric correlations (Spearman’s 
rho) were used to examine the relationship of CMSAS symptom distress with overall 
patient mortality.
The presence of severe chronic diseases was more common among elderly 
patients, however, age was not found to have a significant relationship to overall 
mortality (Table 22), nor was it significantly correlated with symptom distress (Table 23). 
In general, elderly patients have poorer outcomes than do younger patients, but prognosis 
and mortality is more dependent on severity of illness and functional status before 
admission than on high age itself (de Rooij & Hanna, 2005).
Table 22
Age and Relationship to Mortality
A ge o f  subject In -p atien t E xp iration
Age o f subject Pearson Correlation 1.00 -.143
Sig. (2-tailed) .205
In-Patient Expiration Pearson -.143 1.00
Correlation Sig. (2-tailed .205
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Table 23






Lack of energy (fatigue)* .93 0.77 -.22 0.07
Lack of appetite* .18 0.12 .10 0.45
Pain* .16 0.17 .17 0.16
Dry mouth* .15 0.21 .21 0.10
Weight Loss* .04 0.76 -.13 0.36
Feeling drowsy* .07 0.55 -.12 0.34
Shortness of breath* .17 0.13 .04 0.74
Constipation .08 0.51 .06 0.64
Difficulty sleeping* .12 0.29 -.08 0.64
Difficulty concentrating* .02 0.87 -.01 0.92
Nausea .14 0.24 .16 0.22
CMSAS-PHYS Subscale 
No significant correlations
.08 0.49 .07 0.57
Day 1____________________ Day 3
Psychological Symptoms r p-value r p-value
Worrying -.01 0.90 .04 0.76
Feeling sad -.17 0.14 .11 0.40
Feeling nervous -.02 0.87 .07 0.56
CMSAS-PSYCH Subscale .09 0.40 .09 0.46
CMSAS Total Distress .03 0.81 -.03 0.81
No significant correlations
Aim #4: To compare the critically-ill patient-rated symptoms (prevalence, 
intensity, frequency) and distress scores for concordance, with those rated by 
designated surrogate-responders. This will provide a more comprehensive 
approach to understanding the differences in various raters, regarding the 
multidimensional nature o f symptoms at EOL and their impact on different 
aspects o f  quality o f  life.
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Research Question 5: What is the level o f concordance between critically-ill 
patient-rated symptom prevalence, intensity and distress scores, with those rated 
by designated surrogate responders using the Condensed Memorial Symptom 
Assessment Survey (CMSAS)?
Although comparisons of patient symptom ratings and those of significant others 
have been the focus of numerous studies during the past decade, no studies exist among 
the critical care literature, which examines the concurrent, “real time” examination of a 
patient’s perception of their symptom burden, taken at the same time as a surrogate rater. 
In this exploratory study, attempts were made to include family respondents in order to 
determine the utility and accuracy of proxy ratings of patients’ symptoms, and different 
explanatory factors for patterns of disagreement between the two groups. Levels of 
agreement among patient and family raters were analyzed using crosstabs with chi-square 
to test for concordance and the Kappa Statistic. Studies that measure the agreement 
between two or more observers should include a statistic that takes into account the fact 
that observers will sometimes agree or disagree simply by chance. The kappa statistic (or 
kappa coefficient) is the most commonly used statistic for this purpose (Vierra & Garrett, 
2005). A general rule of thumb for significance for the Kappa statistic is any value that is 
greater than .6 indicates significant agreement between the two groups, while a kappa of 
1 indicates perfect agreement, and a kappa of 0 indicates agreement equivalent to chance 
(Sim & Wright, 2005).
Overall family raters reported an average of 9.75 out of 11 physical symptoms 
assessed. The most common and distressful symptoms reported (98.1%), by family raters 
on day-1 was pain and shortness of breath, with a symptom distress score mean of 2.73
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(SD=1.10) and 3.03 (SD=.900) respectively. Three other physiologic symptoms reported 
by 96.2% of FRs were lack of energy (fatigue), lack of appetite, and feeling drowsy, with 
the symptom distress score mean (standard deviation in parentheses) of 3.32 (.53), 2.44 
(0.30), and 2.85 (.83). The next most common symptoms were difficulty concentrating, 
difficulty sleeping, nausea, and weight loss . The least bothersome symptoms reported on 
day-1 were constipation (69.9%) and dry mouth (56.6%).
Psychological symptoms reported most frequently by the FR were worrying 
(98.1%), feeling sad (94.3%) and feeling nervous and (94.3). Symptom distress score 
means for the psychological symptoms (standard deviations in parentheses) were 2.65 
(.81), 2.54 (.83), and 2.66 (.77) respectively. Table 24 provides an overview of family 
ratings on day 1 and day 3.
















Means and Standard Deviations for Mean Symptom Distress Day 1 and Day 3-Family Raters
Day 1
B other or  D istress in  P ast 7 days
Day 3
B oth er  or D istress sin ce 2 D ays A go
P hysical Sym ptom s n(%) Mean Sx Distress Score n (%) Mean Sx Distress Score
(Std Dev) (Std Dev)
Lack o f energy (fatigue)* 51(96.2) 3.32(.539) 46(86.8) 3.94(.199)
Lack o f appetite* 51(96.2) 2.44(1.30) 45(84.9) 3.30(.629)
Pain* 52(98.1) 2.73(1.10) 46(86.8) 3.72(.420)
Dry mouth* 30(56.6) 1.36(1.31) 45(84.9) 2.72(.807)
Weight Loss* 44(83) 1.70(1.53) 26(49.1) 1.93(1.57)
Feeling drowsy* 51(96.2) 2.85(.835) 45(84.9) 3.59(.500)
Shortness o f breath* 52(98.1) 3.03(.900) 45(84.9) 3.80(.423)
Constipation 37(69.8) .864(1.05) 37(69.8) 1.05(1.22)
Difficulty sleeping* 47(88.7) 1.83(1.36) 42(79.2) 2.59(1.15)
Difficulty concentrating* 49(92.5) 3.05(.705) 46(86.8) 3.65(.400)
Nausea 45(84.9) 1.67(1.42) 45(84.9) 2.38(1.21)
CMSAS-PHYS Subscale 2.54(.540) 3.33(.321)
Day-1 (mean/Std. Dev.)
CMSAS-PHYS Subscale is the average of the nine (*) Items
F req u en cy  o f  Sym ptom F req u en cy  o f  O ccurrence S ince 2
O ccurrence in  P a st 7 days D ays A go
Psychological Sym ptom s n (%) Mean Sx Distress n(%) Mean Sx Distress Score
(Std Dev) (Std. Dev.)
Worrying 52(98.1) 2.65(.814) 48(90.6) 3.58(.498)
Feeling sad 50(94.3) 2.54(.838) 48(90.6) 3.71 (.504)
Feeling nervous 50(94.3) 2.66(.772) 48(90.6) 3.54(.582)
CMSAS-PSYCH Subscale 2.58(.706) 3.61(.431)
CMSAS Total Distress Score 2.56(.502) 3.40(.298)
CMSAS-PSYCH Subscale is the average o f the 3 Psychological Symptoms; CMSAS Total Distress Score is average o f all symptoms.
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Patient and Family Member Concordance 
Crosstabs with the Pearson Chi-Square and Cohen’s Kappa statistics were 
computed to assess the concordance between patients and family members on ratings of 
CMSAS symptom presence. These results can be found in Table 25. Only a subset of the 
symptoms are presented in the tables because some of the symptoms had a constant 
reported value of yes for at least one of the reports (i.e., patient, family member) and, 
therefore, the Chi-Square and Kappa statistics could not be computed. The p-value 
associated with the Chi-Square statistic indicates whether the null hypothesis, that the 
patient and family member ratings are independent or unrelated, should be accepted. If 
the p-value is less than .05 then the null hypothesis is rejected indicating that the patient 
and family ratings are related. Cohen’s Kappa statistic was included to measure the 
agreement between the patient and family member ratings of symptom presence.
The Chi-Square results indicated that on Day-1 there was significant relatedness 
between the patients and family members for the physiological symptoms, but not for the 
psychological symptoms. The Kappa statistic for Day-1 symptoms was not as clear in 
which there was significant agreement between patients and family members for lack of 
energy, lack of appetite, weight loss, drowsy, difficulty sleeping, difficulty concentrating, 
and nausea while there was no significant agreement between pain, dry mouth, shortness 
of breath, and constipation.
The Chi-Square results indicated that on Day 3 there was significant relatedness 
between the patients and family members for some of the physiological symptoms 
(weight loss, constipation, and nausea) while none of the psychological symptoms were 
evaluated due to constant values (see Table 25). The Kappa statistic for Day-3 symptoms
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indicated that there was significant agreement between patients and family members for 
weight loss and nausea, but not for constipation.
Table 25
Concordance between Patient and Family Raters on Day 1 and Day 3 CMSAS Symptom
Prevalence
df n X2 (p-value) Kappa
CMSAS Symptom Day 1
Lack o f Energy 1 53 25.99 (p<.05) .66
Lack o f Appetite 1 53 22.80 (p<05) .66
Pain 1 53 18.15 (p<.05) .57
Dry Mouth 1 38 9.89 {p<.05) .49
Weight Loss 1 49 25.42 (p<.05) .72
Drowsy 1 52 21.72 (p<.05) .65
Shortness o f Breath 1 52 5.24 (p=.02) .30
Constipation 1 41 9.90 (p<.05) .49
Difficulty Sleeping 1 52 23.22 (p<05) .67
Difficulty Concentrating 1 53 22.16 (p<.05) .65
Nausea 1 51 26.51 (p <  05) .72
Sad 1 51 0.37 (p=.54) -.09
Nervous 1 52 0.09 (p=.77) -.03
CMSAS Symptom Day 3
Lack o f Appetite 1 44 0.50 (p=. 83) -.03
Dry Mouth 1 43 0.14 (p=.71) -.04
Weight Loss 1 27 12.71 (p<.05) .64
Constipation 1 39 14.45 (p<.05) .58
Difficulty Sleeping 1 42 0.72 (p=.40) .13
Nausea 1 45 29.01 (p<.05) .78
Overall, these results point to some agreement between patients and family 
members regarding the presence of CMSAS physiological symptoms, with higher 
agreement on Day-1 than Day-3. There was no significant agreement found between 
patients and family members regarding the presence of CMSAS psychological 
symptoms. Figure 3 provides an overview of the concordance between symptom ratings 
by patients and families.
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Figure 3. Correlation of Symptom Prevalence: Patient/Family Comparisons (Day-1)
Day 1 Sym ptom  Prevalence: Patient-Family C om parison
ED P a tie n t  ■  F am ily  M e m b e r
Prevalence o f  physical and psychological symptom prevalence reported by patients and fam ilies. The figure show s the percentage o f  patients 
(n=80) and family respondents (n=53) providing self-reports, who responded that the symptom was present.
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Figure 4. Correlation of Symptom Prevalence: Patient/Family Comparisons (Day-3)
Day 3 Sym ptom  Prevalence: Patient-Family Com parison
E3 P a tie n t
E  8 0
£  6 0
Prevalence o f  physical and psychological symptom prevalence reported by patients and fam ilies on day-3 o f  ICU Care. The figure show s the 
percentage o f  patients (n=66) and family respondents (n=48) providing self-reports, w ho responded that the sym ptom  w as present.
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Chapter Summary
This chapter presented the results of the data analysis in three sections—a 
description of the sample and the demographic data; analysis of study aims, and data 
analysis related to each research question. The null hypothesis was only partially 
supported, as there were some correlations noted regarding age, gender and symptom 
distress, yet no correlation between age, severity of illness and overall mortality were 
found. Significant correlations were found in relationship to symptom distress and the 
number of chronic health conditions.
Comparisons were done to measure critically-ill patient-rated symptoms and 
distress scores for concordance, with those rated by designated surrogate-responders. 
Overall, results point to some agreement between patients and family members regarding 
the presence of CMS AS physiological symptoms, with higher agreement on Day-1 than 
Day-3. There was no significant agreement found between patients and family members 
regarding the presence of CMSAS psychological symptoms.
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Summary, Conclusions, Implications, and Recommendations
Overview
In this study, symptom burden (prevalence, intensity, frequency) and overall 
distress among (N=80) critically ill patients at end-of-life was investigated, using the 
University of San Francisco, Symptom Management Conceptual Model (Dodd et al., 
2001; Larson et al., 1994) as a theoretical framework and the Condensed Memorial 
Symptom Assessment Scale (Chang et al., 2004), as the multidimensional instrument to 
measure the symptom experience. Proxy assessment (N=53) was also obtained, to 
provide a greater understanding of a patients’ symptom burden, and to investigate the 
accuracy and utility of observer rated assessment. Symptom assessment is important 
because symptoms directly influence patient distress, quality of life, survival, and family 
experiences during the dying trajectory. Although the goal of patient comfort is embraced 
almost universally, deficiencies in the symptom database and inadequate instrument 
development have hampered research and the achievement of this goal in the ICU. This 
chapter will present the meaning and the significance of the study findings, along with 
correlates in the literature. The strengths and limitations of this study are also reviewed.
139
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Finally, the implications of the study findings and directions for future research are 
outlined.
Symptom Burden Findings 
This is one of the first studies among non-cancer populations in critical care, 
which focused on the symptom burden during critical illness and the first systematic 
examination of symptoms reported in real time by a cohort of ICU patients. The study 
provided strong evidence that among the patients providing self-report, multiple physical 
and psychological symptoms were prevalent, causing substantial patient distress.
Overall patients reported an average of 10.23 out of 11 physical symptoms 
assessed. The two most common physiologic symptoms reported on day-1 by 98.8% of 
patients, were lack of energy (fatigue) and difficulty concentrating, with a mean symptom 
distress rating of 2.96 (SD = 0.70) and 2.79 (SD = 0.80) respectively on a scale of 1 = 
least bothersome to 4 = most bothersome. The next most common symptoms were 
feeling drowsy (97.5%), feeling pain (95%), shortness of breath (95%), dry mouth (95%), 
and difficulty sleeping reported by 93.8% with a mean distress level scores (with standard 
deviations in parentheses) of 2.66 (0.84), 2.52 (1.21), 3.05 (0.88), 1.18 (1.22) and 1.84 
(1.42) respectively. The least bothersome symptoms reported on day-1 were constipation 
(87.5%), and nausea (87.5%) with a mean distress level scores (with standard deviations 
in parentheses) of 1.07 (1.10), and 1.62 (1.28) respectively.
On Day-3 of data collection, 66 patients remained in the study. Attrition was 
related to death (10%), patient discharges (5%), and failed capacity (5%) to complete 
study instrument (s). Overall, there was no significant difference in age, gender, ethnicity, 
and ICU admission source among those who did complete day-3 symptom assessments.
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The most prevalent symptom reported was difficulty sleeping (90.8%), with medium 
intensity 2.79 (SD=1.06).This finding is alarming, since many of the patients were 
receiving intravenous agents to reduce anxiety and improve overall relaxation, therefore, 
sleep should be enhanced. Approximately 80% of patients continued to have symptom 
distress related to lack of energy, lack of appetite, pain, dry mouth, feeling drowsy, 
shortness of breath, and difficulty concentrating, with moderate intensity mean of 3.42. 
Improved and scientifically tested symptom management strategies need to considered in 
order to improve the comfort and well-being of ICU patients near death.
The least bothersome symptoms on day-3 were constipation (72.5%), nausea 
(71.3%) and weight loss (67.5%). The CMSAS-PHYS Subscale mean of 3.07 (SD 
=0.46), compared to a mean of 2.19 (SD=0.71) on day 1. Patients continued to report 
psychological distress (worrying, feeling sad, feeling nervous), with a CMSAS-PSYCH 
Subscale 3.46, SD=0.52 on Day 3, compared to 2.45 (SD=.67) on day 1 of ICU care.
The symptom burden (prevalence, intensity, frequency,) and high distress (see 
Figure 4) found among ICU patients at risk for dying, is supported by prior research 
among cancer and a few non-cancer studies (Arnold & Liao, 2006; Caroci & Lareau, 
2004; Chang et al., 2000; Chang et al., 2004; Chochinov, 2006; Desbiens et al., 1999; 
Desbiens & Wu, 2000; Ellershaw & Ward, 2003; Friedrich et al., 2006; Kutner et al., 
2001; Nelson et al., 2004; Nelson et al., 2001; Solano et al., 2006).
Other sources (procedure-related interventions) of potential pain and suffering 
were examined among the study cohort. A number of frequently used procedures and 
nursing measures were found to be another source of distressing symptoms for patients 
(Table 20). The majority of patients reported procedures as severely painful and
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uncomfortable. These findings are similar to those reported by (Puntillo, 2001) who 
conducted a multisite study to examine the painfulness of procedures commonly 
performed in critical care and (Morrison et al., 1998) who examined rankings of pain and 
discomfort resulting from hospital procedures encountered by advanced dementia 
patients. These findings illuminate added stress and suffering for ICU patients all of 
which can be prevented with opioid and non-opioid agents along with other palliative 
measures to promote comfort. Other environmental/routine stressors reported by patients 
in this study included noise, inability to communicate (attributable to laryngeal 
intubation) and sleep disruptions and are consistent with other studies on discomfort and 
factual recollections in intensive care units (Puntillo, 2001; Puntillo et al., 1997; Rotondi, 
Chelluri, Sirio, Mendelsohn, & Schulz, 2002; van de Leur et al., 2004; van de Leur, 
Zwaveling, Loef, & Van der Schans, 2003).
Nearly all of the critically ill patients (97.9%) reported psychologic symptoms 
(worrying, feeling sad, and feeling nervous) with a mean distress score of 2.58 (SD=0.70) 
as the highest levels of frequency on day-1 and 3.50 (SD=0.58) on day-3. Overall patients 
reported a high level of symptom distress on day 1, with increasing severity and number 
of symptoms on day-3 of ICU care. These findings provide important data that suggests 
that increased severity of physiological symptoms, along with growing psychological 
distress, are important correlates for diminished quality of life and predictors of survival 
in patients with terminal illness and life-limiting illness (Chang et al., 2000; Chang et al., 
2004; Chang et al., 2000; Chang et al., 1998; Finlayson, Moyer, & Sonnad, 2004; Granja 
et al., 2005; Jordhoy, 2001; Kutner et al., 2006; Webb & Norton, 2004).
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Correlational Findings Related to Hypothesis 
Correlational analysis was conducted to examine the relationships between the 
independent variables of demographic characteristics, antecedent conditions (patient 
variables), and symptom burden. Age was also examined as a potential correlate of 
overall mortality. The influence of demographic factors (age, gender) on symptom scores 
was examined first. The correlations among these predictor variables were significant 
among age with physiologic symptoms (r=-.34, .05; r =-.33,p<.05; r =-.32,/><.05; 
r -  -.30,/K.05; and psychologic symptom distress day-1 (r = -.43,/K.05; r=-.22,p<.05 
and day-3 (r=-.32,p=.0l', r=-.25,p=.05; r=-.25,p=.04).
T-tests were computed to examine gender differences among symptom prevalence 
and distress. Females reported higher levels of distress for lack of appetite (r = .26, 
p=.02), dry mouth (r = .26, p=.02), and feeling drowsy (r = .22, p=.05). In contrast, 
males reported higher levels of distress related to constipation (r= -.36, p=.05) on day 1 
and day 3 (r= -.32, p=.01). Age was negatively correlated with pain ( r  = -.27, p=.02) and 
difficulty sleeping (r = -.26, p=.02) on Day-1 and with nausea (r = .34, p=.0\) on Day 3. 
Overall these findings have some limitations/bias, as males represent (63%) of study 
cohort versus (38%) women. In addition, men and women differ with respect to the 
prevalence of diseases such as cardiovascular and autoimmune diseases, the sensory 
perception of pain, symptom report, illness behavior health care use, and treatment 
response (Middendorp; & et al, 2005). Recent research shows (Chen et al., 2005) that 
women are less likely than males to experience typical chest pain/discomfort, 
pain/discomfort in the left side of the chest, and chest pain/discomfort as the most 
worrisome symptom among men and women with acute coronary syndromes (ACS).
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Further studies are needed which include more women, to eliminate research bias and to 
extend our knowledge base regarding the gender differences, in some of the most crucial 
health conditions (e.g. heart disease; pulmonary) which are leading causes of death 
nationally (CDC, 2000).
Pearson correlations were computed to examine the relationship of CMS AS 
symptom distress and chronic health conditions. Findings indicate there are a number of 
chronic health conditions that contribute significantly to the symptom burden among the 
study cohort, with eight of fifteen co-morbidities correlating to significant symptom 
distress. Symptom distress was correlated with several of the top five admitting diagnoses 
to the ICU. Respiratory disease was the #2 top admitting diagnosis to the ICU. Patients 
with respiratory failure had multiple distressing symptoms on Day 1- lack of energy 
(r=0.24 p= .03); feeling drowsy (r=.30 p= .01); shortness of breath (r=.30 p=.01); 
difficulty concentrating (r=.38 p=.05) and a CMSAS PHYS distress score of (r=.25 
p=.03). Trauma had a significant negative correlation with lack of energy (r=-0.68, p = 
0.05, feeling drowsy (r=-0.36, p = <.05) and CMSAS-PHSY subscale (r = - 0.39, p = 
<.05). Hematological disease is significantly positively correlated with feeling drowsy (r 
= 0.26, p = 0.03) and nausea (r = 0.37, p = <.05); muscular skeletal disease has a 
significant negative correlation with shortness of breath (r = - 0.24, p = .05) and difficulty 
concentrating (r = 0.24, p = .05). GI disease is significantly positively correlated with dry 
mouth (r = 0.23, p = .04), and CMSAS-PHYS Subscale (r=0.24 p= .03). Cerebral 
vascular accident has a significant negative correlation with difficulty sleeping (r= 0.28, p 
= .01) and is significantly positively correlated with difficulty concentrating (r= 0.22, p = 
.05). Neurological conditions is significantly positively correlated with weight loss (r =
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0.30, p = .01). Disease severity (using APACHE III risk estimates for mortality risk) and 
a patients’ chronic health status (comorbidities), would appear to be a more important 
factor associated with higher symptom burden and decreased quality of life. The most 
important results clinically from this research, is that persons with advanced, multiple- 
chronic diseases are polysymptomatic, and that symptom prevalence is multifactorial 
(Husain et al., 2007; van Middendorp, 2005).
Age and Relationship to Mortality
Age is thought to be strongly associated with intensive care outcomes, however, 
this relationship is confounded by many clinical variables (Vosylius et al., 2005). Age 
was not found to have a significant relationship to overall mortality (r=-.143, p=.205) and 
(r=-.143, p=1.00) in this study, despite the high mortality (21%), nor was it a correlate of 
severe symptom distress. However, the presence of severe chronic diseases was more 
common among elderly patients. Studies support mortality rates are higher in elderly ICU 
patients than in younger patients (de Rooij & Hanna, 2005), however, it is not age per se 
but associated factors such as severity of illness and premorbid function status, that 
appear to be responsible for the poorer prognosis (Angus et al., 2004; Arabi et al., 2002; 
Chelluri & Grenvik, 1995; Chelluri et al., 1993; Esteban, 2004; Hamel et al., 1999).
Some studies indicate that hospital mortality for patients aged 80-84 years, can be as high 
as 85% for those with infection as their reason for admission, as compared with 58% for 
those with diagnoses of GI disorders (de Rooij et al., 2005). In another study (van Den, 
Vogelaers, Afshrift, & Colardyn, 1999) found in-hospital mortality in elderly patients on 
mechanical ventilation due to pneumonia was 62%, in comparison to 40% in ventilated 
trauma patients. Outcome after brain injury in geriatric trauma patients is notoriously
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poor with mortality and functional disability rates twice those in younger patients (van 
Den et al., 1999). In a general population of all ages it was shown that 13.6% of the 
predictive power of the Acute Physiology and Chronic Health Evaluation (APACHE) III 
model was due to admitting diagnosis. Studies also support, as this study did (25%), that 
mortality after ICU discharge occurred predominantly during the first 3 months, and was 
found to be higher among the elderly (de Rooij et al., 2005). Research also indicates that 
mortality among the elderly is also related to pre-hospital functional independence (Arabi 
et al., 2002), although this was not assessed in the current study.
Assessment o f  Proxy Symptom Report
The use of an integrated symptom assessment approach, involving patient and 
proxy ratings, would be of great value across the spectrum of critically ill patients. For 
cognitively intact patients, a consensus of patient and proxy assessments would be an 
ideal outcome. Even with discordant assessments, the use of such an integrated approach 
could help address apparent differences in symptom assessment among patients, and 
various raters. For cognitively impaired patients, the selection of individuals who may 
best understand and represent the patient’s symptom experience would also be an ideal 
outcome. Hence, it would then be important to determine the degree of consistency of 
ratings across patients and surrogates.
The current study is the first attempt, to examine the reliability of patient and 
proxy symptom ratings concurrently among critically ill patients and families, using the 
Condensed Memorial Symptom Assessment Survey (CMSAS). Every effort was made to 
include family respondents, in order to determine the utility and accuracy of proxy ratings 
of patient symptoms, and different explanatory factors for patterns of disagreement
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between the two groups. Levels of agreement among patient and family raters were 
analyzed using crosstabs with chi-square to test for concordance and the Kappa Statistic.
Overall, family raters reported an average of 9.75 out of 11 physical symptoms 
assessed. The most common and distressful symptoms reported (98.1%), by family raters 
on day-1 was pain and shortness of breath with mean symptom distress scores of a 2.73 
(SD=1.10) and 3.03 (SD=.90). Three other physiologic symptoms rated at 96.2% were 
lack of energy (fatigue), lack of appetite, and feeling drowsy. Other symptoms were 
difficulty concentrating, difficulty sleeping, nausea and weight loss. The least bothersome 
symptoms reported on day-1 were constipation and dry mouth. Figures 5- 6 illustrate the 
comparison of average symptom distress means, reported by patients and families on day 
land day 3.
Psychological symptoms reported most frequently were worrying, feeling sad, 
and feeling nervous. The levels of agreement between patients and significant others 
regarding symptoms indicated that on Dayl there was significant relatedness between the 
patients and family members for the physiological symptoms, but not for the 
psychological symptoms.
For Day 3 there was a significant relationship between the patients and family 
members for some of the physiological symptoms (weight loss, constipation, and nausea). 
None of the psychological symptoms were evaluated due to constant values. The Kappa 
statistic for Day 3 symptoms indicated that there was significant agreement between 
patients and family members for weight loss and nausea, but not for constipation.
Overall, these results point to some agreement between patients and family members 
regarding the presence of CMSAS physiological symptoms, with higher agreement on
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Day 1 than Day 3. There was no significant agreement found between patients and family 
members regarding the presence of CMSAS psychological symptoms.
This study sought to advance our understanding of the relationships among proxy 
and patient reports of symptom distress. A number of studies that compare patient and 
proxy symptom ratings have been conducted, however, many of these have focused on a 
single symptom, such as pain (Desbiens & Mueller-Rizner, 2000; Dudgeon & Lertzman, 
1998; Fraser, 2000.; Gift et al., 2003), using physicians, nurses, and/or primary family 
caregivers as proxy raters. More recently, a number of studies have focused on the role of 
proxy assessment in palliative care (Kristjanson, Nikoletti, & Porock, 1998; Kutner et al., 
2006; Lobchuk et al., 2006; McPherson & Addington-Hall, 2003; McPherson & Hall- 
Addington, 2004; Nekolaichuk et al., 1999). Although research findings remain 
inconsistent across studies, there are also notable trends. Both health care providers and 
significant caregivers tend to underestimate quality of life and performance status of 
patients, while overestimating physiological symptoms. Within the realm of quality of 
life, family proxy most often under-estimate the psychological symptoms and well-being 
of patients.
In contrast, other studies have shown no differences across rater groups. For 
example, results from a study comparing patient and proxy assessments, using the 
Memorial Symptom Assessment Scale (MSAS), revealed that professional assessments 
were comparable to patient and family assessments (Higginson et al., 2003). Similarly 
(Sneew, Aaronson, & Sprangers, 1997) concluded that proxy ratings of quality of life 
were reasonably consistent with patient ratings, although there were greater discrepancies 
in patient-proxy scores in physically and cognitively impaired patients.
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Despite these inconsistent findings, proxy raters play an important role in 
symptom assessment in advanced cancer patients and patients with terminal and life- 
threatening illness. There are a number of key reasons why proxy assessments may be 
helpful or necessary: (1) to provide an additional perspective when patients overreport or 
underreport their symptoms (Coppolino & Ackerson, 2001). (2) to minimize the impact 
of inaccurate assessments of healthcare providers on symptom management (Cleeland et 
al., 2000). (3) to increase the reliability of symptom assessment measures (Nekolaichuk 
et al., 1999), and (4) to reduce the loss of missing data in longitudinal studies (Kutner et 
al., 2006; Mularski & Osborne, 2003; Oi-Ling et al., 2005).
The current study adds to the scientific knowledge of symptom management and 
can serve as a framework to use for regular symptom assessments within various clinical 
settings. Through the development of a reliable integrated symptom assessment approach 
that incorporates multiple raters and multidimensional profiles, effective interventions 
will ultimately enhance patients’ comfort and quality of life can be made. Further 
research is needed in critical care, to study the trajectory of symptoms across their illness 
and to explore individual differences among raters (Coppolino & Ackerson, 2001; 
Desbiens & Mueller-Rizner, 2000; Engelberg et al., 2005; Hayes, 2003; Levenson et al., 
2000; Shalowitz et al., 2006)















Figure 5. Symptom Distress Means: Patient-Family Comparison (Day-1)
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Figure 6. Symptom Distress Means: Patient-Family Comparison (Day-3)
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represents the distress rating scale of 0 to 4.
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Research Strengths and Limitations 
Although researchers have begun to investigate the symptom burden at end-of-life 
in patients with cancer, scant research has been conducted among critically ill patients 
and their families. This has been one of the first studies to systematically examine the 
symptom burden and quality of life in real time, as reported by patients and designated 
proxies, among critically ill patients. This study was important in advancing the science 
of understanding the symptom experience of patients at EOL in intensive care units. The 
symptom management model described by Larson and colleagues (1994), provided a 
strong conceptual framework for the study. Utilizing the symptom management model 
assisted the researcher in building a theoretical framework for exploring symptom 
management in patient with complex diseases, receiving life-prolonging therapies. 
Extending the utilization of the CMS AS instrument to other important populations, was 
an important in bridging the gap of measurement issues in patients at EOL.
Limitations
When interpreting the results of this study, important limitations need to be 
considered. First, this cohort study was conducted as a single-center study. Although this 
yielded a therapeutically homogeneous, and ethnically diverse study population, it may 
preclude wide generalization of the results to other health care centers, because of 
institution-based differences in treatment, patient population, and admission policies. 
Another potential limitation is that APACHE III prognostic model predictions are 
exclusively based on data obtained during the first 24 hours after ICU admission and that 
they do not take into account complications that may develop during treatment. It has 
also been shown that the accuracy of prognostic models based on data from the first 24
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hours after ICU admission is maintained at an acceptable level only in patients who stay 
in the ICU for a short period of time. Finally, although the research instrument was 
designed to be read and completed by patients, many patients were too ill to read the 
CMSAS/and record their responses, thus the researcher read the questionnaire to patients, 
and often recorded their response. This occurred on many occasions, since many ICU 
patients were not free of physical restraints in their hands/wrists due to IVs and 
monitoring devices. This process may have decreased the internal validity of the 
questionnaire responses.
Conclusions
There is limited research addressing the end-of-life needs of critically ill patients 
with life-limiting illness. According to the literature, this is the first study focusing 
specifically on the symptom burden during critical illness, and the first systematic 
examination reported in real time by a cohort of ICU patients in medical/surgical and 
trauma units. This study found that hospitalized ICU patients at high-risk for hospital 
death (APACHE Mortality Risk .60-.80), experience a high prevalence of physical and 
psychological symptoms with only limited treatment of significant distress. These 
findings were supported by proxy raters overall. Given the level of symptom distress 
found, and the high mortality rate, that this research and others have observed, there is an 
urgent need for critical care clinicians to pay greater attention to the dying patients 
overall symptom distress, and provide evidence-based relief of pain and other distressing 
symptoms in this population. Furthermore, given the high probability of death and severe 
functional impairment following critical illness, the critical care team should maximize 
palliative care therapies, while initiating discussions with patients and their surrogates
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about achievable goals for medical care and to establish treatment plans consistent with 
these goals to minimize preventable pain and discomfort and improve their quality of life.
Implications for Nursing Practice
The routine self-assessment of symptoms is beneficial for patients as it give 
patients the opportunity to voice their health-related concerns and provides the most valid 
and reliable method for capturing symptom data. Routine assessments are essential for 
nursing because nurses are responsible for monitoring and managing patient symptoms, 
particularly among vulnerable populations such as ICU patients. Nurses must test and use 
valid instruments to assess their patients more systematically, and identify changes over 
time. Interventions need to be developed and tested through clinical research trials, to 
assure that critically ill patients near end of life receive maximum relief for both 
physiological and psychological symptom distress.
Future Research
Research on the natural trajectory of symptoms for both chronic and critical 
illness is necessary, in order to understand the multi-dimensional nature of the symptom 
experience of diverse patients and to enhance patient care. Further studies should also 
include more formal evaluation of the efficacy of these interventions to help point the 
way to consistent and high quality care for all dying patients. Researchers must continue 
to examine patterns of proxy reporting, because as dying patients become unable to 
communicate, proxy respondents become the primary source of data, whereas 
investigators can contribute to our body of knowledge in multiple ways.
Clinicians must also conduct research developing and testing theoretical 
conceptual models of the experience of dying. This may occur at the level of the study
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section, in which investigators are encouraged to link variable and measurement selection 
to testing specified theoretical constructions. Large scale efforts to improve measurement 
uniformity is currently underway by NHPCO and its advisors, who have identified the 
domains of end of life care, to be further tested among patients and families with a 
variety of illnesses.
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Appendix A 
PI Log and Monitoring Record
Investigator:_____________  Subject Study ID #
Date:
P atien t E nrollm ent Y es N o D ate  o f  P atien t/F am ily
In terv iew
P hone:
Patient must meet A L L  of the following Inclusion Criteria
1) age >18;_______________________________________________________________________
(2) mental capacity to consent, assessed using the Richmond Agitation Sedation Scale (RASS) 
and Cognitive Assessment Method-ICU (CAM-ICU)___________________________________
(3) ability to speak, read and understand English or Spanish;_____________________________
(4) ability to complete the self-report instrument through written, verbal or alternative methods, 
e.g., if questionnaire read to patient by Primary Investigator (PI) or Research Assistant (RA);
(5) a first-day (within 24-h of ICU Admission) Acute Physiology & Chronic Health Evaluation
(APACHE III) risk estimate for hospital death (.60 —.80).________________________________
O ther notes: E X C L U D E : R eason
E xclusion  C riteria  (1) <18 years of age; (2) diagnosis of cancer and receiving related 
treatments; (3) patients with a principal diagnosis of dementia or patients with altered level of 
consciousness.
D em ographic In form ation G ender
□ M ale □ F em ale
L an gu age
Spoken
□ E nglish
□ Spanish  
O ther
H ealthcare In su ran ce A ge R elig ion
□ P rivate/C om m ercia l D O B □ Jew ish
□ M edicare □  M edicaid R ace □ N on e, N ot
□ H M O  D N one /S elf-p ay □ W h ite R elig iou s
□ B lack □ R om an
□ H isp an ic C atholic
□ A sian □ Jehov. W it.
□ N ative □ C hristian
A m erican Scientist
□ O th e r ___ □ Seventh  D ay  
A d ven tist
□ P rotestan t
A d m ission  D iagn ostic  C ategory  
(L ocation  prior to  IC U  A d m ission )
□ ER □ OR: Scheduled □
OR Non-Scheduled □
Other Hospital______________  □
Special Procedure Area □
Medical Floor______
□ Other ICU
H osp ita l A d m it D ate
IC U  A dm it____________
R M # __________________
R eadm ission  from :_________
IC U  M D  T ea m tsl:
M edical/In  ten siv ist/ T rau m a/




Subject Study ID #_
Patient’s Primary Medical 
Doctor
F am ily  In form ation
□Married □ Single □ Widow □ Divorced 
A dv. D irective at A d m ission  □ Yes □ No
Surrogate:_________________
D esignated  F am . R esp on d en t
Spouse □ Patient’s Child □
Pts Parent □ Pts Sibling □
Friend □ Partner □ Other
Phone:__________________
Was this person Pts caregiver? Y es □  N o □
A P A C H E  III A P A C H E  III
P red icted  R isk  for S core (0-299)
H osp ita l D eath
D ay 1 D ay
l(A d m issio n )
D ay  2
D ay  2
D ay
D ay 3
A P A C H E  H I
P red icted  R isk  for
IC U  D eath R A S S  Score
D ay  1 Day 1
Day 3
D ay 2
C A M -IC U
D ay 3 Day 1___□
Negative □
I f  no A P A C H E  III Positive
D ata  on D ay  3 Day 3 □
W hv Negative □
Positive
I f  patient
w ith d raw n  from
study ind icate C ognitive
w hv. C hanges
Patients Admitting Diagnosis:
P lease check  all C h ron ic  H ea lth  C onditions th at apply
□ History of cardiac disease, congestive heart failure, or angina 
(specify)___________________________________________
□ Endocrine (specify other disorders)__
□ Diabetes, type I □ Diabetes, type II _
□ Gastrointestinal (GI) Disease (specify)
□ Neurologic conditions (specify) .
□ Cerebral Vascular Accident________
□ Renal Disease (specify)____________
□ Liver Disease (specify)____________
□ Musculoskeletal Disease(specify)_
□ Hematological disease (specify)_
□ Respiratory Disease (specify)____
□ Sepsis (specify)_______________
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□ Other (please specify)
O u tc o m e  D a ta
H o sp ita l A d m it :___________________ A d m it  to  IC U :__________________
D isc h a r g e  fr o m  IC U  - D a te :__________________D isc h a r g e  L o c a tio n
R e a d m itte d  to  I C U  fr o m  d is c h a r g e  u n it :____________________
L O S : IC U :________________ D is c h a r g e  D a te
H o sp ita l:____________ L O S :__________________
A live -In p atien t D isch a rg ed  F IX ):
W as P atien t m ade a  D N R  b efore transfer from  IC U  to  o th er u n it/or IP D  from  hospital?
□ yes □ no IP D C  L ocation: □ Hom e □ Hom e Health □ LTC □ H ospice □ M W R  
In-P atient E xp iration  (IP E ) D a te :__________________
W as patient D N R  a t tim e o f  death?  □ yes, If yes, date written_____________□ N o _____
W as T reatm ent W ith h eld  o r  W ith d raw n  before death?________________________
30-D ay  O utcom e /  L ocation  /  P a tien t S ta tu s______________________________
P redicted  M orta lity : O bserved  M orta lity:______________________
Standardized M orta lity  R atio  (SM R ) ___________________________________
F inancial O utcom es:
P rim ary D R G ___________ ($)______________________ T otal H osp ita l_C osts($):______________
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Appendix B
Richmond Agitation and Sedation Scale (RASS) and Cognitive Instrument CAMU-ICU
(English/Spanish)
Linking Sedation and Delirium Monitoring 
A Two Step Approach to Assess Consciousness
Step One: Sedation Assessment
The Richmond Agitation and Sedation Scale: The RASS
Score T erm D escription
+4 Combative Overtly combative or violent; immediate danger to staff
+3 Very agitated Pulls on or removes tube(s) or catheter(s) or has aggressive 
behavior toward staff
+2 Agitated Frequent non-purposeful movement, patient fights ventilator
+1 Restless Anxious but movements not aggressive or vigorous
0 Alert and calm
-1 Drowsy Not fully alert, but has sustained awakening 
(eye-opening/eye-contact) to voice (> 10 seconds)
-2 Light sedation Briefly awakens with eye contact to voice (<10 seconds)
-3 Moderate sedation Movement or eye opening to voice (b u t no eye  contact)
-4 Deep sedation No response to voice, but movement or eye opening to 
physical stimulation
-5 Unarousable No response to voice or physical stimulation
IF RASS IS -4 or -5, then Stop and Reassess patient at later time 
IF RASS is above -4 (-3 through +4) then Proceed to Step 2 
*Sessler, & et al.,(2002). Am JR espir Crit Care Med, 166, 1338-1344.
*Ely, et al., (2003). JAMA, 289, 2983-2991.
Step Two: Delirium Assessment
Feature 1: Acute onset of mental status changes 




Feature 3: Disorganized Thinking
— 1 OR 
= DELIRIUM
Feature 4: Altered Level of 
Consciousness
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CAM-ICU Worksheet
Feature I: Acute Onset or Fluctuating Course
Positive if you answer 'yes' to either 1A or IB .
Positive Negative
1 A: Is the pt different than his/her baseline mental status? Or 
1 B: Has the patient had any fluctuation in mental status in the past 24 hours 




Positive if  either score for 2A or 2B is less than 8.
Attempt the ASE letters first. If pt is able to perform this test and the score 
is clear, record this score and move to Feature 3. If pt is unable to perform 
this test or the score is unclear, then perform the ASE Pictures. If you 
perform both tests, use the ASE Pictures' results to score the Feature.
Positive Negative
2A: ASE Letters: record score (enter NT for not tested)
Directions: Say to the patient, "I am going to read you a series o f 10 letters. 
Whenever you hear the letter 'A' indicate by squeezing my hand." Read 
letters from the following letter list in a normal tone. SAVE A HAART 
Scoring: Errors are counted when patient fails to squeeze on the letter "A" 
and when the patient squeezes on any letter other than "A."
Score (out o f  10):
2B: ASE Pictures: record score (enter NT for not tested) 
Directions are included on the picture packets.
Score (out o f 10):
Feature 3: Disorganized Thinking
Positive if  the combined score is less than 4
Positive Negative
3A: Yes/No Questions
(Use either Set A or Set B, alternate on consecutive days if  necessary):
Set A Set B
1. Will a stone float on water? 1. Will a leaf float on water?
2. Are there fish in the sea? 2. Are there elephants in the 
sea?
3. Does one pound weigh more than 3. Do two pounds weigh 
two pounds? more than one pound?
4. Can you use a hammer to pound a nail? 4. Can you use a hammer to 
cut wood?
Score (Patient earns 1 point for each correct answer out o f 4) 
3B:Command
Say to patient: "Hold up this many fingers" (Examiner holds two fingers in 
front o f patient) "Now do the same thing with the other hand" (Not 
repeating
the number o f fingers). *If pt is unable to move both arms, for the second 
part o f the command ask patient "Add one more finger)
Score (Patient gets 1 point if  able to successfully complete the entire 
command)
Combined Score (3A+3B): 
(out o f  5)
Feature 4: Altered Level of Consciousness
Positive if the Actual RASS score is anything other than "0" (zero)
Positive Negative
O vera ll C A M -IC U  (Features 1 and 2 and either Feature 3 or 4): Positive Negative
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Enlazando la Monitoria de la Sedacion y del Delirio: 
Un Enfoque en Dos Pasos para Valorar el Estado de Conciencia
P rim er paso: E va lu acion  de la  Sedacion























Combativo, violento, peligro inmediato para el grupo
Se jala o retira los tubos 6 cateteres; agresivo 
Movimiento frecuentes y sin proposito, lucha con el 
ventilador
Ansioso, pero sin movimientos agresivos o vigorosos
No esta plenamente alerta, pero se mantiene despierto 
(apertura y contacto ocular) al llamado verbal (> 10  
segundos)
Despierta brevemente al llamado verbal con contacto 
ocular (< 10 segundos )
Movimiento o apertura ocular al llamado verbal (pero 
sin contacto v isual)
Sin respuesta al llamado verbal, pero hay movimiento o 
apertura ocular al estimulo fisico
Sin respuesta Sin respuesta a la voz o estimulo fisico
Segundo naso: Evaluacion del Delirio
le r  Criterio: Inicio agudo de la alteracion del estado 





Si RASS es -4 or -5, Detengase y Reevalue el paciente posteriormente 
Si RASS es mayor a - 4 (-3 a + 4 ), entonces Proceda con el Segundo paso
2° Criterio: Inatencion
✓
Criterio 3: Pensamiento desorganizado O Criterio 4: N ivel de conciencia alterado
= DELIRIO
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Criterios > Dcscripeion del t 'A M -K  I
1. Inicio agudo o curso fluctuante | Ausente | Presente
A. Hay evidencia de un cambio agudo en el estado mental sobre el estado basal?
O
B. Ha fluctuado el comportamiento (anormal) en las ultimas 24 horas, es decir, tiende a aparecer y 
desaparecer, o aumenta y disminuye en severidad evidenciado por la fluctuacion en una escala de 
sedacion (p.e., RASS), Escala de Glasgow, o evaluacion previa del Delirio?
2. Innlciicirin Auscntc Presente
,;,Tuvo el paciente dificultad para fijar la atencion, evidenciada por puntajes menores a 8 en cualquiera 
de los
componentes visual o auditivo del Examen de Tamizaje para la Atencion (ASE)? (Instrucciones en la 
pagina siguiente).
3. Pensamiento desorganizado Ausente Presente
^Hay evidencia de pensamiento desorganizado o incoherente evidenciado por respuestas incorrectas a 
2 o mas
de las 4 preguntas, y/o incapacidad para obedecer ordenes?
Preguntas (Altemar grupo A y grupo B):
Grupo A Grupo B
1. ^Podria flotar una piedra en el agua? 1. ^Podria flotar una hoja en el agua?
2. (jExisten peces en el mar? 2. ^Existen elefantes en el mar?
3. ^Pesa mas ima libra que dos libras? 3. ^Pesan mas dos libras que una libra?
4. ^Se puede usar un martillo para pegarle a un clavo? 4. iS e  puede usar un martillo para cortar 
madera?
Otros:
1. ^Tiene usted algun pensamiento confuso o poco claro?
2. Muestre esta cantidad de dedos. (El examinador muestra dos dedos en frente del paciente).
3. Ahora repita lo mismo con la otra mano. (Sin repetir el mismo numero de dedos).
4. Nivel de Conciencia alterado Ausente Presente
^Tiene el paciente un nivel de conciencia diferente al estado de alerta, tales como vigilante, letargico, o
estupor?
(p.e., RASS diferente a “0” al momento de la evaluacidn)
Alerta: espontanea y plenamente conciente del medio ambiente e interactua apropiadamente
Vigilante: hiperalerta
Letargico: somnoliento pero facil de despertar, no conciente de algunos elementos del medio
ambiente, o no interactua de manera apropiada y espontanea con el entrevistador; 
llega a estar plenamente conciente e interactua apropiadamente con estimulos minimos
Estupor: Incompletamente conciente cuando es estimulado fuertemente; puede ser despertado
unicamente con estimulos vigorosos y repetidos, y tan pronto como el estimulo cesa , 
vuelve al estado de no respuesta
CAM-ICU general (Criterios 1 y 2 y cualquiera de los criterios 3 o 4):______ Si_______ No____________
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Appendix C 
Family Respondent Demographic Form (English/Spanish)
Primary Investigator: Peggy Kalowes RN, PhD
Study: Sym ptom  B u rd en  in  P atien ts w ith  L ife  T hreaten ing  Illn ess in  IC U  
R esp on d en t ID  C ode: D ate:
Study In stru m en ts: □  D em ograp h ic Form
C ondensed  M em oria l Sym ptom  A ssessm en t Scale (M SA S): D ay  1 □  Y es □ N o  
D ay 3 □ Y es □  N o  (In person  □ T elephone In terv iew  □ ) I f  D a y  3 is no,
W hv
P le a se  c o m p le te  th e  fo l lo w in g  q u e s t io n s . T h is  in fo r m a tio n  w i l l  b e  k e p t  s tr ic t ly  
c o n f id e n t ia l.
F A M IL Y  R E SP O N D E N T  D E M O G R A P H IC  FO RM
Y ou r D em ograp h ic In form ation: A ge: P hone  
N um ber:
G ender: □ M ale □ F em ale L anguage Spoken: □  E nglish  □ Spanish
□ O ther
R ace R elig ion
□ W hite □ B la ck  □ H isp an ic  □  A sian  □  Jew ish  □ R om an  C ath olic  □
□ N ative A m erican  □ O th er J eh o v a h ’s W itness
□ C hristian  S cientist □  Seventh  D ay  
F am ily  In form ation  A d ven tist
□ M arried  □  S in gle  □  W id ow  □ D ivorced  □ P rotestan t (all o th er  C hristian)
□  N one, N o t R elig ious
1. P lease id en tify  y o u r  relationsh ip  w ith  the patient.
□ Spouse □  P atien ts C hild  □ P a tien t’s S ib ling □ P a tien t’s P aren t D F riend D P artner  
□ O th er
2. A re you  th e  lega l Surrogate to  m ake decisions, i f  the patient is unab le to?
□ Y es □ N o
3. W as the patien t liv in g  at hom e prior to th is hosp italization? □ D o n ’t know  □ Y es □  
N o I f  no. p lease id en tifv  □ L iv in g  alone at hom e □ H om e w ith  fam ilv  or  friends □ 
A ssisted  liv in g  facilityD  N u rsin g  hom e
4. W ere you  p rov id in g  care for y o u r  loved one during  h is/h er  cou rse  o f  illness?
□ Y es □ N o
5. T o y o u r  k n ow led ge w as th e  patien t receiving any hom e health  serv ices, p rior to  
adm ission?
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FAMILY RESPONDENT DEMOGRAPHIC FORM
Your Demographic Information: Age: 
Number:______________________
Phone
Gender: □ Male □ Female Language Spoken: □ English □ Spanish 
□ Other
Race
□ White □ Black □ Hispanic □ Asian
□ Native American □ Other________
Religion
□ Jewish □ Roman Catholic □ 
Jehovah’s Witness
□ C hristian  Scien tist □ Seventh  D ay  
F am ily  In form ation  A d ven tist
□ M arried  □  S ingle □ W id ow  □  D ivorced  □ P rotestan t (all o th er  C hristian)
□ N on e, N o t R elig ious
□ Y es □ N o  □ D o n ’t k now  I f  ves. p lease identify  below
□ H om e health  nurse/a id  □ V isitin g  nurse □ H osp ice  □  R esp ira tory  C are, such  as 
O xygen □  C hurch  based m inistries □ O ther, p lease  specify
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Forma demografica para el respondedor familial 
Investigadora primaria: Peggy Kalowes RN, PhD
Estudio: Carga del sintom a en pacientes con enferm edades peligrosos para la vida en el cuidado 
intensivo
ID C6digo del respondedor:______________________ F ech a :_________________
Instrum entos del estudio: □ Forma demografica
Escala M em orial Condensada de Evaluacion de los Sintomas (CM SAS): Dia 1 □ Si □ No 
Dia 3 □ Si □ N o (En persona □ Entrevista por telefonoD ) Si por D ia 3 responde “N o”, £por 
que? _______________________________________________________________________________________
Por favor conteste las siguientes preguntas. Esta informacion sera mantenida confidencial.
F O R M A  D E M O G R A F IC A  P A R A  E L  R E S P O N D E D O R  F A M IL IA L
Inform acion  d em ografica  d e usted: Edad: 
telefono:
N u m ero de
G enero: □  V aron  □ H em b ra  Id iom a hablada: □ Ingles □ E sp an ol □ O tro
R aza
□ bianco □  negro □  h ispano  
□ asiatico
□ indio nativo am erican o  □ O tro
Inform acion  fam iliar
□ C asado(a) □ Soltero(a) □ V iudo(a)
□  D ivorciado(a)
R elig ion
□ Jud io □ C atolico  □ T estigo  de Jehova
□ C ientifico  cristiano □ A d ven tista  del septim o  
dia
□ P rotestan te (otros cristianos)
□ N ingunos, N o relig ioso
1. P or favor iden tifiq u e su relacion  con  el paciente.
□ Esposo/a □ Nino/a del paciente □ Hermano/a del paciente □ Padre del paciente 
□Amigo/a □ Socio/a DOtro______
2. ^Esta usted el sustito legal para tomar decisiones, si el paciente no pueda? □ Si □
No
3. ^Estaba viviendo el paciente en casa antes de esta hospitalizacion? □ No se □ Si □ No 
Si no. identifique nor favor □ Vive solo en casa □ Vive en casa con familia y/o amigos □ 
Facilidad de vida asistida □ Residencia de ancianos
4. ^Estaba usted cu id an d o  del paciente durante el curso de la  en ferm ed ad ? □  Si □  N o
5. Que usted sepa, ^estaba recibiendo el paciente algunos servicios de salud en casa 
antes de su ingreso?
□ Si □ No □ No Se Si si. identifique abaio
□ Enfermera en casa □ Enfermera visitante □ Residencia para enfermos desahuciados
□ C uidado resp iratorio , com o oxigeno □ M in istros de la  Ig lesia  □ O tro , especiflque  
por favor____________________________________________________________________________________
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F O R M A  D E M O G R A F IC A  P A R A  E L  R E S P O N D E D O R  F A M IL IA L
Inform acion  d em ografica  d e usted: Edad:_ 
telefono: _____________________
N u m ero de
G enero: □ V aron  □  H em b ra  Id iom a hablada: □  Ingles □ E sp an ol □ O tro
R aza
□ bianco □ negro □  h ispano  
□ asiatico
□ indio nativo am erican o □  O tro
Inform acion  fam iliar
□ C asado(a) □  Soltero(a) □  V iudo(a)
□ D ivorciado(a)
R elig ion
□ Jud io  □ C atolico  □  T estigo  de Jeh ova
□ C ientifico  cristiano □  A d ven tista  del septim o  
dia
□ P rotestan te (otros cristianos)
□  N in gu n os, N o religioso
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Appendix D
Patient Treatment and Procedure Survey (TPS)
Symptom Burden Study ICU
Study: R espondent ID Code:______________________ D a te :_________________
Patient Self-R eport Instrum ents: □ M SAS: D ay 1 □ Y es 0  N o D ay 3 □ Yes □ No 
Treatm ent & Procedure Survey (Patient) Day 3 □ Yes □ No I f  no, W hy___________
Painful Uncom fortable
Procedure M oderate Sc\ ere Total M oderate Severe Total
Arterial blood gas puncture 1 2 1 2
Arterial catheter insertion 1 2 1 2
Endotracheal breathing  
tube in place
1 2 1 2
Endotracheal suctioning  
(Airway)
1 2 1 2
Catheter in the bladder 1 2 1 2
M echanical ventilation  
(Breathing) m achine
1 2 1 2
M edications being given,
Intram uscular,
subcutaneous
1 2 1 2
M oving from bed to gurney  
to transport to special 
procedures
1 2 1 2
Nasogastric tube in place 
(nose or mouth)
1 2 1 2
Peripheral IV  catheter  
insertion
1 2 1 2
Central line insertion 1 2 1 2
Turning in bed (bath, 
positioning, upright for x-
ray)
1 2 1 2
Blood being drawn for lab  
specimens
1 2 1 2
Vital Signs being taken
Adapted from Nelson et al., 2001.
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Encuesta del tratamiento y procedimiento 
Estudio del carga del sintoma
Estudio: ID C 6digo del respondedor:_________________________________ F ech a :_______________
Instrum entos del paciente (reportado por si mismo): □ M SAS: Dia 1 □ SI □ No Dia 3 □ SI □ 
No
Encuesta del tratam iento y  procedim iento (Paciente) Dia 3 □ SiD N o Si no, £Por 
que?_________




Total M oderado Severo Total
Perforacion G ases en la 
Sangre Arterial
1 2 1 2
Insercion del Cateter arterial
1 2 1 2
El tubo endotraqueal para 
respirar (en lugar)
1 2 1 2
La succion endotraqueal 
(via aerea)
1 2 1 2
Cateter en vejiga
1 2 1 2
M aquina de ventilacion  
mecanica (respirar)
1 2 1 2
Dar m edicam entos, 
Intram uscular
1 2 1 2
M over de la cama a la Camilla 
para transportar a 
procedim ientos especiales
1 2 1 2
Sonda (tubo) naso gastrica en 
su lugar (nariz o boca)
1 2 1 2
Insercion del suero periferico
1 2 1 2
Insercion de la linea central 
del Cateter
1 2 1 2
Voltearse en la cam a (banos, 
posiciones, rayos x en posicion  
vertical)
1 2 1 2
Sacando sangre para los 
especim enes del laboratorio
1 2 1 2
Tom ando los vitales
Adaptado por Nelson et al., 2001.















In terv iew er ID:
Appendix E
Condensed M emorial Symptom Assessment Scale (CMSAS) Patient Version (English/Spanish) 
____________  Subject C ode:______________
How much did this symptom bother or distress you during the past 7 days?
Sym ptom P resent N o t a t all A  little  B it Som ew h at Q uite a  bit V ery  m uch
Lack o f energy* Y N 0 1 2 3 4
Lack o f appetite* Y N 0 1 2 3 4
Pain* Y N 0 1 2 3 4
Dry mouth* Y N 0 1 2 3 4
Weight Loss* Y N 0 1 2 3 4
Feeling drowsy* Y N 0 1 2 3 4
Shortness o f breath* Y N 0 1 2 3 4
Constipation Y N 0 1 2 3 4
Difficulty sleeping* Y N 0 1 2 3 4
Difficulty concentrating Y N 0 1 2 3 4
Nausea* Y N 0 1 2 3 4
How frequently did you experience these symptoms during the ast week?
Sym ptom P resen t R arely O ccasionally F req u en tly A lm ost
con stan tly
Worrying Y N 1 2 3 4
Feeling sad Y N 1 2 3 4
Feeling nervous Y N 1 2 3 4
OTHER SYMPTOMS
Identify  any other sym ptom s th at you  believe  
bothered you  during the p ast w eek . L ist them  below  
&  identify  how d istressfu l th ey  w ere.
N o t at all A  little B it Som e
w h a t
Q uite a  bit V ery  m uch
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4















Condensed Memorial Symptom Assessment Scale (CMSAS)
H ow  m uch did th is sym ptom  b other or  d istress you since I saw  you  2 days ago?
Sym ptom P resen t N ot at all A  little  B it Som ew hat Q uite a bit V ery  m uch
Lack o f energy* Y N 0 1 2 3 4
Lack o f appetite* Y N 0 1 2 3 4
Pain* Y N 0 1 2 3 4
Dry mouth* Y N 0 1 2 3 4
Weight Loss* Y N 0 1 2 3 4
Feeling drowsy* Y N 0 1 2 3 4
Shortness o f breath* Y N 0 1 2 3 4
Constipation Y N 0 1 2 3 4
Difficulty sleeping* Y N 0 1 2 3 4
Difficulty concentrating* Y N 0 1 2 3 4
Nausea Y N 0 1 2 3 4
How frequently did you experience these symptoms since I saw von 2 days ago?
Sym ptom P resent R arely O ccasionally F requently A lm ost constantly
Worrying Y N 1 2 3 4
Feeling sad Y N 1 2 3 4
Feeling nervous Y N 1 2 3 4
OTHER SYMPTOMS
Identify  any other sym ptom s th at m ay  have  
bothered you  in the past 2 days. L ist them  
below  &  identify how  d istressfu l th ey  w ere.
N ot a t all A  little  B it Som ew h at Q uite a bit V ery  m uch
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4




The scoring for the Condensed Memorial Symptom Assessment Scale (CMSASf is similar to that for the 
MSAS Short Form
For the top box (physical symptoms), weights o f  zero for N, 0.8 for not at all, 1.6 for a little bit, 2.4 for somewhat,
3.2 for quite a bit, and 4.0 for very much. The average o f the starred symptoms would be the PHYS subscale.
For the bottom box (psychological symptoms), weights o f  zero for N, 1 for rarely, 2 for occasionally, 3 for 
frequently, 4 for almost constantly. The average o f the 3 symptoms would be the PSYCH subscale. The average of  
all symptoms would be the CMSAS-SUM subscale. Chang, Hwang, Kasimis &Thaler, (2004). Shorter symptom 
assessment instruments: The condensed memorial symptom assessment scale (CMSAS). Cancer Investigation 22, 
526-536.
Memorial Symptom Assessment Scale (MSAS)
A 10 item MSAS Global Distress Index (MSAS-GDI) is considered to be a measure o f  overall symptom distress. 
The GDI is the average o f  the frequency o f 4 prevalent psychological symptoms (feeling sad, worrying, feeling 
irritable, and feeling nervous) and the distress associated with 6 prevalent physical symptoms (lack o f appetite, lack 
o f energy, pain, feeling drowsy, constipation, dry mouth). Portenoy, Thaler, Komblith, Lepore, Friedlander-Klar, 
Kiyasu E, et al (1994). The Memorial Symptom Assessment Scale: An instrument for the evaluation o f symptom 
prevalence, characteristics and distress. Eur J  Cancer 30(9), 1226-1336.
The Physical Symptom Subscale score (MSAS-PHYS) is the average o f the distress associated with 12 prevalent 
physical symptoms: lack o f appetite, lack o f energy, pain, feeling drowsy, constipation, dry mouth, nausea, 
vomiting, change in taste, weight loss, feeling bloated, and dizziness. Note that the scaling is in increments o f 0.8, 
with zero for no symptom, 0.8 for symptom present but no distress, and upwards for increasing levels of distress.
The Psychological Symptom Subscale score (MSAS-PSYCH) is the average o f  the frequency associated with 6 
prevalent psychological symptoms: worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and 
difficulty concentrating. Scoring is in increments o f one, with zero for no symptom to 4 for “almost constantly”. 
Total MSAS score (TMSAS) is the average o f  the symptom scores o f all 32 symptoms in the MSAS instrument.
Memorial Symptom Assessment Scale Short Form Subscales
In the short form, there is only one dimension for each symptom, distress for physical symptoms and frequency for 
psychological symptoms. The sequence o f  symptoms in the short form is different from that in the long form. 1. 
Chang VT, Hwang S, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom assessment scale short form 
(MSAS-SF). Cancer 2000b;89:l 162-1171.
Scoring of physical symptoms in the MSAS-SF is as follows:
Zero if the symptom is not present Scoring of psychological symptoms is
0.8 if  the symptom is present but causes no distress 0 if  the symptom is absent
1.6 if  the symptom is present and causes a little bit o f 1 if  the symptom is present and occurs rarely
distress
2.4 if the symptom is present and causes somewhat o f  2 if  the symptom is present and occurs occasionally 
distress
3.2 if  the symptom is present and causes quite a bit o f 3 if  the symptom is present and occurs frequently 
distress
4.0 if  the symptom is present and causes very much 4 if  the symptom is present and occurs almost
distress constantly
















Condensed Memorial Symptom Assessment Survey (CMSAS)—Family Respondent Version (English/Spanish) 
Condensed Memorial Symptom Assessment Scale (CMSAS) - Family Respondent (English)
Interviewer ID:_______________  Subject Code:_________
How much did this symptom bother or distress your loved one in the past 7 days?
Sym ptom P resent N ot at all A  little Som e Q uite a V ery N ot A plicab le D o n ’t K now
B it w h a t b it m uch (N /A ) (D /K )
Lack of energy Y N 0 1 2 3 4
Lack of appetite Y N 0 1 2 3 4
Pain Y N 0 1 2 3 4
Dry mouth Y N 0 1 2 3 4
Weight Loss Y N 0 1 2 3 4
Feeling drowsy Y N 0 1 2 3 4
Shortness of breath Y N 0 1 2 3 4
Constipation Y N 0 1 2 3 4
Difficulty sleeping Y N 0 1 2 3 4
Difficulty concentrating Y N 0 1 2 3 4
Nausea Y N 0 1 2 3 4
H ow  frequently did you r loved on e experience these sym ptom s d u rin g  the la st w eek ?
Sym ptom P resent R arely O ccasionally F req u en tly A lm ost
constantly
N ot A plicab le  
(N /A )
D o n ’t K now  
(D /K )
Worrying Y N 1 2 3 4
Feeling sad Y N 1 2 3 4















O T H E R  SY M PT O M S
Identify  any other sym ptom s th at you  believe bothered  
you r loved one in the last w eek . .L ist them  below  & identify  
how  distressful they  w ere.
N ot at 
all




Q uite a bit V ery  m uch
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4















Condensed Memorial Symptom Assessment Scale (CMSAS)- Family Respondent 
Interviewer ID:_______________  Subject Code_____________
H ow  m uch did th is sym ptom  b other or d istress you r loved  one in  the p ast 2 days?
Sym ptom P resent N ot at 
all
A  little  
B it
Som e
w h a t




N ot A plicab le
(N /A )
D o n ’t K now  
(D /K )
Lack of energy Y N 0 1 2 3 4
Lack of appetite Y N 0 1 2 3 4
Pain Y N 0 1 2 3 4
Dry mouth Y N 0 1 2 3 4
Weight Loss Y N 0 1 2 3 4
Feeling drowsy Y N 0 1 2 3 4
Shortness of breath Y N 0 1 2 3 4
Constipation Y N 0 1 2 3 4
Difficulty sleeping Y N 0 1 2 3 4
Difficulty concentrating Y N 0 1 2 3 4
Nausea Y N 0 1 2 3 4
H ow  frequently  did you r loved one experience these sym ptom s d u rin g  the last 2 days?
Sym ptom P resent R arely O ccasionally F requently A lm ost
constantly
N ot A plicab le  
(N /A )
D o n ’t K now  
(D /K )
Worrying Y N 1 2 3 4
Feeling sad Y N 1 2 3 4
Feeling nervous Y N 1 2 3 4
O T H E R  SY M PT O M S
Identify any other sym ptom s that you  believe bothered  
you r loved one. L ist them  below  &  identify  how distressfu l 
they  w ere
N o t at 
a ll




Q uite a bit V ery  m uch
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4















C ondensed  M em orial Sym ptom  A ssessm ent Scale (C M SA S)— R esp on d ed or de la  F am ilia  
E ntrevistador ID:_____________________ C o d ig o  s u j e c t o : _____________
^En que m edida ha m olestado al m iem bro de su  fam ilia  este sin tom a en los u ltim os 7 dias?
Sintom a P resente En absoluto  
(no)
U n P oquito U n P oco B astante M ucho N o A plicab le  
(N A )
N o Se 
(N /S)
Falta de energia S N 0 1 2 3 4
Perdida de apetito S N 0 1 2 3 4
Dolor S N 0 1 2 3 4
Boca Seca S N 0 1 2 3 4
Perdida de peso S N 0 1 2 3 4
Amodorramiento s N 0 1 2 3 4
Dificultad de respirar s N 0 1 2 3 4
Estrenimiento s N 0 1 2 3 4
Dificultad de dormir s N 0 1 2 3 4
Dificultad de concentrar s N 0 1 2 3 4
Nausea s N 0 1 2 3 4
;.Con que frecuencia ha experimentado estos smtomas durante la semana pasada?
Sintom a Presente R aram ente D e v ez  en  
cuando
C on frequencia C asi con stan tam en te N o A plicable  
(N A )
N o S e
(N /S)
Preocupacion S N 1 2 3 I
Tristeza S N 1 2 3 4
Nerviosismo S N 1 2 3 4
O T R O S SIN TO M A S
Identifique cualquier otro  sin tom a que le incom odo a l m iem bro  
de su fam ilia  durante los 7 dias pasados. E n u m erelos abajo  y 
identifique el nivel de afliccion.
P resente U n P oq u ito U n P oco B astante M ucho
S N 1 2 3 4
S N 1 2 3 4
S N 1 2 3 4















Entrevistador ID:______________ Codigo sujecto___________  Appendix G
C ondensed  M em orial Sym ptom  A ssessm ent Scale(C M SA S)—  R esp on d ed or de la  F am ilia
^En que m edida ha m olestado al m iem bro de su  fam ilia  este  sin tom a desde la  u ltim a v ez  que le v i (hace dos d ias)?
Sin tom a P resente E n  absolu to  (no) U n P oq u ito U n P oco B astan te M ucho N o A plicab le  
(N A )
N o  Se 
(N /S)
Falta de energla S N 0 1 2 3 4
Perdida de apetito s N 0 1 2 3 4
Dolor s N 0 1 2 3 4
Boca Seca s N 0 1 2 3 4
Perdida de peso s N 0 1 2 3 4
Amodorramiento s N 0 1 2 3 4
Dificultad de respirar s N 0 1 2 3 4
Estrenimiento s N 0 1 2 3 4
Dificultad de dormir s N 0 1 2 3 4
Dificultad de concentrar s N 0 1 2 3 4
Nausea s N 0 1 2 3 4
^Con que frecuencia ha experim entado el m iem bro de su  fam ilia  estos sin tom as desde la  u ltim a v ez  que le  v i (hace dos d ias)?
Sintom as Presente R aram ente D e vez  en  
cuando
C on  F recuencia C asi
constantam ente
N o A p licab le
(N A )
N o Se 
(N /S)
Preocupacion S N 1 2 3 4
Tristeza S N 1 2 3 4
Nerviosismo S N 1 2 3 4
O T R O S SIN TO M A S
Identifique cualquier otro  sin tom a que le incom odo al m iem bro  
de su fam ilia  durante los dos dias pasados. E num erelos abajo  y  
identifique el nivel de afliccion.
Presente U n P oquito U n P oco B astante M ucho
S N 1 2 3 4
S N 1 2 3 4
S N 1 2 3 4
Symptom Burden 213
Appendix H
IRB Approval Memorial Health Services (MHS) Study (299-05)
M e m o r i a l C a r f
M r  m i ' r i a l  H e a l t h  S e r v i c e s  
R e s e a r c h  A d m i n i s t r a t i o n
MHS-RESEARCH COUNCIL (IRB) APPROVAL LETTER
P.I.: Leslie Kern, RN, PhD/Peggy Kalowes, RN, PhD(c) Date: October 16,2006 
Memorial Heart and Vascular Institute
Project #  and Title: #299-05 "Understanding the Symptom Burden in Patients with Terminal and 
Life Threatening Illness In Intensive Care Units."
Extension Approval Date: October 16,2006 Expiration Date: October 15,2007
_ X _  Regular Review  Direct Review
A request for an extension to  the above project was reviewed and approved at the October 16, 
2006 MHS Research Council meeting for a period of 1 year. The Memorial Health Services 
Research Council serves as foe Institutional Review Board for Long Beach Memorial Medical 
Center. Enclosed please find an official stamped copy of foe Informed Consent Form for foe 
above named project. The previously approved Authorization form for use and disclosure of 
Protected Health Information should continue to be used.
• In compliance with FDA regulations and Memorial Health Services Research Council polities, a 
detailed progress report must be submitted to the Office of Research Administration before 
August 1,2007.
MHS Research Council approvals are provided to Principal investigators subject to the 
following conditions;
In accordance with MHS Policy and Procedures, the MHS Research Council may 
authorize staff to conduct spot checks or audits on their behalf. Please provide the 
Information requested If an audit of your project occurs.
Per ICH guidelines, the MHS Research Council regards the Principal Investigator as 
responsible for the conduct of research trials at his/her site and all associated 
research facilities. Specific responsibilities of the Principal Investigator include 
ensuring;
« Supervision of all research at Long Beach Memorial Medical Center in accordance with 
Memorial Health Services polities and FDA regulations.
• Conduct of research according foe study protocol.
• Use of the most recently approved informed consent form.
•  Provision of a  MHS Research Council-approved consent form in the subject's first language 
to all non-English speaking subjects.
• Approval by the MHS Research Council for all changes in research activity including 
protocol amendments and/or consent form revisions prior to Implementation.
• Prompt reporting (48 hours verbally and 5-10 days In writing) to the MHS Research
T t i !  S T A N D A R D  O f  E X C E L L E N C E  I N  H E A L T H  C A R E  
/S O I A t l a n t i c . A v  i >n <; UkaL H .O A  9 0 8 0 0  •  I’IHHVK: 562-490-A 737 « FAX: 56 2 -4 9 0 -J7 .W
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Council of any significant changes in research activity including changes in Principal 
investigator, changes in research site, addition of research facilities to a previously 
approved site, and study completion.
* Approval by the MHS Research Council of alt advertisements and patient recruiting 
materials prior to use.
* Prompt reporting (48 hours verbally and 5-10 days in writing) to toe MHS Research 
Council of serious and unexpected events related to study procedures as well as protocol 
deviations/violations.
* Timely submission of continuing review and progress reports.
Sincerely,
Harris R. Stutman, MD
Fxecutive Director
Office of Reseatch Administration
Approval letters/299-05 extension October 2006
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Project No. 239-05
Memorial Health Services R esearch Council 
Institutional Review Board 
Long Beach Memorial Hospital
Inform ed Consent to  P artic ipate  in a R esea rch  S tudy
Title: U nderstand ing  th e  Sym ptom  B urden in Patients w ith T erm inal and  Life- 
T hreaten ing  illn ess  in in tensive C are Units
P rincipal Investigator:
Leslie Kern, RN, PhD, FAHA Phone Num ber: (562)933-3320
Principal Investigator:
Peggy Katowes RN, MSN, CNS P hone  Number: (582)225-2545 
MHS P ro jec t Number: 299-05
You are being asked to participate m a  research  study conducted by Leslie Kem RN,
PhD and Peggy K atow es, RN, MSN, CMS, a  doctoral student in nursing a t the University 
of S an  Diego, Peggy is conducting  a dissertation research study to gain a better 
understanding of the pain and suffering that various sym ptom s may cau se  you, related to 
your progressive d isease  and current life-threatening illness.
By participating in this research study, you will be adding to the body of nursing 
knowledge in symptom management, which will help us to improve the types of 
treatments to provide (or withhold) and the types of care and services needed  by patients 
and families at different points in the course of their critical Illness.
WHY YOU ARE ELIGIBLE
You were selected as a possible participant in this study because w e have very little 
information/or research about the severity and frequency of symptoms reported by 
patients in intensive care units. These patients are known to have various illnesses such 
as heart, lung or liver disease, diabetes, stroke or acute traumatic injury. Most of the 
studies about symptoms in critical illness have been conducted on patients with 
advanced cancer, ana the resuiis of these studies may not be a s  helpful in 
understanding issues in the care of patients acutely ill with other diseases.
PURPOSE OF THE STUDY
The primary purpose of this study is to determine the frequency of various kinds of 
symptoms (example: pain, difficulty breathing, nausea), the frequency, severity and 
degree of distress, reported by patients, who have a  progressive d isease  or a sudden 
life-threatening illness, being cared  for in the intensive care  units.
.wealfff
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You can help us learn how to do a better job of caring for critically ill patients, by taking 
the time to answer questions on the attached questionnaire, which asks you to identify 
the symptoms that bother you and rate hew frequently and severe they are. The 
information you provide may help identify any needs you currently have, and will also 
assist us to "develop and further investigate new treatm ents and nursing interventions for 
various symptoms, because  there are currently few therapies that may be availablejo 
provide relief.
PROCEDURES
If you volunteer to participate in this study, you will be asked to complete 
questionnaires (available in English and  Spanish):
•  A 14-ttem questionnaire to a ssess  your symptoms;
•  A Treatment & Procedure Survey
On day 1. of your admission to the ICU, a research assistant will a s s e ss  your ability to 
answer the questions and participate in the study. If you are eligible for the study, you 
will be asked to complete the symptom assessm ent questionnaire. This will tell us about 
your perception of your symptoms and health in the previous week. This will take about 
2-4 minutes to complete. Note: If you are unable to write, you  m ay communicate your 
response in another way understandable to the interviewer, who can record your ratings 
on the questionnaire.
On day 3 of your ICU care, the researcher will return, and again a sse ss  your ability to 
answer the questionnaires. You will be asked to complete the symptom assessm ent 
questionnaire again so  we can se e  if your symptoms have changed after two days in the 
ICU. This will again take about 2-4 minutes to complete, in addition to the symptom 
questionnaire, at the sam e time we wilt have you complete a Treatment and Procedure 
Survey. Because we want to understand why som e patients have additional pain and 
suffering, we would like you to take a moment to tell us how painful or bothersome the 
various treatments or procedures are to you. This will take 1-2 minutes to complete. This 
will complete your participation in the study.
POTENTIAL RISKS AND DISCOMFORTS
There is no foreseeable risk for physical injury for participating in this study, although, 
you may have the potential for fatigue while completing the questionnaire. This cart be 
seduced or prevented by completing the questionnaire at your own pace, or asking the 
researcher to record your responses for you directly on the form.
The foreseeable risks are minimal for psychological harm  through responding to the
symptom questionnaire, primarily because it is very short, and should only take minutes 
to complete. Thus, there should be no associated anxiety, fear or pain. However, if any 
of the questions distress you or moke you uncomfortable, an appropriate referral for 
further support will bo available through pastoral care services.
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This questionnaire has been used in previous research with similar populations withdor- 
report of psychological harm. If you experience distress, you also have a  right to
discontinue participating in the study.
POTENTIAL BENEFITS TO SU BJECTS AND/OR TO SOCIETY
The first and most obvious benefit would be that the questionnaire used would identify 
the presence and intensity of multiple symptoms th a t you are able to describe through 
your own perception. This will help in identifying gaps in your current care, which we will 
try to improve.
There is also the greater benefit of adding to the scientific knowledge of nursing and the 
field of symptom m anagem ent. The study results m ay help us develop new nursing 
therapies to reduce pain and suffering in patients during the course of their life- 
threatening illness.
ALTERNATIVES
There are no other alternatives, other than non-participation.
You have been given the opportunity to ask questions which have been  answered to 
your satisfaction. You understand your physician will answer any questions that you 
might have In the future.
PAYMENT FOR PARTICIPATION
Participants will receive no  paym ents or other forms of an incentive to participate In this
VOLUNTARY PARTICIPATION/ RIGHT TO WITHDRAWAL
You can choose whether to be in this study or not If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind. Participation or non- 
participation will not affect your current treatment and care, or any other personal 
consideration or right you usually expect. You may also  refuse to answer any questions 
you don't want to answer and still remain in the  study, The investigator may withdraw you 
from this research if circum stances arise, which in the opinion of the researcher warrant 
doing so.
CONFIDENTIALITY
You understand that any information that Is obtained abou t you from this research  will be 
kept confidential and your name will never be identified in any report or publication 
unless you sign a  release. All da ta  will be coded using num bers an d  not nam es, to 
assure confidentiality. The consent and the list matching the subject’s  nam e to the 
assigned code number will be kept separate from ail resea rch  m aterials and  will only be 
available to the principal investigator. All data and questionnaires you complete will be 
kept in a locked file cabinet in the researcher's office with a c c e s s  only by the Primary 
Investigator.
study.
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Information regarding your medical records, just like hospital records may be 
subpoenaed by court order. You consent to the publication of study results so  long as 
the Information is anonymous and/or disguised so  that identification cannot be made. 
You also understand that authorized representatives of the Food and Drug 
Administration (FDA), and the MHS Institutional Review Board (MHS Research  
Council) may exam ine your records, and there 'will be no breach o f confidentiality.
IRB CLAUSE
This proposal has been reviewed and approved by the Memorial Health Services 
institutional Review Board (MHS R esearch  Council), which se rv es a s  the  IRB for 
Long Beach Memorial Medical Center, which Is composed of physicians and  lay 
persons. If you have any questions about your rights as a research subject, or 
regarding a treatment related injury, or desire further information concerning the 
availability of com pensation or medical treatment, you may contact Harris R. Stutman, 
MD, the Executive Director, Office of Research Administration, Memorial Health 
Services, at (562) 490-3737.
The primary tnvestigator(s) Leslie Kern RN, PhD and Peggy Kalowes, RN, MSN,
CNS; or one o f their Co-investigators have discussed this study with you. If you have 
any questions you can reach them at (562) 933-3320; (562) 225-2545/ 985-1804.
I certify that i have read the preceding or It has been read to me, that t understand its 
contents, and that any question I have pertaining to the preceding have been, or will 
be answered by my doctor anti that my permission is freely given. I have been  given 
a copy of this consent form along with a copy of the "R ights o f  H um an Subjects in 
Medical Research," and I consent to participate in this study.
Patients Name identifier Code Assigned
Patient’s  Signature
W itness to Patient's Signature
T«Ai,th.
( *  a p p ro v e d
I expires J LMMe 
\  — *
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If the subject Is a  minor, or otherwise unable to  sign, com plete the following;
a) R easo n  subject is unable to  sign ;_________________________________
b)  _______ ______ _____ ______ ____ ______
N am e of Authorized Person  D ate
Signature of Authorized Person Time
Relationship and  Basis of Authorization
To give C onsent
Certificate of P erson  Obtaining Consent;
I have provided an explanation of the above research study, and have encouraged 
the patient to ask questions and request additional information regarding the study, Its 
risks and complications and possible alternatives. A copy of this consent form has 
been given to the patient.
Signature of person  Print nam e of person  D ate
obtaining co n sen t obtaining consent
Certificate of investigator:
I certify that I am the Principal investigator or Co-Investigator responsible for this study, 
for ensuring that the subject is fully informed in accordance with applicable regulations, 
and for advising the WHS Research Council (IRB) of any adverse  reactions or 
unexpected events that may develop from this study
Principal Investigator or Date Time
Co-Investigator
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RIGHTS OF HUMAN SUBJECTS IN 
MEDICAL RESEARCH
Any person  w ho Is requested  to consen t to participate a s  a  subject involving a  medical
experim ent o r w ho is requested  to consen t on behalf of ano ther h a s  th e  right to:
1, Be informed of the nature and  purpose of the experiment.
2, Be given an explanation of the procedures to be  followed in th e  m edical experiment, 
and any drug or device to  be  utilized.
3, B e given a  description of any a ttendant discomforts and  risks reasonab ly  to  be 
expected  from the experim ent.
4, Be given an  explanation of any  benefits to  the subjects reasonab ly  to  be expected 
from the  experim en t
5, Be given a disclosure of any appropriate alternative procedures, drugs or devices 
that might be advanfages to the subject, and their relative risks and  benefits.
6, Be informed of the avenues of medical treatm ent, if any, available to the subject 
after th e  experim ent if complications should arise.
7, B e given a n  opportunity to ask  any questions concerning the  experim ent of the 
p rocedure involved.
3. Be instructed tha t consen t to participate in the m edical experim ent m ay be
withdrawn a t any  time and  the subject may discontinue participation in the medical 
experim ent without prejudice.
9. Be given a copy of any signed and  dated  written consen t form u sed  in relation to the 
experiment,
10. Be given th e  opportunity to decide to consen t or not to  co n sen t to a  medical 
experiment without the intervention of any  elem ent of force, fraud, deceit, duress, 
coercion or undue influences on th e  sub ject's decision.
PATIENT SIGNATURE: DATE:
I a p p r o v e d / /  i f  . ■
^^gCHOOj^
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HIPAA AUTHORIZATION P age 1 of 2
Memorial Health Services Research Council 
Institutional Review Board 
Long Beach Memorial Medical Center
Understanding the Symptom Burden In Patients 
with Terminal and Life Threatening illness in 
Intensive Care Units
How Will Your Confidentiality Be P ro tec ted?
You h a v e  rights regard in g  th e  privacy of your m ed ica l inform ation 
co llec ted  prior to a n d  in th e  c o u r se  o f this re se a rc h . T h is  m edical 
inform ation, c a ile d  " protected  health  information” (PHI), inc ludes 
d em ograp h ic  in form ation , the resu lts  o f  physical e x a m s , b lood  tests, 
x-rays an d  o th er  d ia g n o s t ic  and  m ed ica l p ro c e d u re s , a s  well a s  your 
m edical h istory. Y ou  h a v e  th e  right to  limit th e  u s e  a n d  sh a rin g  of 
your PHI, a n d  you  h a v e  th e  right to s e e  your m edica l re c o rd s  and 
know  w h o  e l s e  is  s e e in g  them .
By sign in g  th is au th oriza tion  form, you  are  allowing th e  re s e a rc h  team  
to  h a v e  a c c e s s  to  you r PHI for the p u r p o s e s  o f  co n d u c tin g  th is study. 
T he r e se a r c h  te a m  in c lu d es  th e  Investiga tors listed  on  th e  co n sen t 
form and  o th er  p e r so n n e l involved  in this specific s tu d y  a t  Long 
B each  M em orial M ed ica l C enter.
Your PH! will b e  u s e d  on ly  for th e  p u r p o se (s )  d e sc r ib e d  in th e  section 
of the inform ed co n sen t entitled . "P urpose of th e  S tu d y ”.
Your PHI will b e  s h a r e d , a s  n e c e s s a r y , with th e  M HS R e s e a rc h  
C ouncil (a ls o  k n ow n  a s  the Institutional R e v ie w  B o a r d  (IRB) a n d  with 
any person  or a g e n c y  required by law.
You a re  au thorizing  u s  to u se  and  d isc lo se  your PH I until 12/31/2008
UURttM** OSrtWWM
Project Number: 2S9-05
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You may revoke this authorization to u se  and  sh a re  your PHI at any 
time by contacting the principal investigator in writing. If you revoke 
this authorization, you will n o  longer participate in this re se a rc h  
program. If you revoke th is authorization, u se  or sh a rin g  of future PHI 
will be stopped . The PH! that has already b een  co llec ted  m ay still be 
used.
The results of clin ical te s ts  and therapy perform ed a s  p a rt of this 
research  m ay b e  included  in your medical record. T h e  information 
from this study m a y  b e published  in scientific jo u rn a ls  o r p resen ted  at 
scientific m e e t in g s  but your identity will b e  kept confidential and  no 
information that m ay  b e  personally  identifiable, su ch  a s  your nam e, 
picture, so c ia l secu r ity  num ber or m edical record n u m b er, will be 
published .
You will be given a  copy of this authorization for your reco rd s.
Patient N am e Patient Signature D ate  and  Time
W itness N am e W itness Signature D ate  and  Time
Name of A uthorized R epresentative R elationsh ip  to Patient




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 223
Appendix J
Page i o f 6 
PI: t o t e  Kem RN,
Project No. 299-05
in fo rm ed  C o n se n t to  P artic ipa te  In a R e s e a rc h  S tu d y  
(Fam ily R esponden t}
Title: U n d ers tan d in g  th e  Symptom Burden in P a tie n ts  w ith  T erm inal and  Life- 
T h rea ten in g  Illn ess  In in tensive  C are U nits
Principal Investigator:
Leslie Kern, RN, PhD, FAHA P h o n e  N um ber: (582)933-3320
Principal In v es tig a to r:
Peggy Katowes RN, MSN, CNS P h o n e  N um ber: (582)225-2545
MHS P ro jec t N um ber: 299-05
You are asked to participate m a research study conducted by Leslie Kern RN, PhD and 
Peggy Katowes, RN, MSN, CNS, a  doctoral student in nursing at the University of San  
Diego, Peggy is conducting a dissertation research study to gain a  better understanding 
of the pain and suffering that various symptoms may cau se  patien ts with chronic d isease
or life-threatening iilness, being cared for in the Intensive c a re  unit (ICU).
The information you provide will give us a valuable and "unique perspective’ from a 
family’s member's observation and perception, regarding a patient’s  symptoms and 
declining health, which often is different than the patient's a ssessm en t.
By participating in this research  study, you will be adding to nursing knowledge in 
symptom managem ent, which will heip us to improve the types of trea tm en ts to provide 
(or withhold) and the types of care  and services needed by patien ts and families at 
different points in the course of their critical illness.
WHY YOU ARE ELIGIBLE
You are being invited to participate in this study because your family member has agreed 
to participate in this research , by telling us about the severity and frequency of their 
disease-related symptoms. We currently have little information/or research, regarding the 
degree of distress and suffering that various symptoms m ay c a u se  patients from their 
own or the family's perspective. Most of the studies about sym ptoms in terminal and 
critical illness have been conducted on patients with advanced cancer, and  not other 




Memorial Health Services Research Council 
Institutional Review Board 
Long Beach Memorial Hospital
WW.Tii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 224
Page 2 of 8
PI; Leslie Kern RN, WiD/Peggy Katowes RN
Pmject No, 299-05
PURPOSE OF THE STUDY
APPftQvED
The primary purpose of this study is to determine the frequency o f various kinds of ' ^ 2 3  
symptoms {example; pain, difficulty breathing, nausea), the frequency, severity and 
degree of distress, reported by patients, who have a  progressive d is e a se  or a  sudden 
life-threatening Illness, Little information i$ available from both patien t’s  and  family's 
perspective at the sam e  time during the course of illness.
Families/friends often s e e  how patients respond to their illness an d  sym ptom s from a 
totally different view than the patient. B ecause families/or friends often provide needed  
c»re to patients who are living at home, when they are very sick, you may be able to 
provide broader Insight to the patients progressive illness.
Your input can  help us learn how to do m  even better job of caring for critically ill 
patients, by taking the time to answ er questions on the a ttached  questionnaire. The 
survey ask s  you to  Identify the various sym ptom s that m ay have bo thered  your loved one 
and rate how frequently they occurred and how severe you thought they were. The
information you provide m ay help identify any current n eed s  th e  patien t m ay  have, and 
the data will a lso  a ss is t u s  to develop and further Investigate new  trea tm en ts  and nursing 
interventions for various sym ptom s, becau se  there are  currently few  therap ies that may 
be available to provide relief,
PROCEDURES
If you volunteer to participate in this study, you will be  a sk ed  to com plete  two 
questionnaires (availab le  in E ng lish  a n d  S pan ish ):
» A short information form that a ss e s se s  family m em ber characteristics (age, sex, 
ethnicity, occupation, rote of care giving to patient)
» A 14-item questionnaire to a s s e s s  your perception of th e  pa tien t's  symptoms;
On dav  1. of the patien t's adm ission to the ICU, you will be  a sk ed  to  com plete  the short 
Information form and the sym ptom assessm en t questionnaire. T he sym ptom  
questionnaire will tell u s  about your perception of the patien t's sym ptom s and  health in 
the previous week. This will take approximately 5-8 minute’s  total.
On dav 3 of the patient’s  ICU care, you will be asked by the re se a rc h e r  to  com plete the 
symptom a ss e ssm e n t questionnaire again. This will tell u s  abou t your perception of the 
patient’s  sym ptom s a n d  quality of life, and w hether this h as ch an g ed  while receiving 
treatments) tor two days. This will take about 2-4 m inutes to com plete.
Note: If you  c a n n o t b e  physically  p re se n t on d av  3, a te le p h o n e  in te rv iew  can be 
sc h e d u le d  a n d  c o n d u c te d  a t  you r co n v en ien ce , s o  y o u  m ay p ro v id e  th is  very 
im portan t in fo rm ation  to  co m p le te  th e  study .
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POTENTIAL RISKS AND DISCOMFORTS
T here is no fo re se e a b le  risk of physical injury for participating in th is  S 
m ay hav e  th e  poten tial for fatigue white com pleting th e  q u estio n n a ire , 
reduced  or p re v en ted  by com pleting the  questionnaire  a t your own p a  
re se a rc h e r  to  reco rd  your re sp o n se s  for you directly on  th e  form.
T here  is a  oniy a  m inim al risk for psychological harm  through responding  to the symptom 
questionnaire , primarily b e c a u se  it is very short, and should only tak e  m inutes to  
com plete. T hus, th e re  shou ld  be  no  a sso c ia ted  anxiety, fear o r pain. However, if 
em otional d is tre s s  sh o u ld  occur, an  appropria te  referral for em otional support wifi be 
available th rough  p as to ra l c a re  serv ices.
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY
T he first a n d  m o st ob v io u s benefit would be  that the q u e stio n n a ire  u se d  would identify 
the p re se n c e  a n d  in tensity  of m ultiple sym ptom s that you p e rce iv e  the  patient may be 
experiencing from  your o b se rv a tio n s. This m ay help  in Identifying g a p s  irt the patient’s 
current care, w hich w e will try to im prove.
There Is a lso  the  g rea te r benefit of add ing  to the scientific know ledge of nursing and the 
field of sym ptom  m an a g em e n t. T he study  resu lts  will h e lp  us develop  interventions to be 
further te s te d  In clinical a re a s ,  which m ay prove to be far m ore effective therap ies to 
reduce pain and  suffering in patients during the course of their life-threatening illness.
ALTERNATIVES T h ere  a re  no o ther a lternatives, other than  non-participation.
You have  b e en  given th e  opportunity  to a sk  questions w hich have b e e n  answ ered to 
your sa tisfaction .
PAYMENT FOR PARTICIPATION
Participants will rece iv e  no paym ents o r o ther forms of an  incentive to  participate in this 
study.
VOLUNTARY PARTICIPATION/ RIGHT TO WITHDRAWAL
Participating in th is s tu d y  is strictly optional, a s  a  family m em ber. If you volunteer to be in 
this study, you m ay  w ithdraw  a t a n y  tim e without c o n s e q u e n c e s  of an y  kind. Participation 
o r  non-participation will no t affect your family m e m b e rs  cu rre n t trea tm en t and care, or 
any o th er p e rso n a! co n sid era tio n  o r right you usually  e x p e c t  You m ay  a lso  refuse to 
answ er any  q u e s tio n s  you don 't w an t to a n sw e r a n d  still rem ain  in th e  s tu d y . T h e  
investigator m ay  w ithdraw  you from this re se a rc h  if c irc u m s ta n c e s  a rise , which In the 
opinion of th e  r e s e a rc h e r  w arran t doing so.
CONFIDENTIALITY
You understand that any information that is obtained abou t you from  th is research  will be 
kept confidential and  your nam e will never be identified in any  report o r publication 
unless you sign a  re lease . Afi da ta  will be coded using num bers an d  no t nam es, to
j APPROVED jj.
I EXPIRES i f  i f  
\afttmsb, ydfb -
Canb% CKcfi#/
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assu re  confidentiality. T he consen t and the fist matching the sub jec t’s  nam e to the 
assigned code num ber will be kept separa te  from all research  m aterials and  will only be 
available to the principal investigator, All data will be  kept in a  locked file cabinet in the 
researcher's office with a c c e ss  only by the Primary Investigator,
You consent to  th e  publication of study results so  long a s  th e  information is anony­
m ous and/or disguised  so  that Identification cannot be m ade,
IRB / FDA CLAUSE
This proposal h a s  b een  reviewed and approved by the Memorial Health Services 
Institutional Review Board (MHS R esearch Council), which se rv es  a s  the IRB for 
Long B each  M em orial M edical C enter, which is com posed of physicians and lay 
persons. If you have any  questions about your rights a s  a resea rch  participant, or 
regarding a treatm ent related  injury, or desire further information concerning the 
availability of com pensation  or medical treatm ent, you m ay contac t Harris R. Stutman, 
MD, the Executive Director, Office of R esearch Administration, Memorial Health 
Services, at (562) 480-373?,
The primary investigators) Leslie Kern RN, PhD and Peggy K atow es, RN, MSN,
CNS; or one of their Co-tnvestlgators have d iscussed this study  with you. If you have 
any questions you can  reach  them  at {(562) 933-3320; (562) 225-2545/ 985-18041,
I certify that I have read  the preceding or it has been  read  to m e, th a t I understand its 
contents, and that any  question  I have pertaining to the preceding h ave  been , or will 
be answ ered by th e  investigators and that my perm ission is freely given. I have been 
given a  copy of this co n sen t form along with a copy of the *Rights o f Human Subjects 
in Medical Research,'' an d  I consen t to participate in this study.
Family R esponden ts N am e Identifier Coder A ssigned
Family R esponden ts S ignature Date Time
Witness to Family R esp o n d en ts  Signature Date t im e
’ hr
! *' . lC]rmiMS. J
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If the subject is a  minor, or otherwise unable to sign, com plete the  following;
a) R eason  sub jec t is unable to s ig n :_ _____________ _______ __
b> ............................  _____
Nam e of A uthorized Person D ate
S ignature o f Authorized Person Tim e
Relationship an d  B asis of Authorization 
to give C onsen t
Certificate of P erson  Obtaining Consent:
i have provided a n  ex p lan a tio n  of the  ab o v e  re se a rc h  study, a n d  have  encouraged 
the family r e sp o n d e n t  to  a s k  q u estio n s  an d  req u est add itional information regarding 
the study, its risks and  complications and possible a lternatives. A copy of this 
consent form h as  b een  given to the family respondent.
Signature of person  Print nam e of person D ate
obtaining consen t obtaining consent
Certificate of Investigator:
1 certify that I am  the Principal Investigator or Co-Investigator responsib le  for this study, 
for ensuring that the sub jec t is fully informed In accordance  with applicable regulations, 
and for advising the MHS R esearch  Council (IRB) of any  ad v e rse  reactions or 
unexpected even ts that m ay develop from this study.
Principal Investigator o r Date Time
Co-Investigator
NOT VALID WITHOUT IRB STAMP OF APPROVAL
1 /vhd<_L
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RIGHTS OF HUMAN SU BJECTS IN 
MEDICAL RESEARCH
Any person  w ho is requested  to consen t to participate a s  a  subject involving a  medical
experim ent o r  w ho is requested  to co n se n t on  behalf of another h a s  the right to:
1. Be informed of the nature and purpose of the experim ent
2. Be given a n  explanation of the procedures to b e  followed in th e  m edical experiment, 
and  any drug or device to be utilized.
3. Be g iven  a  descrip tion  of any attendant discomforts and risks reasonably to  be 
expected from  the experiment.
4. Be given an  explanation of any benefits to the subjects reasonably to be expected  
from the experiment.
5. Be given a disclosure of any appropriate alternative procedures, d rugs or devices 
that might b e  ad van tages to the subject, and their relative risks and  benefits.
6. Be in form ed  of th e  a v e n u e s  of m edical treatm ent, if any, available to the subject 
a fte r  th e  e x p erim en t if complications should arise,
7. Be given an opportunity to  a sk  any  questions concerning th e  experim ent of the 
procedure involved.
8. Be in stru c ted  that consen t to participate in the medical experim ent m ay be 
withdrawn a t a n y  tim e a n d  the  subject m ay discontinue participation in the medical 
experiment w ithout prejudice.
9. B e given a  copy  of any  signed and  da ted  written consen t form u sed  in relation to the 
experim ent.
10. Be given th e  opportunity to decide to consen t or not to c o n sen t to a  medical 
experim ent without the intervention of any  elem ent of force, fraud, deceit, duress, 
coercion or u n d u e  in flu en ces on th e  su b je c t’s  decision .
PATIENT SIGNATURE: DATE:
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Memorial H ealth S erv ices R e se a rc h  C o u n c il 
Institu tional Review B oard  
L o n g  B each  M em orial M edical C e n te r
Request for Waiver of Authorization 
For the Use and Disclosure of Protected Health Information in
R esea rc h
INTRODUCTION
Patients have rights regarding the privacy of their medical information collected prior to and in 
the course of this research . This medical information, called '’protected  health information* 
(PHI), includes dem ographic information, the results of histories and  physical exam s, blood 
tests, x - r a y s  and o ther d iagnostic  and  medical procedures, a s  well a s  Individually Identifiable 
tissues or body fluids. Patients must authorize the use of PHI when used  or disclosed for all 
purposes other than  treatm ent, payment and healthcare operations. This includes the use and 
disclosure of PHI for research . In som e cases , it is appropriate to  seek  a waVer of such 
authorization, such a s  for chart reviews and data registries.
1, Leslie Kern RN, PhD / Peggy  Kalowaa RN. PhD(c). Primary Investioatorf s lan d  Louise DuBos 
RN, BSN, Co-Investigator, req u es t a waiver of authorization for th e  u se  and  disclosure of 
protected health information, consequent to a  research project entitled, U nderstanding the
The waiver of authorization for u se  and  disclosure of PHI is for 1-year from IRB Approval.
The soedffo information that will b e  u sed  and disclosed includes the following: age , ethnicity, 
religion, health information, m edications that may affect patient’s level of consciousness, 
admission S discharge information (outcom es) and APPACHE III Mortality Risk & APS Score.
The members of the re sea rch  team  a t Long Beach Memorial Medical C enter, who will be using 
the described PHI include the following (persons or groups of persons): Leslie Kern RN, PhD / 
Peggy Katowes RN, PhD(c). Louise DuBos RN, BSN,
t further certify the following (p lea se  initial box next to each  statem ent):
Patients/families will b e  informed verbatiy/and on the informed consen t, that any 
information ob ta ined  from this research study, will be kept confidential, The subject 
name will never b e  identified in any report or publication un less a  re le a se  Is signed. 
All data will b e  co d ed  using numbers and not names, to assure confidentiality. The
REQUEST FOR WAIVER
Symptom Burden in Patients with T ermlrtal and Life-Threatening illness in Intensive C are Units
The use or disclosure of PHI involves no more than minimal risk to  th e  privacy of 
individuals, based  on th e  p re sen ce  of the following elem ents;
1. An adequate  plan to protect the identifiers from improper use  and disclosure.
Describe.
tevised. WO 3/2004
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 230
WAIVER O f  AUTHORIZATION PAGE 2 OF 2
consent and the list matching the subject's nam e to the  a ss igned  code number w i be 
kept separa te  from all research  materials and will only be  available to the principal 
investigator. Alt da ta  and questionnaires you com plete will be kept in a  locked file 
cabinet in the re sea rch e r 's  office with a cce ss  only by th e  Primary Investigator.
2. An adequa te  plan to  destroy the identifiers a t the earliest opportunity consistent with 
conduct of the research , unless there is a specific health o r research  justification for 
retaining the identifiers, or such retention is otherw ise required by law; and
3. The PHI wilt not be  reused  or disclosed to any o ther person  or entity, except as 
required by law, for authorized oversight of the research  project, or for other research
for which the u se  o r disclosure of PHI may be  subsequently  permitted.
The research couid not practicably be conducted without th e  waiver; and 
The research  could not practicably be conducted without a c c e s s  to and  u se  of the PHI.
PR! >At INVESTIGATOR NAI DATE S/TI^E
/ 4 / w
PRINCIPAL INVESTIGATOR NAME
CO-INVESTIGATOR NAME SIGNATURE
DATE & T1ME“ 
&TIME
FOR USE OF THE OFFICE OF RESEARCH ADMINISTRATION ONLY
Name of institutional Review Board Date of Approval of W aiver
H a r r i s  R . i i tu tm . 'm , HO
Research Council (IRB) Chair o r 
Designee
Signature
a / j / /s i  /jCrQ 
D ate & Time
XRflvw* 101130064
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February 17, 2006
Leslie Kern, RN, PhD/Peggy Katowes, RN, MSN, CNS, PhD(c)
Subj: Spanish Informed Consent for project #299-05 "Understanding the 
Symptom Burden in Patients with Terminal and Life Threatening Illness in 
Intensive Care Units."
t e a r  Dr. Kem/Ms. Katowes:
Enclosed please find a stamped copy of the approved Spanish version of the Informed 
consents along with the Authorization for the Use and Disclosure of Protected Health 
Information for the above-mentioned project. This project was last reviewed and 
approved by the MHS Research Council (MHS-IRB) for activation on November 28, 2005 
for a period of 1 year; these dates are reflected on attached consent and Authorization 
for the Use and Disclosure of Protected Health Information. Because the Spanish 
version of the consent was not directly reviewed by the MHS Research Council, the 
dates reflect the most currently reviewed and approved version of the English consent 
for the  above mentioned study, it is the policy of the MHS Research Council (MHS-IRB) 
that the patient and the witness must also sign an approved English informed consent 
form.
The Office of Research Administration notes that a notarized letter of attestation was 
received from Cynthia D. Connelly, PhD, RN noting that Blanca Mantillas and Norma 
Tatamentes, of the  Child and Adolescent Services Research Center, Children's Hospital 
and Health Center, San Diego, Spanish Interpreters, were responsible for this Spanish 
translation of the MHS-IR8 approved English version of the informed consents and 
Authorization for the  Use and Dlsdosum of Prot< (fed Health Information.




Office of Research Administration
Cover letters for mtsc consent form items/Spanish consent; cover letters/299-05 Spanish consent cover letter 
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M c n io i iu !  Health Services Council 
In s ti tu tio n .! !  R e v i e w  Board
Long B e a c h  M e m o r i a l  H ospital EXPIRES
INITIALS.
M A R  2  # 2006
Coiisentlm iento Infai mudo para participar en un estudio de la investigacidn
TituIaiLa Omipreitsir'm di la cm ga del sintoma en I os pacientes con 
enfermedados u-i minalcs, \ mfci im-dadi-s graves, cit el cuidado intensive.
Investigadora Principal: L e -d ic  Kem RN. Phi). TMI A  Nt'imerode TelAfono: (562) 933-3320
Investigadora Principal: Pcugs Kaiowes RN. MSN. CHS Ntimero de Telffaao: (562) 225-2545
Asisteirte al Investigadora: Louise DuBos RN, BSN Numero de Telefono; (562) 522-9893
N&mero del proyeeto MHS: 299-05
St. h a  s><!<> p r c g u n t a d o  a l i s t e d  p .u a  p a r t i t i p a r  e n  un estudio d e  in v e s t  o w e  to n  c o n d u c id o  p o r  L e s l ie  
K e n t  RN. P h D  y  P e g g y  K a l o v e s  R N , MSN, u n  e s tu d i a m t  d o c t o r a l  t-tt el p io g r im w  d e  e n f e r m e r a s  
en ta t 'm v e r f id a d  J e  Sett D ie g o ,  P e g g y  i-stft v o p d u u t n d o  tm a  d i w r t a e i d n  en la  f o r m a  de u n  estudio 
de inceMsgacidn p a r a  c o r t t p r c o d t r  mas cl <Jok« y r u f r - m u t i t o  que p r e s t n t a  c o n  v a r i o s  sintomas, 
rc la c io n n d o s  u k  o i t e r m c d a d  p r o g r c s iv o  y la e n f e r m e d a d  g -av s .
Al participar en estc estudio de la irsvesttgaciun. se alladtri al conocitniento del oficio de enfermera 
e t t c l  tnartcjo tie los sintomas, lo q u e  puvric ayudamos en mejorar los tipos de tratamientos que 
ptxlemos p r o p m ctonar t o  no dan  y los tipos de culdado y servicios que se necesitan los pacientes y
I.ss familus en varios p u n to s  diuunte el curso tie !a enfermedad critics.
iPOR Q U t ES IJSTED 1 I ICIBI I ?
Se h .m  s id e  sekvei, m u d o  tK ie d  como c a n d id u M  po-thlc • n este e s tu d i o  p o r t j u e  t e n e m o s  poquito 
in f o t m a c id n ;o  investtgacioti sohic k  sevcridad j hi ii<-< n c t ic ia  de lo s  s in to m a s  r e p o r t  ados por los 
pacterstes en el c u i d a d o  m tc n s iw i .  F e tu s . p a c ie n te s  p n e d c  u n c i  v u r ta s  en lenned td c s  c o m o  las d e l  
cotazon, pulm6n. higado. k  diabetes, cl unique cerebral, o una lerion traumat c.t aguda. Se conduce 
k  mavoit.i do los e s t u d i o , < o h re  los s m to m a s  e n  lo ;  p u n e n f c a  cnticos con el t u m u  uvanzado.
Itstos estudios no son tan prowcluwos para mejorar el cuidado de los pacientes con otras 
e n f c r m e d u d e s  a g u d a s .
PROP6SITO DEL ESTUDIO
Li propdsitn primario del estudio cs dctctminarse cl piedomtno tie varios tipos de sintomas (por
e je m p io :  d o lo r ,  dificultad J c  icspiiar, n .lu $ c a ) , la f i e e u e n e iu .  y la  s e v e r ! d a d  d e  afliccidn de los 
pacientes que tiene una cnfcnmdml ptogrcsivo « u n a  enfermedad repent! na que es peligrosa para la 
\ u i a ,  q u e  s e  c t t id a n  cn e: cuujado intensivo.
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I’ t a s lc  n s tc d  a v t id e n 'o s  cnmm cmlcf c o m o  h a c e r  a t in  m e io t  u i 1 11 t i id a d  > do k »  p u c ie m e s
iHUi ;im «iu vnfcrm<'s, pm conk-star 1* s p  p r e g tm ta s  cn el uaM iom iiio a d j u n to .  que It- prepintu 
ttlcnuficur los ftmmnas one Se in n j e r tn ,  v < l a o f i c a r  hi tk-eu n u a  y s t w - n d u J  dc los sintomas. La 
in io im a .  on quo p io jH r . i io n u  t:-k>d pm d c  ,u  n d .ir  i >1 ia nkm ijieueion d e  las n e c e s id u d c s  que ftene, >
.u L m a s  avudat cn la dc'UrroSI,. \ la  m vcstipeuvii ik b .i t a v n k 'n to s  n u e v o s  y in l e r v tm c io t ie s  del o t l c w  
(it In c n t c m i c r a  por c 'm s  ontomas, p o r q a c  a r t i u h n u i t e  Itay pocas t e r i .p ia s  d isp iM iib lc-s  q u e  p u t-d c  
a l iv ia r ,
P R O C T W . M U I M O
Si se presents voluntario cn el estudio, se pregtsntart completar dos cuestionarios (disponibies en
ingMs y e s p a r to ! )
* Un cuestionario de 14 puntos para detcrminar sus sintomas;
» Una c n c u e s t a  dc traiamiento y ptoeedimicnto
Un e! printer dia del tngreso al cuidado intensive, tin aMstcnk de la invest iwk i6n deterrninart su
c a p a c id u d  tie c o n t e s t a r  las prcguntas y parfitipar cn el e< tudio Si sa t i" a c t  u s t e d  los c r i t e r io s ,  se 
p fe g tm ta rr i  iermmar el c u e s t io n a r io  del gravamen d e l  sintoma k s t c  c u e M io n e n o  nos d ir t  su 
p t r c e p c io n  de los s in to m a s  y la saltid c n  la s c m a n a  anterior f im uru 2 ,t 4 im n u to s  para completar.
Nota: Si usted no puede e*n (hr, puede comunicar las respucsun en otra manera que comprende el
entrevistador, quien puede reem'Jar las respuestas m  el auMiomtttu
F n  c l  t o r c c r  d m  d e l  t  i- id a r io . e l e n t r e v i s t a d o r  r e g r e s a r t  y  d e t t n i - u w r , '  mi c a p a c u k td  d e  r e s p o n d e r  d e  
l a - p r e g u n ta s  o n  . v c /  S e  p r e g u n t a i a  c o m p le te - -  e l  e u c s t w t u n o  d e l  g r a v a m e n  d e l  s i r t k m u  o t r a  vez. 
p a t  a  q u e  p e d a m o s  ev a i u a r  U  c M a w s  d c  m s  s m to m a s  d c s p u e s  d e  d o  d ia s  c n  e l  h o s p i ta l  F o n ia r a  2  a 
4  im m ito s  p a r a  c o r a p le i . t i  -V J ic io n u Im c o tc . e o n ’ pIea< M  e l t n e s t i o n a r io  d c  t r a i a m ie n to  y  
p i o c o d m u e n t o  <tl m t s m o  t i e n tp o  T’n iq m ' v n in p t  u n d e r  p o rq u t*  a l g u n o s  p a c i e n t e s  t i e n e n
d o lo r  y  s u f n m ie n U ' a d iv  to n a l ,  q t i e ie m o s  o t ic  • • m u  u d e d  tin  m o m e n f o  p a in  d c c i n i o s  e l  d o lo r  o  el 
f a s t id io  q u e  c \ p e n  u ie m a  d u ra n k *  lo s  v a r io s  t r a U n u e 't t o s  <, p r o c t  d i i n ie n t o s .  1 o n w r tM l t t l . $ f iM t t t« : :0 u t c a .  
p a r a  c o m p k t a t .  V s io  e o m p le t .u a  s u  p a n i c ip a c id n  t-ii e ! e s iu d to  A r r n Q V E D
M A R  |  f t  ■
RII M OS Y MALESTAMEN FO IK M 't \ l  F.S
txnmsjiAj^
W  h a y  r i e s g o  prt-v i ta b le  p a r a  lesion ft.sicii cuando p a i 'u  ip t en el e s tu d io .  a tm q u e .  cs 
luiiga c tn m d o  ro s p o n d e  a! e u t - t o m a n o .  Puede r e d o u t  o prcvenir la kitiga por com pletar el 
uicstinm ino cn su piopm  paso, o preguntar el investigador recordar las tc.sjnicstus para usted 
dwec tamen'c u i I a  fonna.
! a t  ncsyts pie-wsibk™ sen tnimmos pntu <!afio p.,ii'ol.'i’ic<t cuando respond© al cuestionario de los
•m i tm ru s , p o u p i t  e s  iiiuv  s o n o  v t ' i l i '  d e b e  to m a r  2 a  4 m in u to s  p a r a  c o m p l e t a r  B n to n c e s ,  n o  d e b e  
-*,! a n s ic d a d , rn ie d o  o  cto'or a so e t.u lo . Sin e m b a rg o , si e l e s t r t s  ocnrrc. sc  c s ta  dtsponible una 
ic m is io n  a p to p ia d . t  p  >i i a v u d a  a d i c to n a l  a  t r a s c s  d e  lo s  s e r v ic io s  d e l  c u i d a d o  p a s to ra l .
Estc cuestionario h a b ia  s id e  u s a d o  e n  i n v e s t i g a c io n e s  anteriores eon populacioucs similares s in  
in fo rm c  del d a f io  psirologieo. Si e x p e r i m e n t a  u s te d  afltccidn, tieiw e! d c r e c h o  de discontim iar su 
p a r t i c ip a c td n  e n  c l  e s tu d io
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VENTAJ AS Pi)-| I NC! \ \  m  p a r a  PARI K IP W  f l  v Y/O LA SOCIEDAD
La pnmcra ventaia y la mir- obvu, serfa que c! cuestionario usaclo puede iderttificar laprcsencia e
luUTsidad de varies jmtomus <|ue no pued<? usted desetilur a traces de sus percepdones propias.
Ayudara cn la idcntificacicn de lagunas en m  cuntudo aetnalmentc, lo que podriamos tratarde 
meioiar
Ailemas, hay lit ventaja de aiiadir al conoomiesrto cientiTico del ofieio de las enfcrmeras y cl campo
del manejo del sintoma. Fs posible que cste estudio nos ayude en el desarroilo de nuevas terapias 
para raHicit ct dolor y sufrinnenio i n los pacientes durante el curso de su enferm edad peligrosa para 
la % ida.
ALTERNATJVOS
\ . i  hay altertumv.-,, fuera de no pattieipai 1 uvo la oporuttiidad pata preguntar a los 
iuvcssigadorcs. v el los le respondieron a sit «uti»iacci6n. Compiende listed qtte sti medico 
contestant olias pregtmtas quo pneda teuer en el futuro.
RFM M ERA O dN  POR LA Pa RTICIPAC.TON
Partioipairtes no van a recihir renitmcrackm tit otra forma de incentive para participar en el estudio.
F A R  1 11.11’A l l lO N  V O l { N ! ARIO/DS- R l.<  H O  UK RF.TIM A.RSE
Puede usted clegtr si quictes pnrHcipar en este estudio o no. Si se presents volnntario en este 
estudio, sc puede tuirar en cualquici nwmento sin consecuencias, Partwipacidn o la falta de 
participation no va a afcctar su tratainiento m su cuidado, ni otras consideraciones personates que 
espura normalmente Ticne el d ucclw  rc e lw a r  a contestar las preguntus que bo quiere contestar y 
puede quedavse en el c studio todavia, f a investigation! puede remo\ crle del estudio si presenta 
vu’cunstaticiaa que. en la opsna dc la invest igudox a, constituya cl retiro.
< O NH D hN CIA l IUAD
( ’oniprendc usted que la irfon’iaeion ohtenida sobre usted en o ta  imestigacion se queda
confidem ml y nunca sc utentifica su nombre cn un informe o ptiblicaektn a nienos que finrte usted 
un deseargo. Se usa un cddigo dc mimcros en ve/ dc nombrcs pata todos los datos para asegurarse 
cnniidcncialuiud. 1: ! consentim'omo. y la li s t a  que empateja el nombre del participant a l codigo 
.tsigjiado scran manfemdo sep.ti id«< dc todas ias inaierialcs de la invcstigaeiou. v srilo las 
investigudwas princtpalcs podritn lencr acccso Todos los datos y cuestionarios que completa sera 
mantenido ui un gable.cm bloqueado en la oficina del ittvcstigador. y solo lo» invcstigadores tendran 
aeceso.
La infornacum sobre sus arehtvos medicos, c « n »  los archives del hospital, se pueclen obtener tins 
citation por ordcn del juscio, ("onsicnte usted a la publicacidn de los rcsuitados del estudio mientras 
la tnformacson so t anomma >/o disfrazado dc m odo que no se piteda hacer ana identificacidn,
AdumK comprende usted que los reprcsentattles autnrizados dt la Administration de drogue v 
alimentos (ADA), y ei MILS institutional Review Board {.MHS Research Council i. puede txamirsar 
sus arclmos, y no hay m u  abertuta de la conlidenoalidad. ,-!HS ^ p p R Q y g Q  f,:’*t
M M  I  %
E X P tflE S ie^c^
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!’!• ! c«l«! Kodi RN , PhD /Peggy K alow es RN , MSN
Prujeci No INN) .05
Cfcfasnta tie IRB / FDA
b e  r e p a s a  v  a p n x  bj> vst?  piopueM A  p o t M a in o i ta l  I k  oltli S e r v i c e  h ia t i t u t io n a !  R ev iew  B o ard  
. \ H f o  P v e u - s i  h  i. t . r - i  i>,N ' f " ,  e p .11.1 M IR B  d .  I m i”  i f o a r l i  M e m o r i a l  H o s p i t a l ,  q u e  
c n o t iu u .  a m b u s  m e d 'e o s  \  p u s m i d s  d e l g ta r  p u h tu -o  S i t i e m  l i s te d  a lg u n a  p r e p u n t a  s o b re  sus 
tk te e h o s  corrto  i v a i u t p a u t e  d e l  cM utlio , o  e i t u v m K n 'o  r e l a t i o n a l  lo  eo n  la  le s io n , o  q u ie r e  m ds 
i i i l .n m a c io n  so b re  la d isp o sb 'h ifd a d  d e  re m im e ia e io ti o  9  a t a m i c n to f  m e d ic a t e s ,  p u e d e  c o n ta c ta r  
H a u i s  R  S tu tm .m , M i l ,  l i i tu n o r  c ie cu tiw - . e l o f ie io  t k  j d m m i s i r a e i o n  d e  la  m v e s t ig a c io n , 
M e m o r ia l  Ifoaltli Net v ice s , a l n u i n e i o  (562) 490  3737 .
La(s) invest)gadnrals i  p n m ’ip a l f o s )  I eslie Kem RN. i ’h D  y Peggy Katowes, R N , MSN, CNS; o  
u n o  de los asistenies A, las mvestigadoras le h a n  d i$ ( 'n l id o  este estudio. Si ticne algunas 
pregimtas. puede c w H a c ta i to *  a  { (5 6 2 )  9 3 3 -3 3 2 0 -  < 5 6 2 )  2 2 5  2 5 4 5 /9 8 5 - 1 8 0 4 3 -
3 <> < u  U lu ru  q iu  h e  le a k )  e l  t e x to  qut p - e c e d e  o  alt uio i me iv i ie id o ,  v  quo c o m p r u x i o  el 
< oi.i' t id u , v q u e  1 1 n u d t f  o h a  respomJuio ic s p o iK k u -  a iiw U nnerpiegi ma one tv igo  q u e  
oeittiieti, al te x to  q u e  p u i  cdc v q u t. doy U p< im w  H nutien tc  Se in- da  sum cttput dc e s ta  
In rm ad e  uuiscunHuentt) peito con un.t to p ia  de “ /•’'c / io  , 7»m  i »  S i P ' i  i t w ’ t ' u ' m  a  
P ,  > i  ' y c o i i.s ie n to  a  11 p 'd t i u p a c i o n  e n  e l  e«UMtio
Nombre del paciente Codigo de identificacidn asignado
Firma del paciente Fecha Flora
Testigo a la firma del pacieate Fecha Bora
Si el participants es menor <lc edud, o  por alguna razon no puede lirniar, complete al siguicnte: 
a) Razon que el pjrticipante no puede ilrmar:__ ___ _____ __ ________ _________
b) . .  ...............    _ _ _ _ _ _
Nombre de persona au ton /ada  Fecha
Finns de persona autoii/uda 1-fora
Reiacidn y base dc la autorizacidn para dar coresentiroiento 
< m i f i c m i u  ( le  l a  ( u - r - i m n  a m  n h t i e n e  r n n s e n t i n i i c n t o
l b  j , T , I,, m i c \ p l u ‘:ici('ui d e l  c v im l iu  d c  " t t  r ' l a r r i b a ,  y  l i t  a m m a d i ,  a l  p a c ie a t e  a  
p r i - u r d a r  i  p e d i r  p u t  i n l 'u m c x - i d o  a d i c i im u l  w d t r e  c l  c t t i d i o ,  sn $  r i r s g o s  \  r o m p l 't c a i ' i o n e *  y  
a l t c i  n a t i v d s  p o i ib l t  s . S e  d a  u m i  e n p i a  d c  c l ,  Im  in .i  d c  i i m i e n t t t n l e n t n s  a l  p a c ic n U '.MHp PeOj 'HOH r-,
APPROVED ‘ 
?.’/,> •- () /
E X P ia C S
s f -t .a l s
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Firma de persona inint wn.i nombre tie la persona Fecha
gut ohtittie consentirniento qnc obtiene el consentimiento
C e r l i l i c a r to  d e l  i n a e s t i e m l i i t :
'• o  c e r t i l t c o  q u e  c s to v  ei t n v e s t t g a d o r  p r in c ip a l  o  e l u r iM c n te  del i m  t s i t g u d u r  i c s p o n s a b l e  para ei 
C 'tn d io .  M e  a s e g t tm  q u e  ei jw rtK  ipanie o  c n n m tc fu m o iH e  m f o r m u d o  de actieido con r c g u la c io n e s  
a p i iC jb k -a , > p .) ia  ei a v i s o  del M H S  R o c a - c h  < e u in c ) ' i l .R B )  de a lg u n a s  i c - a c r to n e s  adversas o 
aconteeiiim'niof . i i e s p u u i k *1 q u e  p n e .k  <U sarro lkr d c h id o  a este estudio.
ltnesligtidoTprincipal o 1 i i Flora Codigo l.D. del investigaJor
A s i s t e n te  al i n v e s t ig a d o r
INYAJLIBO SIN ESTAMI‘11 1 V I)!. LA APROBACION DE I R B
MHS
s b s ® " *
M A R  2  ft 2 0 0 6
P X P IR P S  tl'30
INlTIALSu
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PI I» !»  Krm RN, PhD/Peggy Kaiowes RN, MSN
P i p k . t N » 2W  05
D E R E C ilO S  D E  SUJETOS IH ’M W O K  I N LAS INVESTIGACIONES M A M C A L IS .
Alguna persona que ba -ido solicitado jv m  p.ir'n spar corn© sujeto de un expcritnento medical o que 
ha sid e  solicitado para el eonsentimiento a favor de otro tiene el dereebo:
1. Ser informado de ’I HI* NA TU RE y el p reposito  tie la investiga tion .
2. Ser dado una explication de los piocedimientos seguidos on el experimento m edical, y 
algunas drogas a  aptuutos mmdos
3. Ser dado una descripcidn  de algunas molestias y  riesgos razonables para csperar durante el
experim ento
4. Scr dado una ex p lica tio n  <ic alguncw ticncfie*»«■ para los SU IE T O S razonablcs para esperar 
durante el experim ento
5. Scr dado non tevelurLn; tie aigimos pun tditmeotos altemalixos aptorudoe, drogas o 
apaiatox qut jHiede xcr venu.oso U SUH i (3 \ s t i-1sesgns y Kncft< ios 'dattvos.
6. Ser mformado de las vjas de traumuetttos m edical, si hay, disponiblcs al SU JE T O  despucs 
del experim ento, si hay  cotnplicaciones.
7. Ser dado la oportunidad ptcgutiiai algo so lve  d  experim ento  del procedimiento implicado.
8. Ser mitndado que sc  puetV M in n  el cim»uniiniicuto para  partictpar en el experimento en
alguno m om ento  y el M ,JL  TO puedc par as la parneipaoion en  este  experim ento  sin
9. Ser dado una copia de a! gun consentimiento que es firmado o escrito , usado con relacion al 
experimento
10, Ser dado ia u p o i i u i t i d . t d  tlecidir al c o t 's e n t i m i u n t o ,  o  n o  al consen tim ien to , al experim ento 
m edical sin l.t t n t o n  s - n u d n  de a l g u n  e l c m e n i o  de fuer/a , fiaude, e n g n h o .  com pulsion, 
c o e r c i o n  o  i n f h i c n c i . i s  sisdehitl.is e n  la d e c i s i o n  d e 1 S U J F 10 ,
prejm cio.




MAR i  ft
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HIPAA AUTHORIZATION Page 1 of 2
Memorial Health Services Research Council 
Institutional Review Board
(Long Beach M em orial Medical C enter)
Tffulo del pr m e e m : ( ' oniprendientlo la earga de ios sln tom as en los 
pacientes con enfennedudes n-rmimilcs, \ con enferm edades que
^Cdmo se protege su confidencialidad?
Tiene listed dereehos relacionados a la privacidad de su itiibrm acion m edica,
que ha sido recogida antes de y durante el curso de esta investigaeion . Esta 
infhrmacidn medica se ilama “ infonnaeibn de la salud protcgida” (PH I), y 
incluyc mformaridn deinogratica, resultados do los extVmcnes tlsicos, pruebas de 
sangre, radiograflas y otros procednnientos diugnosticos y medicos, al igual que
su historia medical. Tiene usfed el detccho para limitar el uso y  el 
compartimiento de ms P il l,  y tiene el derecho para vcr los registros medicos y 
saber quien los ve,
Al ftrmar esta forma de autorizacidn, le permite al equipo de investigaeion el 
acceso a su PHI para el propdsito de llcvar a calm este estud io . El equipo de 
imesfigacion incluye los invcstigadores inertcionmkis en la fonna de  
consentim iento y otio  persona! espcciticn  imolucrado en la investigaeion en 
Long Beach Memorial Medical Center.
Sc utilizari su PH I solo para los proposito(s) deseritos en la seccidn del
consentimiento informado llamado jCom prcndiendo la carga de los stntom as en  
los pacientcs con  enferm edades term inales, \  con enferm edades que amenazan 
la vida, en las nnidades del cuidado intensive,]
Se com partiri su Pi l l ,  cuantas voces sea nceesario con el MHS Research 
Council (tam bien conocido  como cl t 'omite de R evision  Tnstitucional) y con
alguna persona o agenda requerida por la  ley.
last Rsased: W '1SS»4
Ntfimero del provecto: 299-05
la vida, en las unidades del cuidado intensive.
Antortzaetdn de uso y rcvclai-ion.de inform acidn de sa lnd  pn  __ 
APPROVÊ  AC.'
IWTIAIS M  ,
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Usted nos esta autorizando el uso v la rcvelacion de su PHI por un periodo de 2
alios despuds del final de la investigaeidn.; 31/1.2/2008
Puede listed revocar esta autorizacidn para el uso y el compartimicnto de su PHI 
en cualquicr momunto por medio de confactar la investigadora principal por 
escrito. Si revoca esta autorizacidn, ya no participant en este programa de 
investigaeion Si usted revoca esta autorizacidn, el uso o el compartimicnto de 
PHI en el future sc parara. Sin embargo, sc puedc usar el PHI que ya ha sido 
recogido.
Los resultados de las pruebas clinicas y la terapia efcctuadas como parte de esta 
investigaeion pucden ser incluidas en su icgistro medico. Se puede publicar la 
informacidn de esta investigaeion en los periddicos cientificos o se puede 
prcscntar en reunioncs ciontiilcas. Sin embargo sc mantenclra eonfidcncial su
idcntidad y no se publican! ningunu informacioti cjuc kv'la pucda idem i Hear, 
como su nutubre, foto, nuinero de scguridad social, o cl nttmero dc rtgistro 
medico.
Se le tiara una cppia de esta forma de autorizacidn para sus archivos.
Nombre del paciente Firma del paciente Fecha y hora
Nombre del lestigo Firma del testigo Fecha y hora
Nombre del representante autorizado ReJacidn con el paciente
Firma del representante autorizado Fecha y hora
Last Revise* W1V2O04
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P i K  U  L en t RN, P hD /Peggy RN, M SN
N )  299-05
M e m o i ia l  H e a l th  S m i c e s  ( ouncil 
insirtulKinal R c\ ich B oard 
Long Bench M omenta! H ospital
Consentinitenlo I n for mad o p a r a  participar en un estudio d e  la iuvesltgacitm  
(R espondedor F a m ilia r )
TilulorLa Compren.sidn de la eargii del •tlntoma m  los pacientes cm  
enfermedades terminates, y eiiferiiicdmles graves, en el cu idado  intensive.
I ora Principal: Leslie K ern  R N , PhD Nttmero de TeUfono: (562) 933-3326
Investigadora Princ ipa l; P«-»a> K alowes RN, MSN, CNS N uinero de Tclefono: (562) 225-2545 
Asistente al Investigadora: Louise DuBos RN, BSN N&mero de Tclfefono: (562) 522-9893 
Numero del proyeete  M B S ; 299-05
S t  h a  s  dt) p i t g u n L id o  a u s te d  p ara  p a r t i c i p a r  en. u n  e s tu d io  d t u n  t , t i  u n i  c o n d u c id o  p o r  L e s lie  
K e in  R N  P h D  > P i ea >  K .tio w  t s ,  R N . M S N ,  u n  e s tu d i a n t e  d«u lo i .d  u i  ,1 j v o g r a m a d e  e n f e m ie r a s
e n  .’a  I ' t u i m i d u d  d t  S .m  I it* g o  I 'e g e y  e s t a  c o n d u c t*  t J  , t  w d i,»  !j< i i m u  la  fo rm a  d e  u n  e s tu d io  
de  s> u  M iiM u o n  p .n e  u A n p ie m k t  m a s  el d o le ,  \  ~u o n . iu i l  > q u e  p re s e u ta  c o n  v a r ie s  s m to tn a s ,  
r t l .u  i >» n lo  a  h i e i ik n n i . - iU d  tu o g s e s iv o  v  e n f t n r u  t! td  y t a n
I , snfn iiiiatiiv ii q u e  p ic p o tv  sorui lis ted  n o s  d .a a  >>i„. |)u<-p c, <6 a i d u s -a  <fu i d e  la  |1  u  p i  u d* 
un  *iK-od)in ik  la  f a m i i i . . u s  n  ,pi to  a  los < ii m o w , . hut d i ! p ,„  i s>! q n , u rian  < m  1 t m u  
c m  , m l  p u u e n t e .
A1 p.s'ii. ipas en t ,it e,,u_d>>,, dt la tio cstigacion, se atiadira al conocimicnto de! oficio de ettfcrmera
e n  e l n u n c io  d e  los s m t o t n a , .  to q m  p in  d e  a y  id sis o . «ts tiie io ia i lo s  t i p o s  tie  t r a t a m ie n to s  que  
p o d e m o s  p r o p o r c i o n a r  t o  n u  d a i  t \ lo s  t ip o s  d t  t  u u iu d o  '  s t  n  n  sos q u e  se  n e c e s i t a n  lo s  p a c ie n te s  y 
las f a m i h a s e n  v a r ie s  p u n t " -  d m n n tc  e l < u r s o  d e  1 m i d t i i i u  d a d  i il t ic a .
^ p o R o u i  k s  F s i r i )  1 1 1  t . n u  i ?
S c  h a  s td o  s e k v i  lo n a d o  tic  l t d  t o n t o  , u n d id , '!  > p  > iM  n - i t  i -a u d io  p m q u e  u n  m i c m b r o  d e  s u
t .e n d ia  h .t a c tm la d o  jM ilK ip  u i n la t in  tsts* as ,o .i '  k  a  n o ,  ,obrc la  s t \«  i'd.u.1 y la f r c c u e n c ia  de  
s u '  - in to r i . t s  t c l a c i o n a d a  a  - i t  c n t ,  im e i l a d  A i t iu ln t i  n it U i c m o s  p o q u t to  ,i’ l<’i m c i 6 n /o  
i in e s tu v k io n  s o b ie  k v -g :a J i> s  rk . t ih ic n h ,  t * t t i l 'n i  uu> d  \ , u , o  s in to m  is  tn  1 1 p a c ie n te  d e  u n a  
p u s p t c t n a  f a m il ia r .  S c  u  in d u c e  la  m u y o n n  dc !o ,  t ' i t d n n  s o ln e  lo s  M iu o m a s  e n  p a c ie n te s  c r itie o s  
c o n  e l c /m ccr a v a ir /a d o , y  o t r n s  ilc so rd en .es  c o m m ie s  c o m o  la s  e n fe rm e d a d e s  d e l  c o ra z o n , p u lm o n , 
lu iu d o ,  1, d i.ib eu  s , c l  a b s q u e  c e i e b t a l ,  o  u n a  le s io n  t r a u i ’ tu iu  a a u d u  E sto s  e s tu d i o s  no  s o n  tan  
p ro v e c h o so ',  p a ra  m c jiu  a s  el c u n !  n lo  d e  lo s  p a c ie n te s  c o n  o il  a t  e n U  i t i i e d a d e s  a g u d a s .
MHS RESiEARCH CO UNCIL
APPROVED
M A R  2  0  2 0 0 6
E X P I R E S  i  
IN IT IA L S
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in te s tis  Kent RN, PKWeggj? Kulowes RN, MSN 
Project No. 29SMW
PROPdSITO l)Ki, E ST U D IO
HI proprisito jwimano del estudio es determinarse el predomiiio de varios tipos de sintomas (por
ejemplo: dolor, diticuftad de respirar, iifasea), la jfrecucncia, y la severidad de afliccidn de los 
par tentes que tiene una enfermedad ptogresivo o una enfemiedad repentina que es peligroso para la
v id a , q u e  s e  cuidan e n  el cuidado intensive. H a y  poca in fo n n a e ir in  disponibie de arnbos ios 
perepcctivos d e  lo s  p a c ie n te s  y  la s  femitias d u ra n te  e l curso d e  la enfermedad.
Famiiias/smigos vean c o rn s  io s  p a c ie n te s  responde a  sus enfermedades y ssmtomas en una mancra 
completamehte diferente d e  la p e rc e p c id n  del p a c ien te , A d c m fa , la s  familias a a m ig o s  a  mcnudo 
pm potdm m  e l  c u id a d o  tiecesario para, los p a c ie n te s  q u e  riven e n  c a s a  cuando e s ta n  enfermas. 
Entonees, puede proporciona u n a  p e rs p ic a c ia  m&s atnpiia a la  enfermedad d e l  p a c ie n te ,
Entonees, p u e d e  u s ted  ayudaniD-s compraitlci c o m o  harer a«'m mojor en cl c u id a d o  tie  lo s  p a c ien te s  
criiicameate e n fe rm a s , s i c o n te s ts  a las prcguntas on o! cucsiiotuno adjunto, q u e  le  pregunta
identificar lo s  sintomas q u o  le  n to lc s ia  e l miembro tte  su tenuita, y  e la s if ie w  la  fre c u e n c ia  y  
s e v e rid a d  d e  lo s  sintomas (como a; mi e ce  a  usted). 1 .n mformacidn q u e  proporciona u s ted  puede 
ayudar e n  Sa t d e n t i i k a a d n  d e  la s  necesidades q u e  tie n e , y  a d e m a r  ayudar e n  to desarrolla y ! a  
in v e s tig ae io n  d e  t ra ta m ie n to s  nuwos y  intcrventioncs del olicto d e  la  enfennera p o r  v a rio s  
s in to m a s, porque aetualnwnie h»v p o e a s  tempi as dispombles q u e  p u e d e  proporcionar e l  alivio.
PROCE DIMIE NTO
S i se  p re s e n ta  voluntario e n  el e s tu d io ,  s e  preguntaricompletar dos cuestiauarios (d is p o n ib ie  e n  
ingids y  espafio!)
» Tjna forma cortn en que puede evuluar la* earacteristious del m iem bro de la famitia (edad,
sex a. etnieidad. ocuparuin, papet dd c u id a d o  a l  p a c k  n k )
* Um  encuesta de 14 cosas pant evaluar su percepcidn tie los sirttomas del paciente.
* En cl primer dia. dt! miava.) del paeieitto .d ■'■ui.ludo intensive, le preguntara terminal una 
forma detnografica; y un a i c s tw n a r io  del gtavamen del stntoma. El cuestionario de
s in to m a s  w as dird s«  p e rc e p c id n  d e  lo s  sintomas del p a c ie n te  y  to salud d u ra n te  la semana 
antcrioi. Tomara aptoxintadamente 5 a 8 tninutos e n  to ta l
* Eff.e l  t e r c c r  dia tic! e u k la  d e l paetcntt, los invcstigadores v a n  a  prcguntarle te n ti in a r  el 
c u e s tio n a r io  d e l  g ra v a m e n  d e l sm to n w  otra vci. N o s  diia su  p e rc c p c io n  d e  lo s  sintomas d e l 
p a c ie n te  y  c aK d sd  d e  v id a ,  y  s i e s ta  h a  cambiailn, ru a ih io  ic c ib e  tratamiento(s) p o r  v a rio s  
d la s . Tomara apioximadamente 2 a  4 m im rto s  pat a te ra tiu a r .
Not.*: di n« p uede  este r presente ffsicam ente en ei terccr diit, se puede arreglar y  conducir una
e u t r f ,  ista p o r  teI6f«aio en s«» convert iencia, asi q u e  puede dstr esta iiiformacidn muy
importante p ara  teriniaar ei estudio. IdHS ^pEAFto^COlJNCIL
MAR 2 (I 2008
EXPIRES,tMmAL _
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J*‘ I r  *u kv. n  UN", P M V F eg g y  K a i o w s  R N , M S N  
I'm « i \n  >*>') <>5
MEN*.OS % M SI 1 "I SKI s  I’l l l i  \<  I U I s
No hav r.cseo p i t " . , bit p 11J ’ >ion i- •>< ■ ti mi In '(H .>> c! e aurtque, es posible tener la
fu tiga  i li.m do it sp e n d  al t >,sf>('ii.m o f’m .k  t , |,A1i o j u  \ em i la  I .’u  a p is  < m n p k  tar e l 
< ti.'N m n .if’o  tn  mi pi 4110 p > ,0 , o  |» i  >>11111,11 , 1 n u t  - n e  1 *<>■ i e t ‘ii<iai la: u u p m  si,is p a ra  u s ted  
iliuoumii'tiio en 11 toon *
I o  i i s M 'o s  p io v i s ib le s  s o  1 m i n im u s  p . t u  d .n io  p , i ,  o lo a u  o c u a n d o  r c s p o n d c s  al cuestionario de lo s  
s in to m a s  poique t s m u t  otto \ < In debt, t<*nni 2 .1 4 m inutes para c o m p ie t a r .  Asi, no dcbe ser 
.u ia iu U d ,  ttitetlo o dolo- . ait mdo ,Sm cntb.ugo, si cl -'sires oeurre, se esta disponibie una r e m is id n  
a p r o p ia d a  para a y in ia  atK iuital .t l i a s e s  de los s e r v i c io s  del cuidado pastoral.
VENTAJAS POTENCIALES PARA PARTICIPANT ES Y/O LA SOCIEDAD
i a printer.! \e n t j |a  v Ls m s  o ’m .t  sciia que 1 1 uiestion  11 in ii'.itlo puede identificar la presencia e 
mtonsidad il>* varios i» itw u s  que no pnede listed di‘«cnbn a tiavcs tie sus percepciones propias.
A vtK luia en !a id e u t i fT a t io n  dt boquelen en mi -m datlo  a r tu a ln te n le ,  lo que podemos tratar de 
n ie jo tiu .
Ademnx, buy la vcntaja tit af>.id,i al conocimiento cientlfico d e l o f ie io  d e  la s  enferm eras v cl cam p o
del m a tR io  tU 1 s tn to tn a . Iks fu sib le  q u e  el e s tu d io  n o s  ay rn ie  cn  c l  d e s a r r o l l o  d e  n u e v a s  te r a p ia s
p a ia  l e . iu tu  c l d o lo r  y s u fn n u e n to  c n  lo s  p a c ie n te s  d u ra n te  e l c u rs o  d e  su  e n fe rm e d a d  p c lig ro so
pal a U vnla MHS RESEARCH COUNCIL
A! II RN S i n  (A
N o  luu, a l t e r n a t i v e ' .  f v . u  d e  n o  p  u t n i p  u  1 mu> l.i u p ' t i u n i d a d  p a r a  p r e g u n t a r  a  Io s  <j I  2006
n is e s lig a d o it 's .  s c H .e  k  t f i i .n d -  lo ll ,1 y„ 1*1 ! *, t in n
Panicipantes n o  vart a recibir leivi’nu.u mu ",i >l<u fm rn a  d e  in c e n tiv e  p a ra  p a r t ic ip a r  e n  el estu d io .
PART1CIPACION VOLUNTARIO/ DERECHG PAR S RFTIRARSE
Participation e n  el e s tu d io  e s  opcion.tl c o m o  mserabro <k i.i l.umlia. S i participa e n  el e s tu d io , se 
podra rclirar e n  cuaiquier moment© sin c o n s m ie n c ia s .  Particip.u i6n 0  la  falta d e  participacidn n o  va  
a a fc c ta r  e l tratamienco n i el c u id a d o  del miembio de  su  farmb.i T ie n e  e l derecho rechazar 
contextur la s  preeuntas que n o  quiet u eontCitoi y puede quul.usc e n  e l e s tu d io  todavta. L a  
111 vest igadora puul 1 emoverle del estudio si presenta circunstancias que, en la  opina dc la 
mvoxtipadora, a u to u M  un d e s p td o  d e l estudio.
fO M lO I'S T I si ID \r)
t o itipu-nd i ikVi! qn. U *nltrtrMuon obtenida sobre lis te d  e n  e s ta  m v e s i ip a c io n  s e  tju ed a  
i t i i i f u k n t  i.tl > tmnej m. id. 1 a !u a ,11 n o m b re  e n  u n  informe o pu b lic  a v io n  a mcnos q u e  f tn n e  u s ted  
. )i dcci j r f u  S e  11 a  u r  . < t*n o  d e  m m  1 sros en t c /  d t  noinbres p a w  U das los d a to s  p a ra  a se g u ra rs e  
MHdnknualKlui 1 1 t.uin'ntm "  <iio, \  1 s !r  s 1 q u e  el iii'inbtc de  p .  jlicipartte al co d ig o
<tMi n a d o  s i  i i n  m a i l ,  n u to  t p  eado , t i e  Usla l e e .  .itn.ilt ^ dc la  mve n e a c io n ,  y  s o lo  las  
itne ag<> lo ra s  p n ’K pm p idtun ic v i ,» 1  so 1 o . lo .  los d a lo s  y  u i f s o o n d r s u s  quo c o m p le te  sera
APPROVED
R E N ’U M E R A O O N  P O R  L A  l ‘ V R I l t  I P  S< l< i n
E X P IR tb d . 
INlTIAtb .
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PI I \ k  mi RN, PhD /Peggy £:>!«> • * P \  M SN 
K oje  No H t 05
unmiensdo c i un gabinete McH»ie,.mi i n la oficina del investigador, y solo los investigadores tciulran
C o n s ie n t a  u s te d  a. la p u b l i e a c i o n  de ios resultados d e l  e s tu d i o  m i e n t r a s  la in f o r m a c ib n  sea 
a n d n i tn a  y /o  d i s f r a z a d a  ass que t ia ti ie  se ptieda h a c e r  u n a  id e n t i f i c a e id n .
CLASULA DE IRB / ADA
Se itp.isa v u p n ie b a  eon p i - >pm sta p o i M t  m u riis l I S eallh  S erv  iec.s I n s t i t u t io n a l  R e v ie w  Board 
(MILS Research C o u n c i l ) ,  que s u v e  p a r a  el IRB de l . o n g  B e a c h  M e m o r i a l  H o s p i t a l ,  qite 
c o n t i .  ne at a l io s  medicos y per-.onas d e l  g u m  p u b l i c o  Si tiene usted a l g u n a  p r e g u n t a  s o b r e  sus 
t k r u h o s  c o m o  p jx i ic t jw n tc  d e l  e s tu d io ,  o  el ( r .d j im ie n to  lo ln c io n a i lo  c o n  la  lesion, o  q  th e r e  m a s
ittioniuitidn. s o b itf  la dLpomW lkiid de t e u u m e u i n v m  o  u a t a m i e n t o s  m edicates, puede c o n t a c t®  
H a r r is  R. S tu tm a n . Ml), d n c e t o r  c j e a i i i v o, e l oficm de adutinisiracuSn tie la investigaeion. 
Memorial H e a l th  S e t t  io c s ,  al m to ic io  ( 56? )  490-3737
1 ,i(si mvc'tigftdoiafs) pnm  ipji(c=) Leslie Kem RN, P h D  y  P e g g y  K a lo w e s ,  RN, MSN; o  im o
tie los asistentcs tie l.t* m v e - l i iM t lu r a s  le ban d is c u t id o  este estudio. Si tiene algunas pregtmtas, 
j i t ic d e  to n i a r iu i l c .s  a  { ( 5 6 ? !  O B  3 1 2 0 ;  (5 6 2 }  2 2 5 - 2 5 4 5 /  9 8 5 - 1 8 0 4 ] .
Yi tt  HiSi< o qm Ik f id.) >! U \ l r >  qut p tu  ede it .d. n .u i m t ba k u io , y que c o m p r e n d o  el 
ton* it in t quo u  l it .  t!iu> I j  ictpondadn i, qiufuLni a t 'u lq m u  prt ; aita que tel)go que 
p .r i . t e  a tec q u  pit-tMii • q u e  dot e l p< mium, mm ntenk i t  un tLi una c o p r a  tie esta 
f  >ti> o k  o  n . t n l  t " o  |Ui'U) ( mi mi i eopta .’ i / >n ' /"<,>, i v  >s in  M a i m d  
i f,  , , t u t t s j e u i  u  1 1 p a i i n  >pai lo t . e ’t t’l e s tu d io .
Si ef participanle es menm de i dad. o por alguna nizdo no puede firmar, com plete al siguienlc;
a) Razon que el p.tiueipjnu no pue.de firman _ __ ______ ________
MHS RESEATO t i  a • O il
APPROVPO
N o m b re  del responde-tlor familiar C c k lig o  asignado
MAR 2 ft 2005
firm a de los r c s p o n a n td i  it. s Fecha H o ra E X P IR E SiNims
Testigo a t l  n-.pom laloi lumtliar Fecha Hora
b)
Nombre de persona autorizada Fecha
Firma de persona atrtorizada Hora
Relacion y base de la ion para, dar consentimiento
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Symptom Burden 244
Page 5 o f  6
i*L Leslie K a n  RN , P hD /Peggy Kalosves SIN, M S N  
IV geet No. 2994)5
< Y r t i f i c a d o  de la p e r s o n a  n u e  o t n i c n c  o o iiM -n iim io iii i)
H e  p n i p o r c t o i i a t f o  u n  c x p f i ti te lo i t  tit-S c s i i u lm  <h i n u s t i u a t  io n  a r r i l t a .  v l ie  a n i m a d o  a l p a c i e n t e  a  
p i e g i u i t a r  y p e d i r  p o r  i n f o r m a c f t i n  u d i r i n u u l  m >Iuo t l  iM i i i l io .  m is  r i e s g u s  y  c o m p l i c a c U m e s  y 
a l t e r n a t i v e s  p o s ib le s .  S e  d a  m m  copia d e  e s ta  f o r m a  tie  c o n s e n t f i n i r n f o t  al p a c ie n te .,
In n s u  do  p e r s o n a  l u t p n m . i  n u m b s c  tic Us p e t w r .a  F e c h a
quo o h iio n e  consentimiento q u o  o b t t e n e  e i c o n s e n t im ie n to
Y o  ec rtiliit o  ijtit, c s to y  c l  n v e s i i p .n io i  p r in c ip a l  o  cl a s i s le n tc  d e l  in v e s l i t ' . i t ln t  ie s p < .u s a b le  p a r a  c t 
(’s P u i io  M i1 a s e p m o  q u o  <‘l p n r tu  fp<m!e e s  c o m p le s u in c i t te  in fo n n a c lo  d e  a t  n e t  d o  t o n  r e g u la c io n .e s  
•ip l.t j b l e s ,  y  p a t 4  e l  , « t - o  d v i M H S  K o cean , h f ’u u in  il f l R B t  t ie  a lg u n a '-  r e a e e i o n t s  a d v e r s a s  o  
a r o n l t ,  im io n to e  m e - p a .M u '  .p ie  p u e d e  l i c c a r io i la i  d e h id o  a  e s tc  e s tu d io .
In v e s tig a d o r p r in c ip a l  o  F e c h a  H o ra  Cdcfigo S.). d e l in v e s t i g a d o r
A s is te n te  al i n v e s t i g a d o r
INVALIOO SIN ESTAM.PJLLA DE I.-A APROBACION DE IRB
MHS RESEARCH COUNCIL
APPROVED 
MAR t  ft 2006
E X P lR E S iL A - .nlNSTlA
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IH I ' ^ v  Knn RN, PhD/Peggy Kalowcs RN, MSNPkm*,i V) 2V)-OS
DERKCHOS DE SUJETOS HUMANOb1 M  VS I.NVESTIGACIQNE8 MEDICATES.
Alguna persona que ha sido solicitado para paun ip.u t onto sujeto tie un experim ento medical o  que 
ha sido solicitado para el consentimiento a tar or d e  ol’o tiene el derecho:
1.. Ser infonnado de THE NATURE y el proposito de la investigaeion,
2. Ser dado una explicaeibn de los procedimientos seguidos en e! experimento medical, y 
algunas drogas o aparatos usados,
3. Ser dado una descripcidn de algunas n • riesgos razonables para esperar durante el
experimento
4. Ser dado ima explication de algunos beneficios para los SUJETOS razonables para esperar
durante el r\p< runento.
5. Ser dado una revelacion de algunos procedimientos alternatives apropiados, drogas o 
aparatos que puede ser ventajoso al SUJETO, y sus riesgos y beneficios relatives.
6. S<‘i itifoniMdo de las vtas de ti<ilamicnto> medical,, si hay, disponibles al SUJETO dcspues 
del ixponnvnto, si hay compile aeiunes
7. Ser dado la o p o r t im id a d  preguntar algo sobre cl experimento del procedimicnto implicado.
S. Ser mandado que sc pwik u-ttiar d  tnn'-uif it*’ ’• it.» p,ti,i participar en ei experimento en 
alguna momcnto \ ei SI I! iOpuctk p,f ,tt ! tp.n'u jwaotten estc experimento sin
9 . S u  dado ima copia de algiitt c o n s e n t im i e n to  que es f im in d o  o  e s c r i t o ,  ttsado con reiacion al 
c .x p e im ic n to
10. Ser dado la opmtunidad decidir ai conrcnfimicnto, o no al consentimiento, al experimento 
medical sin la mtervencion de algdn elem tnio  dc fuerca, Iraude, engano, compulsion, 
coercion o infhiejida-, imicbidas en la decision del SUJETO.
p r e ju te io .
FIRMA D EL PACIENTE: FECHA:
MNS r e s e a r c h  c o u n c i l
APPROVED
M A R  2 I  ZOOS
EXPIRES H 
INITIALS
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Appendix O 
Letter of Translator Certification
C hild &  A dolescent S ervices R esearch C enter
.W 20 I l u M w i \  W ax .  M l 510.1 •  S an  D k r h , ( a i i f i .n n a
(050) 9M-7DV1 •  FAX (S5KJ W.I.-7702 •  n«iw .r«re.nrj!
TO: Hams R. Sun man. Ml), Fxeetitiu' Dikcum
Memorial Health Sen tecs 
( Hike o f  Research Administration
Long Beach M e m o ria l Medical Center 
2801 A t kit i tic  B hv i 
Long Beach. CA W806
l i t  vf; Cynthia 13, Connelly, Ph.D.
DATE: 1/20/06
RE; Symptom Burden in Patients with Terminal awl Life-Threatening
Illness in Intensive t are I huts
Dear Dr. Stutman:
Attached please find copies o f the English version o f  putient/farmiv respondent consents 
forms, PHI fben; family demographic questionnaire, and patient treatment. & procedure sun ev lor
tlx  abo ve-named protocol and the eorrespoacling Spanish translations. Ms. Blanca Mutn'tlkis and 
Horma Talamentes employed hv the Chid and. Adolescent Services Research < enter. ( hikircnN 
Hospital ami .Health Center, San Diego CA .have reversed translated the consent and av-ent forms, 
and. they are satisfied that they are accurate and comprehetBiSjle. Both Ms. MimctlSas and 
Talantentes are native Spanish speakers with over 10 years o f  experience in translation ami reverse 
translation with u particular focus on behavioral health research.
Thank you lor \our assistance with this protocol i’lease do not hesitate to contact me if  you lave 
any questions.
C y n th ia  I) , C o n n e lly . P h .D .. RN
Reseaich Scientist ( 'hild and Adolescent Sen ices Research < enter 
Associate Professor Haim School o f  Nursing and Health Seictiee 
Hnlvcisity o f Sun Diego, San Diego CA
A Nttfitnml fnmmre u f Mrntal ffrahh fmtU'd K 'mh?r 
in coliitbaratwn nifh:
* San Diego State Oftiversits * The tlmvcs'su* a t  GiWorma S.m i Jicfo 
* San Diego Cotuti} Probation Departtiicnt * S.sti f heeo \ k-aith aiul Human Serv ices Agency
Cl H U  i l l n si




0 M : \  .i *r i i C  .
MfSVlORJAt HCALTH SfRViCES 
R e :  r  a  r c  h  A.! >m  i 's  \ r , a  n o n
MHS-RESEARCH COUHCIi (IRB) APPROVAL LETTER
P.I.: Leslie Kern, RN, PhD/Peggy Kaiowes, RN, PhD(c) Date; October 16, 2006 
Memorial Heart and Vascular Institute
Project #  and Tide; #299*05 "Understanding the Symptom Burden in Patients with Terminal and 
Life Threatening Illness in Intensive Care Units,"
Extension Approval Date: October 16, 2006 Expiration to te :  October 15, 2007
_ X ,_  Regular Review Direct Review
A request for an  extension to  th e  above project was reviewed and approved a t  the  October 16, 
2006 MHS Research Council meeting for a  period of I year, The Memorial Health Services 
Research Council serves a s  the  Institutional Review Board for Long Beach Memorial Medical 
Center. Enclosed please find an official stamped copy of the Informed Consent Form for foe 
above named project. The previously approved Authorization form for use and disclosure of 
Protected Health Information should continue to be used.
« In compliance with FDA regulations and Memorial Health Services Research Council policies, a 
detailed progress report must be submitted to the Office of Research Administration before 
August 1, 2007.
MHS Research Council approvals are provided to  Principal Investigators subject to toe 
following conditions;
In accordance with MHS Policy and Procedures, the MHS Research Council may 
authorize staff to  conduct spot checks or audits on their behalf. Please provide toe 
information requested if an audit of your project occurs.
Per ICH guidelines, the  MHS Research Council regards the Principal Investigator as 
responsible for the conduct of research trials a t  his/her site and aii associated 
research facilities. Specific responsibilities of toe Principal investigator Include 
ensurings
« Supervision of all research a t Long Beach Memorial Medical Center in accordance with 
Memorial Health Services policies are! FDA regulations.
•  Conduct of research according foe study protocol,
» Use o f the  roost recently approved informed consent form,
« Provision of a  MHS Research Council-approved consent form in foe subject's first language 
to ail non-English speaking subjects.
•  Approval by foe MHS Research Council for ail changes In research activity including 
protocol amendm ents and/or consent form revisions prior to Implementation.
• Prompt reporting (48 hours verbally and 5-10 days in writing) to the MHS Research
i f o O  I :\"i I. V N  i ,H : V>. s f o f ! -  *  f . f  A T  B f . ' X H ,  C  \  ■; / . ? "  *  j ,V ;-L S
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Council of any significant changes in research activity including changes in Principal 
Investigator, changes in research site, addition of research facilities to a previously 
approved site, and study completion,
* Approval by the m hs Research Council of al! advertisements and patient recruiting 
materials prior to use.
« Prompt reporting (48 hours verbally and 5*10 days In writing) to the MHS Research 
Council of serious and unexpected events related to study procedures as well as protocol 
deviatlons/vloiatlaos.
•  T im e ly  s u b m is s io n  of continuing review and progress reports.
Sncerely,
Harris R. stutman, md
Executive Director
Office of Research Administration
Approval tetters/299-05 extension October 2006
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